HIGH MOLECULAR WEIGHT SURFACE PROTEINS OF NON-TYPEABLE HAEMOPHILUS

Abstract: High molecular weight surface proteins of non-typeable Haemophilus influenzae which exhibit immunogenic properties and genes encoding the same are described. Specifically, genes coding for two immunodominant high molecular weight proteins, HMW1 and HMW2, have been cloned, expressed and sequenced, while genes coding for high molecular proteins HMW3 and HMW4 have also been cloned, expressed and sequenced.

Description: TITLE OF INVENTION HIGH MOLECULAR WEIGHT -SURFACE PROTEINS OF NON-TYPEABLE HAEMOPHILϋfi FIELD OF INVENTION This invention relates to high molecular weight proteins of non-typeable haemophilus. BACKGROUND TO THE INVENTION Non-typeable Haemophilus influenzae are non- encapsulated organisms that are defined by their lack of reactivity with antisera against known H. influenzae capsular antigens. These organisms commonly inhabit the upper respiratory tract of humans and are frequently responsible for a variety of common mucosal surface infections, such as otitis media, sinusitis, conjunctivitis, chronic bronchitis and pneumonia. Otitis media remains an important health problem for children and most children have had at least one episode of otitis by their third birthday and approximately one-third of children have had three or more episodes. Non-typeable Haemophilus influenzae generally accounts for about 20 to 25% of acute otitis media and for a larger percentage of cases of chronic otitis media with effusion. A critical first step in the pathogenesis of these infections is colonization of the respiratory tract mucosa. Bacterial surface molecules which mediate adherence, therefore, are of particular interest as possible vaccine candidates. Since the non-typeable organisms do not have a polysaccharide capsule, they are not controlled by the present Haemophilus influenzae type b (Hib) vaccines, which are directed towards Hib bacterial capsular polysaccharides. The non-typeable strains, however, do produce surface antigens that can elicit bactericidal antibodies. Two of the major outer membrane proteins, P2 and P6, have been identified as targets of human serum bactericidal activity. However, it has been shown that the P2 protein sequence is variable, in particular in the non-typeable Haemophilus strains. Thus, a P2-based vaccine would not protect against all strains of the organism. There have previously been identified by Barenkamp et al fPediatr. Infect. Pis. J.. 9:333-339, 1990) a group of high-molecular-weight (HM ) proteins of non-typeable Haemophilus influenzae that appeared to be major targets of antibodies present in human convalescent sera. Examination of a series of middle ear isolates revealed the presence of one or two such proteins in most strains. However, prior to the present invention, the structures of these proteins and their encoding nucleic acid sequences were unknown as were pure isolates of such proteins. In addition, the identification of surface accessible epitopes of such proteins was unknown. SUMMARY OF INVENTION The inventor, in an effort to further characterize the high molecular weight (HMW) non-typeable Haemophilus proteins, has cloned, expressed and sequenced the genes coding for two i munodominant HMW proteins (designated HMWl and HMW2) from a prototype non-typeable Haemophilus strain and has cloned, expressed and sequenced the genes coding for two additional immunodominant HMW proteins (designated HMW3 and HMW4) from another non-typeable Haemophilus strain. In accordance with one aspect of the present invention, therefore, there is provided an isolated and purified nucleic acid molecule coding for a high molecular weight protein of a non-typeable Haemophilus strain, particularly a nucleic acid molecule coding for protein HMWl, HMW2, HMW3 or HMW4, as well as any variant or fragment of such protein which retains the i munological ability to protect against disease caused by a non-typeable Haemophilus strain. The nucleic acid molecule may have a DNA sequence shown in Figure l (SEQ ID No: 1) and encoding HMWl for strain 12 having the derived amino acid sequence of Figure 2 (SEQ ID No: 2) . The nucleic acid molecule may have the DNA sequence shown in Figure 3 (SEQ ID No: 3) and encoding protein HMW2 for strain 12 having the derived amino acid sequence of Figure -4 (SEQ ID No: 4) . The nucleic acid molecule may have the DNA sequence shown in Figure 8 (SEQ ID No: 7) and encoding HMW3 for strain 5 having the derived amino acid sequence of Figure 10 (SEQ ID No: 9) . The nucleic acid molecule may have a DNA sequence shown in Figure 9 (SEQ ID No: 8) and encoding protein HMW4 for strain 5 having the derived amino acid sequence of Figure 10 (SEQ ID No: 10). In another aspect of the invention, there is provided an isolated and purified nucleic acid molecule encoding a high molecular weight protein of a non- typeable Haemophilus strain, which is selected from the group consisting of: (a) a DNA sequence as shown in any one of Figures 1, 3, 8 and 9 (SEQ ID Nos: 1, 3, 7 and 8); . „ (b) a DNA sequence encoding an amino acid sequence as shown in any one of Figures 2, 4 and 10 (SEQ ID Nos: 2, 4, 9 and 10); and (c) a DNA sequence which hybridizes under stringent conditions to any one of the sequences of (a) and (b). A DNA sequence according to (c) may be one having at least about 90% identity of sequence to the DNA sequences (a) or (b). The inventor has further found correct processing of the HMW protein requires the presence of additional downstream nucleic acid sequences. Accordingly, a further aspect of the present invention provides an isolated and purified gene cluster comprising a first nucleotide sequence encoding a high molecular weight protein of a non-typeable Haemophilus strain and at least one downstream nucleotide sequence for effecting expression of a gene product of the first nucleotide sequence fully encoded by the structural gene. The gene cluster may comprise a DNA sequence encoding high molecular weight protein HMWl or HMW2 and two downstream accessory genes. The gene cluster may have the DNA sequence shown in Figure 6 (SEQ ID No: 5) or Figure 7 (SEQ ID No. 6). In an additional aspect, the present invention includes a vector adapted for transformation of a host, comprising a nucleic acid molecule as provided herein, particularly the gene cluster provided herein. The vector may be an expression vector or a plasmid adapted for expression of the encoded high molecular weight protein, fragments or analogs thereof, in a heterologous or homologous host and comprising expression means operatively coupled to the nucleic acid molecule. The expression means may include a nucleic acid portion encoding a leader sequence for secretion from the host of the high molecular weight protein. The expression means may include a nucleic acid portion encoding a lipidation signal for expression from the host of a lipidated form of the high molecular weight protein. The host may be selected from, for example, E. coli. Bacillus. Haemophilus . fungi, yeast, baculovirus and Semliki Forest Virus expression systems. The invention further includes a recombinant high molecular weight protein of non- typeable Haemophilus or fragment or analog thereof producible by the transformed host. In another aspect, the invention provides an isolated and purified high molecular weight protein of non-typeable Haemophilus influenzae which is encoded by a nucleic acid molecule as provided herein. Such high molecular weight proteins may be produced recombinantly to be devoid of non-high molecular weight proteins of non-typeable Haemophilus influenzae or from natural sources. Such protein may be characterized by at least one surface-exposed B-cell epitope which is recognized by monoclonal antibody AD6 (ATCC ) . Such protein may be HMWl encoded by the DNA sequence shown in Figure 1 (SEQ ID No: 1) and having the derived amino acid sequence of Figure 2 (SEQ ID No: 2) and having an apparent molecular weight of 125 kDa. Such protein may be HMW2 encoded by the DNA sequence shown in Figure 3 (SEQ ID No: 3) and having the derived amino acid sequence of Figure 4 (SEQ ID No: 4) and having an apparent molecular weight of 120 kDA. Such protein may be HMW3 encoded by the DNA sequence shown in Figure 8 (SEQ ID No: 7) and having the derived amino acid sequence of Figure 10 (SEQ ID No: 9) and having an apparent molecular weight of 125 kDa. Such protein may be HMW encoded by the DNA sequence shown in Figure 9 (SEQ ID No: 8) and having the derived amino acid sequence shown in Figure 10 (SEQ ID No: 10) and having the apparent molecular weight of l23kDa. A further aspect of the invention provides an isolated and purified high molecular weight protein of non-typeable Haemophilus influenzae which is antigenically related to the filamentous hemagglutinin surface protein of Bordetella pertussis f particularly HMWl, HMW2, HMW3 or HMW4. The novel high molecular weight proteins of non- typeable Haemophilus may be used as carrier molecules by linking to an antigen, hapten or polysaccharide for eliciting an immune response to the antigen, hapten or polysaccharide. An example of such polysaccharide is a protective polysaccharide against Haemophilus influenzae type b. In a further aspect of the invention, there is provided a synthetic peptide having an amino acid sequence containing at least six amino acids and no more than 150 amino acids and corresponding to at least one protective epitope of a high molecular weight protein of non-typeable Haemophilus influenzae. specifically HMWl, HMW2, HMW3 or HMW4. The epitope may be one recognized by at least one of the monoclonal antibodies AD6 (ATCC ) and 10C5 (ATCC ) . Specifically, the epitope may be located within 75 amino acids of the carboxy terminus of the HMWl or HMW2 protein and recognized by the monoclonal antibody AD6. The present invention also provides an immunogenic composition comprising an immunoeffective amount of an active component, which may be the novel high molecular weight protein or synthetic peptide provided herein, which may be formulated along with a pharmaceutically acceptable carrier therefor. The immunogenic composition may be formulated as a vaccine for in vivo administration to a host. The immunogenic composition may be formulated as a microparticle, capsule, ISCOM or liposome preparation. The immunogenic composition may be used in combination with a targeting molecule for delivery to specific cells of the immune system or to mucosal surfaces. Some targeting molecules include vitamin B12 and fragments of bacterial toxins, as described in WO 92/17167 (Biotech Australia Pty. Ltd.), and monoclonal antibodies, as described in U.S. Patent No. 5,194,254 (Barber et al) . The immunogenic compositions of the invention (including vaccines) may further comprise at least one other immunogenic or immunostimulating material and the immunostimulating material may be at least one adjuvant. Suitable adjuvants for use in the present invention include, (but are not limited to) aluminum phosphate, aluminum hydroxide, QS21, Quil A, derivatives and components thereof, ISCOM matrix, calcium phosphate, calcium hydroxide, zinc hydroxide, a glycolipid analog, an octadecyl ester of an amino acid, a mura yl dipeptide polyphosphazare, ISCOPRP, DC-chol, DDBA and a lipoprotein and other adjuvants to induce a Thl response. Advantageous combinations of adjuvants are described in copending United States patent Application Serial No. 08/261,194 filed June 16, 1994, assigned to Connaught Laboratories Limited and the disclosure of which is incorporated herein by reference. In a further aspect of the invention, there is provided a method of generating an immune response in a host, comprising administering thereto an immuno- effective amount of the immunogenic composition as provided herein. The immune response may be a humoral or a cell-mediated immune response. Hosts in which protection against disease may be conferred include primates including humans. The present invention additionally provides a method of producing antibodies specific for a high molecular weight protein of non-typeable Haemophilus influenzae f comprising: (a) administering the high molecular weight protein or epitope containing peptide provided herein to at least one mouse to produce at least one immunized mouse; (b) removing B-lymphocytes from the at least one immunized mouse; (c) fusing the B-lymphocytes from the at least one immunized mouse with myeloma cells, thereby producing hybridomas; (d) cloning the hybridomas; (e) selecting clones which produce anti-high molecular weight protein antibody; (f) culturing the anti-high molecular weight protein antibody-producing clones; and then (g) isolating anti-high molecular weight protein antibodies from the cultures. Additional aspects of the present invention include monoclonal antibody AD6 and monoclonal antibody 10C5. The present invention provides, in an additional aspect thereof, a method for producing an immunogenic composition, comprising administering the immunogenic composition provided herein to a first test host to determine an amount and a frequency of administration thereof to elicit a selected immune response against a high molecular weight protein of non-typeable Haemophilus influenzae: and formulating the immunogenic composition in a form suitable for administration to a second host in accordance with the determined amount and frequency of administration. The second host may be a human. The novel envelope protein provided herein is useful in diagnostic procedures and kits for detecting antibodies to high molecular weight proteins of non- typeable Haemophilus influenzae. Further monoclonal antibodies specific for the high molecular protein or epitopes thereof are useful in diagnostic procedure and kits for detecting the presence of the high molecular weight protein. Accordingly, a further aspect of the invention provides a method of determining the presence in a sample, of antibodies specifically reactive with a high molecular weight protein of Haemophilus influenzae comprising the steps of: (a) contacting the sample with the high molecular weight protein or epitope-containing peptide as provided herein to produce complexes comprising the protein and any said antibodies present in the sample specifically reactive therewith; and (b) determining production of the complexes. In a further aspect of the invention, there is provided a method of determining the presence, in a sample, of a high molecular weight protein of Haemophilus influenzae or an epitope-containing peptide, comprising the steps of: (a) immunizing a host with the protein or peptide as provided herein, to produce antibodies specific for the protein or peptide; (b) contacting the sample with the antibodies to produce complexes comprising any high molecular weight protein or epitope-containing peptide present in the sample and said specific antibodies; and (c) determining production of the complexes. A further aspect of the invention provides a diagnostic kit for determining the presence of antibodies in a sample specifically reactive with a high molecular weight protein of non-typeable Haemophilus influenzae or epitope-containing peptide, comprising: (a) the high molecular weight protein or epitope- containing peptide as provided herein; (b) means for contacting the protein or peptide with the sample to produce complexes comprising the protein or peptide and any said antibodies present in the sample; and (c) means for determining production of the complexes. The invention also provides a diagnostic kit for detecting the presence, in a sample, of a high molecular weight protein of Haemophilus influenzae or epitope- containing peptide, comprising: (a) an antibody specific for the novel envelope protein as provided herein; (b) means for contacting the antibody with the sample to produce a complex comprising the protein or peptide and protein-specific antibody; and (c) means for determining production of the complex. In this application, the term "high molecular weight protein" is used to define a family of high molecular weight proteins of Haemophilus influenzae. generally having an apparent molecular weight of from about 120 to about 130 kDa and includes proteins having variations in their amino acid sequences. In this application, a first protein or peptide is a "functional analog" of a second protein or peptide if the first protein or peptide is immunologically related to and/or has the same function as the second protein or peptide. The functional analog may be, for example, a fragment of the protein or a substitution, addition or deletion mutant thereof. The invention also extends to such functional analogs. Advantages of the present invention include: an isolated and purified envelope high molecular weight protein of Haemophilus influenzae produced recombinantly to be devoid of non-high molecular weight proteins of Haemophilus influenzae or from natural sources as well as nucleic acid molecules encoding the same; high molecular weight protein specific human monoclonal antibodies which recognize conserved epitopes in such protein; and - diagnostic kits and immunological reagents for specific identification of hosts infected by Haemophilus influenzae. BRIEF DESCRIPTION OF DRAWINGS Figures 1A to 1G contain the DNA sequence of a gene coding for protein HMWl (SEQ ID No: 1) . The hmwlA open reading frame extends from nucleotides 351 to 4958; Figures 2A and 2B contain the derived amino acid sequence of protein HMWl (SEQ ID No: 2) ; Figures 3A to 3G contain the DNA sequence of a gene coding for protein HMW2 (SEQ ID No: 3) . The open hmw2A open reading frame extends from nucleotides 382 to 4782; Figures 4A and 4B contain the derived amino acid sequence of HMW2 (SEQ ID No: 4) ; Figure 5A shows restriction maps of representative reco binant phages which contained the HMWl or HMW2 structural genes and of HMWl plasmid subclones. The shaded boxes indicate the location of the structural genes. In the recombinant phage, transcription proceeds from left to right for the HMWl gene and from right to left for the HMW2 gene; Figure 5B shows the restriction map of the T7 expression vector pT7-7. This vector contains the T7 RNA polymerase promoter ΦlO, a ribosomal binding site (rbs) and the translational start site for the T7 gene 10 protein upstream from a multiple cloning site; Figures 6A to 6L contain the DNA sequence of a gene cluster for the h wl gene (SEQ ID NO: 5) , comprising nucleotides 351 to 4958 (ORF a) (as in Figure 1) , as well as two additional downstream genes in the 3' flanking region, comprising ORFs b, nucleotides 5114 to 6748 and c nucleotides 7062 to 9011; Figures 7A to 7L contain the DNA sequence of a gene cluster for the hmw2 gene (SEQ ID NO: 6) , comprising nucleotides 792 to 5222 (ORF a) (as in Figure 3) , as well as two additional downstream genes in the 3' flanking region, comprising ORFs b_, nucleotides 5375 to 7009, and c, nucleotides 7249 to 9198; Figures 8A and 8B contain the DNA sequence of a gene coding for protein HMW3 (SEQ ID NO: 7) ; Figures 9A and 9B contain the DNA sequence of a gene coding for protein HMW4 (SEQ ID NO: 8) ; Figures 10A to 10L contain a comparison table for the derived amino acid sequence for proteins HMWl (SEQ ID No: 2), HMW2 (SEQ ID No: 4), HMW3 (SEQ ID No: 9) and HMW4 (SEQ ID No: 10) ; Figure 11 illustrates a Western immunoblot assay of phage lysates containing either the HMWl or HMW2 recombinant proteins. Lysates were probed with an E. coli-absorbed adult serum sample with high-titer antibody against high molecular weight proteins. The arrows indicate the major immunoreactive bands of 125 and 120 kDa in the HMWl and HMW2 lysates respectively; Figure 12 is a Western immunoblot assay of cell sonicates prepared from E. coli transformed with plasmid pT7-7 (lanes 1 and 2), pHMWl-2 (lanes 3 and 4), pHMWl-4 (lanes 5 and 6) or pHMWl-14 (lanes 7 and 8) . The sonicates were probed with an E. co1i-absorbed adult serum sample with high-titer antibody against high- molecular weight proteins. Lanes labelled U and I sequence sonicates prepared before and after indication of the growing samples with IPTG, respectively. The arrows indicate protein bands of interest as discussed below; Figure 13 is a graphical illustration of an ELISA with rHMWl antiserum assayed against purified filamentous haemagglutinin of B. pertussis. Ab «= antibody; Figure 14 is a Western immunoblot assay of cell sonicates from a panel of epidemiologically unrelated non-typeable H. influenzae strains. The sonicates were probed with rabbit antiserum prepared against HMW1-4 recombinant protein. The strain designations are indicated by the numbers below each line; Figure 15 is a Western immunoblot assay of cell sonicates from a panel of epidemiologically unrelated non-typeable H. influenzae strains. The sonicates were probed with monoclonal antibody X3C, a urine lgG antibody which recognizes the filamentous hemagglutinin of B. pertussis. The strain designations are indicated by the numbers below each line; Figure 16 shows an immunoblot assay of cell sonicates of non-typeable H. influenzae strain 12 derivatives. The sonicates were probed with rabbit antiserum prepared against HMW-1 recombinant protein. Lanes: 1, wild-type strain; 2, HMW2" mutant; 3, HMWl" mutant; 4. HMWl" HMW2" double mutant; Figure 17 shows middle ear bacterial counts in PBS- immunized control animals (left panel) and HMW1/HMW2- immunized animals (right panel) seven days after middle ear inoculation with non-typeable Haemophilus influenzae strain 12. Data are log-transformed and the horizontal lanes indicate the means and standard deviations of middle ear fluid bacterial counts for only the infected animals in each group; Figure 18 is a schematic diagram of pGEMEX»-hmwl recombinant plasmids. The restriction enzymes are B- BamHl, E-EcoRI, C-Clai, RV-EcoRV, Bst-BstEII and H- Jϊindlll; Figure 19 is a schematic diagram of pGEMEX»-hmw2 recombinant plasmids. The restriction enzymes are E- EcoRI, H-HjjQdlll, Hc-HincII, M-M2ul and X-XIIQI; Figure 20 is an immunoelectron micrograph of representative non-typeable Haemophilus influenzae strains after incubation with monoclonal antibody AD6 followed by incubation with goat anti-mouse IgG conjugated with 10~nm colloidal gold particles. Strains are: upper left panel-strain 12; upper right panel-strain 12 mutant deficient in expression of the high molecular weight proteins; lower left panel-strain 5; lower right panel-strain 15; Figure 21 is a Western immunoblot assay with Mab AD6 and HMWl or HMW2 recombinant proteins. The upper left panel indicates the segments of hmwlA or hmw2A structural genes which are being expressed in the recombinant proteins. The lane numbers correspond to the indicated segments; Figure 22 is a Western immunoblot assay with MAb 10C5 and HMWl or HMW2 recombinant proteins. The upper panel indicates the segments of the hmwlA or hmw2A structural genes which are being expressed in the recombinant proteins. The lane numbers correspond to the indicated segments; and Figure 23 is a Western immunoblot assay with MAb AD6 and a panel of unrelated non-typeable Haemophilus influenzae strains which express HMWl/HMW-2 like protein. Cell sonicates were prepared from freshly grown samples of each strain prior to analysis in the Western blot. GENERAL DESCRIPTION OF INVENTION The DNA sequences of the genes coding for the HMWl and HMW2 proteins of non-typeable Haemophilus influenzae strain 12, shown in Figures 1 and 3 respectively, were shown to be about 80% identical, with the first 1259 base pairs of the genes being identical. The open reading frame extend from nucleotides 351 to 4958 and from nucleotide 382 to 4782 respectively. The derived amino acid sequences of the two HMW proteins, shown in Figures 2 and 4 respectively, are about 70% identical. Furthermore, the encoded proteins are antigenically related to the filamentous hemagglutinin surface protein of Bordetella pertussis. A monoclonal antibody prepared against filamentous hemagglutinin (FHA) of Bordetella pertussis was found to recognize both of the high molecular weight proteins. This data suggests that the HMW and FHA proteins may serve similar biological functions. The derived amino acid sequences of the HMWl and HMW2 proteins show sequence similarity to that for the FHA protein. It has further been shown that these antigenically-related proteins are produced by the majority of the non-typeable strains of Haemophilus. Antisera raised against the protein expressed by the HMWl gene recognizes both the HMW2 protein and the B. pertussis FHA. The present invention includes an isolated and purified high molecular weight protein of non-typeable haemophilus which is antigenically related to the B. pertussis FHA and which may be obtained from natural sources or produced recombinantly. A phage genomic library of a known strain of non-typeable Haemophilus was prepared by standard methods and the library was screened for clones expressing high molecular weight proteins, using a high titre antiserum against HMW's. A number of strongly reactive DNA clones were plaque-purified and sub-cloned into a T7 expression plasmid. It was found that they all expressed either one or the other of the two high-molecular-weight proteins designated HMWl and HMW2, with apparent molecular weights of 125 and 120 kDa, respectively, encoded by open reading frames of 4.6 kb and 4.4 kb, respectively. Representative clones expressing either HMWl or HMW2 were further characterized and the genes isolated, purified and sequenced. The DNA sequence of HMWl is shown in Figure l and the corresponding derived amino acid sequence in Figure 2. Similarly, the DNA sequence of HMW2 is shown in Figure 3 and the corresponding derived amino acid sequence in Figure 4. Partial purification of the isolated proteins and N-terminal sequence analysis indicated that the expressed proteins are truncated since their sequence starts at residue number 442 of both full length HMWl and HMW2 gene products. Subcloning studies with respect to the hmwl and hmw2 genes indicated that correct processing of the HMW proteins required the products of additional downstream genes. It has been found that both the hmwl and hmw2 genes are flanked by two additional downstream open reading frames (ORFs) , designated b_ and c, respectively, (see Figures 6 and 7) . The b_ ORFs are 1635 bp in length, extending from nucleotides 5114 to 6748 in the case of hmwl and nucleotides 5375 to 7009 in the case of hmw2. with their derived amino acid sequences being 99% identical. The derived amino acid sequences demonstrate similarity with the derived amino acid sequences of two genes which encode proteins required for secretion and activation of hemolysins of P. mirabilis and S. marcescens. The c ORFs are 1950 bp in length, extending from nucleotides 7062 to 9011 in the case of hmwl and nucleotides 7249 to 9198 in the case of hmw2. with their derived amino acid sequences 96% identical. The hmwl c. ORF is preceded by a series of 9 bp direct tandem repeats. In plasmid εubcloneε, interruption of the hmwl b or c ORF results in defective processing and secretion of the hmwl structural gene product. The two high molecular weight proteins HMWl and HMW2 have been isolated and purified by the procedures described below in the Examples and shown to be protective against otitis media in chinchillas and to function as adhesins. These results indicate the potential for use of such high molecular proteins and structurally-related proteins of other non-typeable strains of Haemophilus influenzae as components in immunogenic compositions for protecting a susceptible host, such as a human infant, against disease caused by infection with non-typeable Haemophilus influenzae. Since the proteins provided herein are good cross-reactive antigens and are present in the majority of non-typeable Haemophilus strains, it is evident that these HMW proteins may become integral constituents of a universal Haemophilus vaccine. Indeed, these proteins may be used not only as protective antigens against otitis, sinusitis and bronchitis caused by the non-typeable Haemophilus strains, but also may be used as carriers for the protective Hib polysaccharideε in a conjugate vaccine against meningitis. The proteins also may be used as carriers for other antigens, haptens and polysaccharides from other organisms, so as to induce immunity to such antigens, haptens and polysaccharides. The nucleotide sequences encoding two high molecular weight proteins of a different non-typeable Haemophilus strain (designated HMW3 and HMW4) , namely strain 5 have been elucidated, and are presented in Figures 8 and 9 (SEQ ID Nos: 7 and 8) . HMW3 has an apparent molecular weight of 125 kDa while HMW4 has an apparent molecular weight of 123 kDa. These high molecular weight proteins are antigenically related to the HMWl and HMW2 proteins and to FHA. Figure 10 contains a multiple sequence comparison of the derived amino acid sequences for the four high molecular weight proteins identified herein (HMWl, SEQ ID No: 2; HMW2, SEQ ID No: 4; HMW3, SEQ ID No: 9; HMW4, SEQ ID No. 10). As may be seen from this comparison, stretches of identical amino acid sequence may be found throughout the length of the comparison, with HMW3 more closely resembling HMWl and HMW4 more closely resembling HMW2. This information is highly suggestive of a considerable sequence homology between high molecular weight proteins from various non-typeable Haemophilus strains. This information is also suggestive that the HMW3 and HMW4 proteins will have the same immunological properties as the HMWl and HMW2 proteins and that corresponding HMW proteins from other non- typeable Haemophilus strains will have the same immunological properties as the HMWl and HMW2 proteins. In addition, mutants of non-typeable H. influenzae strains that are deficient in expression of HMWl or HMW2 or both have been constructed and examined for their capacity to adhere to cultured human epithelial cells. The hmwl and hmw2 gene clusters have been expressed in E. coli and have been examined for in vitro adherence. The results of such experimentation, described below, demonstrate that both HMWl and HMW2 mediate attachment and hence are adhesins and that this function is present even in the absence of other H. influenzae surface structures. The ability of a bacterial surface protein to function as an adhesin provides strong in vitro evidence for its potential role as a protective antigen. In view of the considerable sequence homology between the HMW3 and HMW4 proteins and the HMWl and HMW2 proteins, these results indicate that HMW3 and HMW4 also are likely to function as adhesins and that other HMW proteins of other strains of non-typeable Haemophilus influenzae similarly are likely to function as adhesins. This expectation is borne out by the results described in the Examples below. With the isolation and purification of the high molecular weight proteins, the inventor is able to determine the major protective epi opes of the proteins by conventional epitope mapping and synthesizing peptides corresponding to these determinants for incorporation into fully synthetic or recombinant vaccines. Accordingly, the invention also comprises a synthetic peptide having at least six and no more than 150 amino acids and having an amino acid sequence corresponding to at least one protective epitope of a high molecular weight protein of a non-typeable Haemophilus influenzae. Such peptides are of varying length that constitute portions of the high molecular weight proteins, that can be used to induce immunity, either directly or as part of a conjugate, against the respective organisms and thus constitute active components of immunogenic compositions for protection against the corresponding diseases. In particular, the applicant has sought to identify regions of the high molecular weight proteins which are demonstrated experimentally to be surface-exposed B-cell epitopeε and which are common to all or at least a large number of non-typeable strains of Haemophilus influenzae. The strategy which has been adopted by the inventor has been to: (a) generate a panel of monoclonal antibodies reactive with the high molecular weight proteins; (b) screen those monoclonal antibodies for reactivity with surface epitopes of intact bacteria using immunoelectron microεcopy or other suitable screening technique; (c) map the epitopes recognized by the monoclonal antibody by determining the reactivity of the monoclonals with a panel of recombinant fusion proteins; and (d) determining the reactivity of the monoclonal antibodieswithheterologous non-typableHaemophilus influenzae strains using standard Western blot assays. Using this approach, the inventor has identified one monoclonal antibody, designated AD6 (ATCC ) , which recognized a surface-exposed B-cell epitope common to all non-typeable H. influenzae which express the HMWl and HMW2 proteins. The epitope recognized by this antibody was mapped to a 75 amino acid sequence at the carboxy termini of both HMWl and HMW2 proteins. The ability to identify shared surface-exposed epitopes on the high molecular weight adhesion proteins suggests that it would be possible to develop recombinant or synthetic peptide based vaccines which would be protective against disease caused by the majority of non-typeable Haemophilus influenzae. The present invention also provides any variant or fragment of the proteins that retains the potential immunological ability to protect against disease caused by non-typeable Haemophilus strains. The variants may be constructed by partial deletions or mutations of the genes and expression of the resulting modified genes to give the protein variants. It is clearly apparent to one skilled in the art, that the various embodiments of the present invention have many applications in the fields of vaccination, diagnosis, treatment of bacterial infections and the generation of immunological reagents. A further non- limiting discussion of such useε is further presented below. 1. Vaccine Preparation and Use Immunogenic compositions, suitable to be used as vaccines, may be prepared from the high molecular weight proteins of Haemophilus influenzae. as well as analogs and fragmentε thereof, and εynthetic peptides containing epitopes of the protein, as disclosed herein. The immunogenic composition elicits an immune response which produces antibodies, including anti-high molecular weight protein antibodies and antibodies that are opsonizing or bactericidal. Immunogenic compositions, including vaccines, maybe prepared as injeσtableε, aε liquid solutions or emulsionε. The active component may be mixed with pharmaceutically acceptable excipientε which are compatible therewith. Such excipients may include, water, saline, dextrose, glycerol, ethanol, and combinations thereof. The immunogenic compositions and vaccines may further contain auxiliary substances, such as wetting or emulsifying agents, pH buffering agents, or adjuvants to enhance the effectiveness thereof. Immunogenic compositions and vaccines may be administered parenterally, by injection subcutaneously or intramuscularly. Alternatively, the immunogenic compositionε formed according to the present invention, may be formulated and delivered in a manner to evoke an immune response at mucosal εurfaceε. Thus, the immunogenic composition may be administered to mucosal surfaces by, for example, the nasal or oral (intragastric) routes. Alternatively, other modes of administration including suppositories and oral formulations may be desirable. For suppositories, binders and carriers may include, for example, polyalkalene glycols or triglycerides. Oral formulations may include normally employed incipients such as, for example, pharmaceutical grades of saccharine, cellulose and magnesium carbonate. These compositions can take the form of solutions, suspensionε, tabletε, pills, capsules, sustained release formulations or powders and contain about l to 95% of the active component. The immunogenic preparations and vaccines are administered in a manner compatible with the dosage formulation, and in such amount aε will be therapeutically effective, protective and immunogenic. The quantity to be administered depends on the subject to be treated, including, for example, the capacity of the individual's immune system to synthesize antibodies, and if needed, to produce a cell-mediated immune response. Precise amounts of active ingredient required to be administered depend on the judgment of the practitioner. However, suitable dosage ranges are readily determinable by one skilled in the art and may be of the order of micrograms of the HMW proteins. Suitable regimes for initial administration and booster doses are also variable, but may include an initial administration followed by subsequent administrations. The dosage may also depend on the route of administration and will vary according to the size of the host. The concentration of the active component in an immunogenic composition according to the invention is in general about 1 to 95%. A vaccine which contains antigenic material of only one pathogen is a monovalent vaccine. Vaccines which contain antigenic material of several pathogens are combined vaccines and also belong to the present invention. Such combined vaccines contain, for example, material from various pathogens or from various strains of the same pathogen, or from combinations of various pathogens. Immunogenicity can be significantly improved if the antigens are co-administered with adjuvants, commonly used as 0.05 to 0.1 percent solution in phosphate- buffered saline. Adjuvants enhance the immunogenicity of an antigen but are not necessarily immunogenic themselveε. Adjuvants may act by retaining the antigen locally near the site of administration to produce a depot effect facilitating a slow, sustained release of antigen to cells of the immune system. Adjuvants can also attract cells of the immune system to an antigen depot and stimulate such cells to elicit immune responses. Immunostimulatory agents or adjuvantε have been uεed for many yearε to improve the host immune responses to, for example, vaccines. Intrinsic adjuvantε, εuch aε lipopolyεaccharideε, normally are the components of the killed or attenuated bacteria used as vaccines. Extrinsic adjuvants are immunomodulatorε which are typically non-covalently linked to antigenε and are formulated to enhance the host immune responses. Thus, adjuvants have been identified that enhance the immune response to antigens delivered parenterally. Some of these adjuvants are toxic, however, and can cause undesirable side-effects, making them unsuitable for use in humans and many animals. Indeed, only aluminum hydroxide and aluminum phosphate (collectively commonly referred to as alum) are routinely used as adjuvants in human and veterinary vaccines. The efficacy of alum in increasing antibody responses to diphtheria and tetanus toxoids is well establiεhed and a HBsAg vaccine has been adjuvanted with alum. While the usefulness of alum is well established for some applications, it has limitations. For example, alum is ineffective for influenza vaccination and inconsistently elicits a cell mediated immune response. The antibodies elicited by alum-adjuvanted antigens are mainly of the IgGl isotype in the mouse, which may not be optimal for protection by some vaccinal agents. A wide range of extrinsic adjuvants can provoke potent immune responses to antigens. These include saponins complexed to membrane protein antigens (immune stimulating complexes) , pluronic polymers with mineral oil, killed mycobacteria in mineral oil, Freund's complete adjuvant, bacterial products, such as muramyl dipeptide (MDP) and lipopolysaccharide (LPS) , as well as lipid A, and liposomes. To efficiently induce humoral immune responses (HIR) and cell-mediated immunity (CMI) , immunogens are often emulsified in adjuvants. Many adjuvants are toxic, inducing granulomas, acute and chronic inflammationε (Freund's complete adjuvant, FCA) , cytolysis (saponins and Pluronic polymers) and pyrogenicity, arthritis and anterior uveitis (LPS and MDP) . Although FCA is an excellent adjuvant and widely used in research, it is not licensed for use in human or veterinary vaccines because of its toxicity. Desirable characteristics of ideal adjuvants include: (1) lack of toxicity; (2) ability to stimulate a long-lasting immune response; (3) simplicity of manufacture and stability in long-term storage; (4) ability to elicit both CMI and HIR to antigens administered by various routes, if required; (5) synergy with other adjuvantε; (6) capability of εelectively interacting with populations of antigen presenting cells (APC) ; (7) ability to specifically elicit appropriate T H 1 or T H 2 cell-specific immune responses; and (8) ability to εelectively increase appropriate antibody isotype levels (for example, IgA) against antigens. U.S. Patent No. 4,855,283 granted to Lockhoff et al on August 8, 1989 which is incorporated herein by reference thereto teaches glycolipid analogues including N-glycosylamide , N-glycoεylureaε and N- glycoεylcarbamateε, each of which iε substituted in the sugar residue by an amino acid, as immuno-modulators or adjuvantε. Thuε, Lockhoff et al. (US Patent No. 4,855,283 and ref. 29) reported that N-glycolipid analogε diεplaying εtructural similarities to the naturally- occurring glycolipids, such as glycosphingolipids and glycoglycerolipidε, are capable of eliciting strong immune responses in both herpes simplex virus vaccine and pseudorabieε viruε vaccine. Some glycolipidε have been εyntheεized from long chain-alkylamines and fatty acids that are linked directly with the sugars through the anomeric carbon atom, to mimic the functions of the naturally occurring lipid residues. U.S. Patent No. 4,258,029 granted to Moloney, incorporated herein by reference thereto, teaches that octadecyl tyrosine hydrochloride (OTH) functioned as an adjuvant when complexed with tetanus toxoid and formalin inactivated type I, II and III poliomyelitis virus vaccine. Also, Nixon-George et al. (ref. 30) , reported that octadecyl esters of aromatic amino acids complexed with a recombinant hepatitis B surface antigen, enhanced the hoεt immune responses against hepatitis B virus. Lipidation of synthetic peptides has also been used to increase their immunogenicity. Thus, Wies uller 1989, describes a peptide with a sequence homologous to a foot- and-mouth disease viral protein coupled to an adjuvant tripalmityl-s-glyceryl-cysteinylserylεerine, being a synthetic analogue of the N-terminal part of the lipoprotein from Gram negative bacteria. Furthermore, Dereε et al. 1989, reported in vivo priming of virus- specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine which comprised of modified synthetic peptides derived from influenza virus nucleoprotein by linkage to a lipopeptide, N-palmityl-s-[2,3- bis(palmitylxy)-(2RS)-propyl-[R]-cyεteine (TPC) . 2. immunoassays The high molecular weight protein of Haemophilus influenzae of the present invention is useful as an immunogen for the generation of anti-protein antibodies, as an antigen in immunoasεayε including enzyme-linked immunosorbent assays (ELISA) , RIAs and other non-enzyme linked antibody binding assays or procedures known in the art for the detection of antibodies. In ELISA assays, the protein is immobilized onto a selected surface, for example, a surface capable of binding proteins, such as the wells of a polystyrene icrotiter plate. After washing to remove incompletely adsorbed protein, a nonspecific protein, such as a solution of bovine serum albumin (BSA) that is known to be antigenically neutral with regard to the test sample, may be bound to the selected surface. This allows for blocking of nonspecific adsorption sites on the immobilizing surface and thus reduces the background caused by nonspecific bindings of antisera onto the surface. The immobilizing surface is then contacted with a sample, such as clinical or biological materials, to be tested in a manner conducive to immune complex (antigen/antibody) formation. This may include diluting the sample with diluents, such as solutions of BSA, bovine gamma globulin (BGG) and/or phosphate buffered saline (PBS)/Tween. The sample is then allowed to incubate for from about 2 to 4 hours, at temperatures such as of the order of about 25 * to 37 * C. Following incubation, the sample-contacted surface is washed to remove non-immunocomplexed material. The washing procedure may include washing with a solution, such as PBS/Tween or a borate buffer. Following formation of specific immunocomplexes between the teεt sample and the bound protein, and subsequent washing, the occurrence, and even amount, of immunocomplex formation may be determined by subjecting the immunocomplex to a second antibody having specificity for the first antibody. If the test sample is of human origin, the second antibody is an antibody having specificity for human immunoglobulins and in general IgG. To provide detecting means, the second antibody may have an associated activity such aε an enzymatic activity that will generate, for example, a colour development upon incubating with an appropriate chromogenic substrate. Quantification may then be achieved by measuring the degree of colour generation using, for example, a viεible spectra spectrophotometer. 3. use of Sequences as Hybridization Probes The nucleotide sequences of the present invention, comprising the sequences of the genes encoding the high molecular weight proteins of specific strains of non- typeable Haemophilus influenzae f now allow for the identification and cloning of the genes from any species of non-typeable Haemophilus and other strains of non- typeable Haemophilus influenzae. The nucleotide sequences comprising the sequences of the genes of the present invention are useful for their ability to selectively form duplex molecules with complementary stretches of other genes of high molecular weight proteins of non-typeable Haemophilus. Depending on the application, a variety of hybridization conditions may be employed to achieve varying degrees of selectivity of the probe toward the other genes. For a high degree of selectivity, relatively stringent conditions are used to form the duplexes, such as low salt and/or high temperature conditions, such as provided by 0.02 M to 0.15 M NaCl at temperatures of between about 50 * C to 70 * C. For some applications, less stringent hybridization conditions are required such as 0.15 M to 0.9 M salt, at temperatures ranging from between about 20 * C to 55 * C. Hybridization conditions can also be rendered more stringent by the addition of increasing amounts of formamide, to destabilize the hybrid duplex. Thus, particular hybridization conditions can be readily manipulated, and will generally be a method of choice depending on the desired results. In general, convenient hybridization temperatures in the presence of 50% formamide are: 42 * C for a probe which is 95 to 100% homologous to the target fragment, 37 * C for 90 to 95% homology and 32 * C for 85 to 90% homology. ' In a clinical diagnostic embodiment, the nucleic acid sequences of the genes of the present invention may be used in combination with an appropriate means, such as a label, for determining hybridization. A wide variety of appropriate indicator means are known in the art, including radioactive, enzymatic or other ligands, such as avidin/biotin, which are capable of providing a detectable signal. In some diagnostic embodiments, an enzyme tag such as urease, alkaline phosphatase or peroxidase, instead of a radioactive tag may be used. In the case of enzyme tags, colorimetric indicator substrates are known which can be employed to provide a means viεible to the human eye or εpectrophotometrically, to identify specific hybridization with samples containing gene sequences encoding high molecular weight proteins of non-typeable Haemophilus. The nucleic acid sequences of genes of the present invention are useful as hybridization probes in solution hybridizations and in embodiments employing solid-phase procedures. In embodiments involving solid-phase procedures, the test DNA (or RNA) from samples, such as clinical samples, including exudates, body fluids (e. g. , serum, amniotic fluid, middle ear effusion, sputum, bronchoalveolar lavage fluid) or even tissues, is adsorbed or otherwiεe affixed to a εelected matrix or εurface. The fixed, single-stranded nucleic acid is then subjected to specific hybridization with selected probes comprising the nucleic acid sequences of the genes or fragments thereof of the present invention under desired conditions. The selected conditions will depend on the particular circumstances based on the particular criteria required depending on, for example, the G+C contents, type of target nucleic acid, source of nucleic acid, size of hybridization probe etc. Following washing of the hybridization surface so as to remove non-specifically bound probe molecules, specific hybridization is detected, or even quantified, by means of the label. As with the selection of peptides, it is preferred to select nucleic acid sequence portions which are conserved among specieε of non-typeable Haemophiluε. The selected probe may be at leaεt about 18 bp and may be in the range of about 30 bp to about 90 bp long. 4. Expression of the High Molecular Weight Protein Genes Plaεmid vectors containing replicon and control sequences which are derived from species compatible with the host cell may be used for the expression of the genes encoding high molecular weight proteins of non-typeable Haemophilus in expression systems. The vector ordinarily carries a replication site, as well as marking sequences which are capable of providing phenotypic selection in transformed cells. For example, E. coli may be transformed using pBR322 which contains genes for ampicillin and tetracycline resistance and thus provides easy means for identifying transformed cells. The pBR322 plaεmid, or other microbial plaεmid or phage must also contain, or be modified to contain, promoters which can be used by the host cell for expression of its own proteins. In addition, phage vectors containing replicon and control sequences that are compatible with the host can be used as a transforming vector in connection with these hosts. For example, the phage in lambda GEM™-ll may be utilized in making recombinant phage vectors which can be used to transform host cells, such as E. coli LE392. Promoters commonly used in recombinant DNA construction include the 3-lactamase (penicillinase) and lactose promoter systems (Chang et al., 1978: Itakura et al . , 1977 Goeddel et al . , 1979; Goeddel et al . , 1980) and other microbial promoters such as the T7 promoter system (U.S. Patent 4,952,496). Details concerning the nucleotide sequences of promoters are known, enabling a skilled worker to ligate them functionally with genes. The particular promoter used will generally be a matter of choice depending upon the desired results. Hosts that are appropriate for expression of the genes encoding the high molecular weight proteins, fragment analogs or variants thereof, include E. coli f Bacillus species, Haemophilus. fungi, yeast or the baculovirus expresεion system may be used. In accordance with this invention, it is preferred to make the high molecular weight proteins by recombinant methods, particularly since the naturally occurring high molecular weight protein as purified from a culture of a species of non-typeable Haemophilus may include trace amounts of toxic materials or other contaminants. This problem can be avoided by using recombinantly produced proteins in heterologous εystems which can be isolated from the host in a manner to minimize comtaminants in the purified material. Particularly desirable hosts for expression in this regard include Gram positive bacteria which do not have LPS and are, therefore, endotoxin free. Such hosts include specieε of Bacillus and may b e particularly useful for the production of non-pyrogenic high molecular weight protein, fragments or analogs thereof. Furthermore, recombinant methods of production permit the manufacture of HMWl, HMW2, HMW3 or HMW4, and corresponding HMW proteins from other non-typeable Haemophilus influenzae strains, or fragments thereof, separate from one another and devoid of non-HMW protein of non-typeable Haemophilus influenzae. Biological Deposits Certain hybridomas producing monoclonal antibodies specific for high molecular weight protein of Haemophilus influenzae according to aspects of the present invention that are described and referred to herein have been deposited with the American Type Culture Collection (ATCC) located at 12301 Parklawn Drive, Rockville, Maryland, USA, 20852, pursuant to the Budapest Treaty and prior to the filing of this application. Samples of the deposited hybridomas will become available to the public upon grant of a patent based upon this United Stateε patent application. The invention described and claimed herein is not to be limited in scope by the hybridomas deposited, since the deposited embodiment is intended only as an illustration of the invention. Any equivalent or similar hybridomas that produce similar or equivalent antibodies aε described in this application are within the scope of the invention. Deposit Summary Hybridomas ATCC Designation Date Deposited AD6 10C5 EXAMPLES The above disclosure generally describeε the present invention. A more complete understanding can be obtained by reference to the following specific Examples. These Examples are described solely for purposes of illustration and are not intended to limit the scope of the invention. Changes in form and substitution of equivalents are contemplated as circumstances may suggest or render expedient. Although specific terms have been employed herein, such terms are intended in a descriptive sense and not for purposes of limitations. Methods of molecular genetics, protein biochemistry, and immunology used but not explicitly described in this discloεure and theεe Examples are amply reported in the scientif c literature and are well within the ability of those skilled in the art. Example 1: This Example describes the isolation of DNA encoding HMWl and HMW2 proteins, cloning and expression of such proteins, and sequencing and sequence analysis of the DNA molecules encoding the HMWl and HMW2 proteins. Non-typeable H.influenzae strains 5 and 12 were isolated in pure culture from the middle ear fluid of children with acute otitis media. Chromosomal DNA from strain 12, providing genes encoding proteins HMWl and HMW2, was prepared by preparing Sau3A partial restriction digests of chromosomal DNA and fractionating on sucrose gradients. Fractions containing DNA fragments in the 9 to 20 kbp range were pooled and a library was prepared by ligation into XEMBL3 arms. Ligation mixtures were packaged in vitro and plate-amplified in a P2 lysogen of E. coli LE392. For plaεmid subcloning studies, DNA from a representative recombinant phage was εubcloned into the T7 expression plasmid pT7-7, containing the T7 RNA polymerase promoter ΦlO, a ribosome-binding site and the translational start site for the T7 gene 10 protein upstream from a multiple cloning site (see Figure 5B) . DNA sequence analysiε was performed by the dideoxy method and both εtrands of the HMWl gene and a single strand of the HMW2 gene were sequenced. Western immunoblot analysis was performed to identify the recombinant proteins being produced by reactive phage clones (Figure 11) . Phage lysates grown in LE392 cells or plaques picked directly from a lawn of LE392 cells on YT plates were solubilized in gel electrophoresis sample buffer prior to electrophoresis. Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was performed on 7.5% or 11% polyacrylamide modified Laemmli gels. After transfer of the proteins to nitrocellulose sheets, the sheets were probed sequentially with an E. coli-absorbed human serum sample containing high-titer antibody to the high-molecular- weight proteins and then with alkaline phosphataεe- conjugated goat anti-human immunoglobulin G (IgG) second antibody. Sera from healthy adults contains high-titer antibodydirected against surface-exposedhigh-molecular- weight proteins of non-typeable H. influenzae. One such serum sample was used aε the screening antiserum after having been extensively absorbed with LE392 cells. To identify recombinant proteins being produced by E. coli transformed with recombinant plasmids, the plasmids of interest were used to transform E. coli BL21 (DE3)/pLysS. The transformed strains were grown to an A β oo of 0.5 in L broth containing 50 μg of ampicillin per ml. IPTG was then added to 1 mM. One hour later, cells were harvested, and a sonicate of the cells was prepared. The protein concentrations of the samples were determined by the bicinchoninic acid method. Cell sonicates containing 100 μg of total protein were solubilized in electrophoresis sample buffer, subjected to SDS- polyacrylamide gel electrophoresis, and transferred to nitrocellulose. The nitrocellulose was then probed sequentially with the E. coli-abεorbed adult serum sample and then with alkaline phosphataεe-conjugated goat anti- human IgG second antibody. Western immunoblot analysis also was performed to determine whether homologous and heterologous non- typeable H. influenzae strains expressed high-molecular- weight proteins antigenically related to the protein encoded by the cloned HMWl gene (rHMWl) . Cell sonicates of bacterial cells were solubilized in electrophoresis sample buffer, subjected to SDS-polyacrylamide gel electrophoresis, and transferred to nitrocellulose. Nitrocellulose was probed sequentially with polyclonal rabbit rHMWl antiserum and then with alkaline phosphatase-conjugated goat anti-rabbit IgG second antibody. Finally, Western immunoblot analysis was performed to determine whether non-typeable Haemophilus strains expressed proteins antigenically related to the filamentous hemagglutinin protein of Bordetella pertuεεis. Monoclonal antibody X3C, a murine immunoglobulin G (IgG) antibody which recognizeε filamentous hemagglutinin, was uεed to probe cell sonicates by Western blot. An alkaline phosphatase- conjugated goat anti-mouse IgG second antibody was used for detection. To generate recombinant protein antiserum, E. coli BL21(DE3)/pLysS was transformed with pHMWl-4, and expresεion of recombinant protein waε induced with IPTG, aε described above. A cell sonicate of the bacterial cells was prepared and εeparated into a supernatant and pellet fraction by centrifugation at 10,000 x g for 30 min. The recombinant protein fractionated with the pellet fraction. A rabbit was subcutaneously immunized on biweekly schedule with 1 mg of protein from the pellet fraction, the first dose given with Freund's complete adjuvant and subsequent doses with Freund's incomplete adjuvant. Following the fourth injection, the rabbit was bled. Prior to use in the Western blot assay, the antiserum was absorbed extensively with sonicates of the host E. coli strain transformed with cloning vector alone. To assess the sharing of antigenic determinants between HMWl and filamentous hemagglutinin, enzyme-linked immunosorbent assay (ELISA) plates (Costar, Cambridge, Masε.) were coated with 60 μl of a 4-μg/ml solution of filamentous hemagglutinin in Dulbecco's phosphate- buffered saline per well for 2 h at room temperature. Wellε were blocked for 1 h with 1% bovine serum albumin in Dulbecco's phosphate-buffered saline prior to addition of serum dilutions. rHMWl antiserum was serially diluted in 0.1% Brij (Sigma, St. Louis, Mo.) in Dulbecco's phosphate-buffered saline and incubated for 3 h at room temperature. After being washed, the plates were incubated with peroxidase-conjugated goat anti-rabbit IgG antibody (Bio-Rad) for 2 h at room temperature and subse¬ quently developed with 2 , 2 ' -azino-bis (3- ethylbenzthiazoline-6-εulfonic acid) (Sigma) at a concentration of 0.54 in mg/ml in 0.1 M εodium citrate buffer, pH 4.2, containing 0.03% Αp 2 . Absorbances were read on an automated ELISA reader. Recombinant phage expressing HMWl or HMW2 were recovered as follows. The non-typeable H. influenzae strain 12 genomic library was screened for clones expressing high-molecular-weight proteins with an E A . coli-absorbed human serum sample containing a high titer of antibodies directed against the high-molecular-weight proteins. Numerous strongly reactive clones were identified along with more weakly reactive ones. Twenty strongly reactive clones were plaque-purified and examined by Western blot for expresεion of recombinant proteinε. Each of the strongly reactive clones expressed one of two types of high-molecular-weight proteins, designated HMWl and HMW2. The major immunoreactive protein bands in the HMWl and HMW2 lysates migrated with apparent molecular masses of 125 and 120 kDa, respectively. In addition to the major bands, each lysate contained minor protein bands of higher apparent molecular weight. Protein bands seen in the HMW2 lysates at molecular masses of less than 120 kDa were not regularly observed and presumably represent proteolytic degradation products. Lysates of LE 92 infected with the λEMBL3 cloning vector alone were non-reactive when immunologically screened with the same serum εample. Thus, the observed activity was not due to cross-reactive E. coli proteins or XEMBL3-encoded pro- teins. Furthermore, the recombinant proteins were not simply binding immunoglobulin nonspecifically, since the proteins were not reactive with the goat anti-human IgG conjugate alone, with normal rabbit sera, or with serum from a number of healthy young infants. Representative clones expressing either the HMWl or HMW2 recombinant proteins were characterized further. The restriction maps of the two phage types were different from each other, including the regions encoding the HMWl and HMW2 structural genes. Figure 5A shows restriction maps of representative recombinant phage which contained the HMWl or HMW2 structural genes. The locations of the structural genes are indicated by the shaded bars. HMWl plasmid subcloneε were constructed by using the T7 expression plasmid T7-7 (Fig. 5A and B) . HMW2 plasmid subclones also were constructed, and the results with these latter subclones were similar to those observed with the HMWl conεtructs. The approximate location and direction of transcription of the HMWl structure gene were initially determined by using plaεmid pHMWl (Fig. 5A) . This plasmid was constructed by inserting the 8.5-kb Ba HI- Sall fragment from λHMWl into BamHI- and Sail-cut pT7-7. E. coli transformed with pHMWl expressed an immunoreactive recombinant protein with an apparent molecular mass of 115 kDa, which was strongly inducible with IPTG. This protein waε εignificantly smaller than the 125-kDa major protein expressed by the parent phage, indicating that it either was being expressed as a fusion protein or was truncated at the carboxy terminus. To more precisely localize the 3' end of the structural gene, additional plasmids were constructed with progressive deletions from the 3' end of the pHMWl construct. Plasmid pHMWl-1 was constructed by digestion of pHMWl with PstI, isolation of the resulting 8.8-kb fragment, and religation. Plasmid pHMWl-2 was constructed by digestion of pHMWl with Hindlll, isolation of the resulting 7.5-kb fragment, and religation. E. coli transformed with either plasmid pHMWl-1 or pHMWl-2 also expressed an immunoreactive recombinant protein with an apparent molecular mass of 115 kDa. These results indicated that the 3' end of the structural gene was 5' of the Hindlll site. Figure 12 demonstrates the Western blot resultε with pHMWl-2 transformed cells before and after IPTG indicates (lanes 3 and 4, respectively). The 115 kDa recombinant protein is indicated by the arrow. Transformants also demonstrated cross-reactive bands of lower apparent molecular weight, and probably represent partial degradation products. Shown for comparison and the results for E. coli transformed with the pT7-7 cloning vector alone (Fig. 12, lanes 1 and 2) . To more precisely localize the 5' end of the gene, plasmids pHMWl-4 and pHMWl-7 were constructed. Plasmid pHMWl-4 was constructed by cloning the 5.1-kb B_amHI- Hindlll fragment from λHMWl into a pT7-7-derived plasmid containing the upstream 3.8-kb EcoRI-BamHi fragment. E. coli transformed with pHMWl-4 expressed an immunoreactive protein with an apparent molecular mass of approximately 160 kDa (Fig. 12, lane 6). Although protein production was inducible with IPTG, the levels of protein production in these transformants were substantially lower than those with the pHMWl-2 transformants described above. Plasmid pHMWl-7 was constructed by digesting pHMWl-4 with Ndel and Spel. The 9.0-kbp fragment generated by this double digestion was isolated, blunt ended, and religated. E. coli transformed with pHMWl-7 also expressed an immunoreactive protein with an apparent molecular mass of 160 kDa, a protein identical in size to that expressed by the pHMWl-4 transformants. The result indicated that the initiation codon for the HMWl structural gene was 3' of the Spel site. DNA sequence analysis (described below) confirmed this conclusion. As noted above, the λHMWl phage clones expressed a major immunoreactive band of 125 kDa, whereas the HMWl plasmid clones pHMWl-4 and pHMWl-7, which contained what waε believed to be the full-length gene, expreεεed an immunoreactive protein of approximately 160 kDa. Thiε size discrepancy was disconcerting. One possible explanation was that an additional gene or genes necessary for correct processing of the HMWl gene product were deleted in the process of subcloning. To address this possibility, plaεmid pHMWl-14 was constructed. This construct was generated by digesting pHMWl with Ndel and Mlul and inserting the 7.6-kbp Ndel-Mlul fragment isolated from pHMWl-4. Such a construct would contain the full-length HMWl gene as well as the DNA 3' of the HMWl gene which waε present in the original HMWl phage. E. coli transformed with this plasmid expressed major immunoreactive proteins with apparent molecular masses of 125 and 160 kDa as well as additional degradation products (Fig. 12, lanes 7 and 8). The 125- and 160-kDa bands were identical to the major and minor immunoreactive bands detected in the HMWl phage lysates. Interestingly, the pHMWl-14 construct also expressed significant amounts of protein in the uninduced condition, a situation not observed with the earlier constructs. The relationship between the 125- and 160-kDa proteins remains somewhat unclear. Sequence analysis, described below, reveals that the HMWl gene would be predicted to encode a protein of 159 kDa. It is believed that the 160-kDa protein is a precursor form of the mature 125-kDa protein, with the conversion from one protein to the other being dependent on the products of the two downstream genes. Sequence analysis of the HMWl gene (Figure l) revealed a 4,608-bp open reading frame (ORF), beginning with an ATG codon at nucleotide 351 and ending with a TAG stop codon at nucleotide 4959. A putative ribosome- binding site with the sequence AGGAG begins 10 bp up¬ stream of the putative initiation codon. Five other in- frame ATG codons are located within 250 bp of the beginning of the ORF, but none of these is preceded by a typical ribosome-binding site. The 5'-flanking region of the ORF contains a series of direct tandem repeats, with the 7-bp sequence ATCTTTC repeated 16 times. These tandem repeats stop 100 bp 5' of the putative initiation codon. An 8-bp inverted repeat characteristic of a rho- independent transcriptional terminator is present, beginning at nucleotide 4983, 25 bp 3' of the presumed translational stop. Multiple termination codons are present in all three reading frames both upstream and downstream of the ORF. The derived amino acid sequence of the protein encoded by the HMWl gene (Figure 2) has a molecular weight of 159,000, in good agreement with the apparent molecular weights of the proteins expressed by the HMWl-4 and HMW1-7 transformants. The derived amino acid sequence of the amino terminus does not demonstrate the characteristics of a typical signal sequence. The BamHI site used in generation of pHMWl comprises bp 1743 through 1748 of the nucleotide sequence. The ORF downstream of the BamHI site would be predicted to encode a protein of 111 kDa, in good agreement with the 115 kDa estimated for the apparent molecular mass of the pHMWl- encoded fusion protein. The sequence of the HMW2 gene (Figure 3) consists of a 4,431-bp ORF, beginning with an ATG codon at nucleotide 352 and ending with a TAG stop codon at nucleotide 4783. The first 1,259 bp of the ORF of the HMW2 gene are identical to those of the HMWl gene. Thereafter, the sequences begin to diverge but are 80% identical overall. With the exception of a single base addition at nucleotide 93 of the HMW2 sequence, the 5'-flanking regions of the HMWl and HMW2 genes are identical for 310 bp upstream from the respective initiation codons. Thus, the HMW2 gene is preceded by the same set of tandem repeats and the same putative ribosome-binding εite which lies 5' of the HMWl gene. A putative transcriptional terminator identical to that identified 3' of the HMWl ORF iε noted, beginning at nucleotide 4804. The diεcrepancy in the lengthε of the two geneε iε principally accounted for by a 186-bp gap in the HMW2 sequence, beginning at nucleotide position 3839. The derived amino acid sequence of the protein encoded by the HMW2 gene (Figure 4) has a molecular weight of 155,000 and is 71% identical with the derived amino acid sequence of the HMWl gene. The derived amino acid sequences of both the HMWl and HMW2 genes (Figures 2 and 4) demonstrated sequence similarity with the derived amino acid sequence of filamentous hemagglutinin of Bordetella pertussis, a surface-associated protein of this organism. The initial and optimized TFASTA scores for the HMWl-filamentous hemagglutinin sequence comparison were 87 and 186, respectively, with a word size of 2. The z score for the comparison was 45.8. The initial and optimized TFASTA scores for the HMW2-filamentous hemagglutinin sequence comparison were 68 and 196, respectively. The z εcore for the latter compariεon was 48.7. The magnitudes of the initial and optimized TFASTA scoreε and the z scores suggeεted that a biologically εignificant relationεhip exiεted between the HMWl and HMW2 gene products and filamentous hemagglutinin. When the derived amino acid sequences of HMWl, HMW2, and filamentous hemagglutinin genes were aligned and compared, the similarities were most notable at the amino-terminal ends of the three sequences. Twelve of the first 22 amino acids in the predicted peptide sequences were identical. In addition, the sequences demonstrated a common five-amino-acid stretch, Aεn-Pro-Asn-Gly-Ile, and several shorter stretches of sequence identity within the first 200 amino acids. Example 2: This Example describes the relationship of filamentous hemagglutinin and the HMWl protein. To further explore the HMWl-filamentous hemagglutinin relationship, the ability of antiserum prepared against the HMW1-4 recombinant protein (rHMWl) to recognize purified filamentous hemagglutinin was assessed (Figure 13) . The rHMWl antiserum demonstrated ELISA reactivity with filamentous hemagglutinin in a dose-dependent manner. Preimmune rabbit serum had minimal reactivity in this assay. The rHMWl antiserum also was examined in a Western blot assay and demonstrated weak but positive reactivity with purified filamentous hemagglutinin in this system also. To identify the native Haemophilus protein corresponding to the HMWl gene product and to determine the extent to which proteins antigenically related to the HMWl cloned gene product were common among other non- typeable H. influenzae strains, a panel of Haemophilus strains was screened by Western blot with the rHMWl antiserum. The antiserum recognized both a 125- and a 120-kDa protein band in the homologous strain 12 (Figure 14) , the putative mature protein products of the HMWl and HMW2 genes, respectively. The 120-kDa protein appears as a single band in Figure 14, wherein it appeared as a doublet in the HMW2 phage lysates (Figure 11) . When used to screen heterologous non-typeable H. influenzae strains, rHMWl antiserum recognized high- molecular-weight proteins in 75% of 125 epidemiologically unrelated strains. In general, the antiserum reacted with one or two protein bands in the 100- to 150-kDa range in each of the heterologous strainε in a pattern similar but not identical to that seen in the homologous strain (Figure 14) . Monoclonal antibody X3C is a murine IgG antibody directed against the filamentous hemagglutinin protein of B. pertussiε. Thiε antibody can inhibit the binding of B. pertussis cells to Chinese hamster ovary cells and HeLa cells in culture and will inhibit hemagglutination of erythrocytes by purified filamentous hemagglutinin. A Western blot assay was performed in which thiε monoclonal antibody was screened against the same panel of non-typeable H. influenzae strains discussed above (Figure 14) . Monoclonal antibody X3C recognized both the high-molecular-weight proteins in non-typeable H. influenzae strain 12 which were recognized by the reco binant-protein antiserum (Figure 15) . In addition, the monoclonal antibody recognized protein bands in a subεet of heterologous non-typeable H. influenzae strains which were identical to thoεe recognized by the recombinant-protein antiserum, aε may be seen by comparison of Figures 14 and 15. On occasion, the filamentous hemagglutininmonoclonal antibody appeared to recognize only one of the two bands which had been recognized by the recombinant-protein antiserum (compare strain lane 18 in Figures 14 and 15, for example) . Overall, monoclonal antibody X3C recognized high- molecular-weight protein bands identical to those recognized by the rHMWl antiserum in approximately 35% of our collection of non-typeable H. influenzae strains. Example 3: This Example describes the adhesin properties of the HMWl and HMW2 proteins. Mutants deficient in expresεion of HMWl, HMW2 or both proteinε were constructed to examine the role of these proteins in bacterial adherence. The following strategy was employed. pHMWl-14 (see Example 1, Figure 5A) was digested with BamHI and then ligated to a kanamycin cassette isolated on a 1.3-kb BamHI fragment from pUC4K. The resultant plasmid (pHMWl-17) was linearized by digestion with Xbal and transformed into non-typeable H. influenzae strain 12, followed by selection for kanamycin resistant colonies. Southern analysis of a serieε of theεe colonies demonstrated two populations of transformants, one with an insertion in the HMWl structural gene and the other with an insertion in the HMW2. structural gene. One mutant from each of these classes was selected for further studies. Mutants deficient in expression of both proteinε were recovered using the following protocol. After deletion of the 2.1-kb fragment of DNA between two EsρRI siteε spanning the 3'-portion of the HMWl structural gene and the 5'-portion of a downstream gene encoding an aσcesεory proceεεing protein in pHMW-15, the kanamycin cassette from pUC4K was inserted as a 1.3-kb EcoRl fragment. The resulting plasmid (pHMWl-16) waε linearized by digestion with Xbal and transformed into strain 12, followed again by selection for kanamycin resistant colonies. Southern analysis of a representative sampling of theεe colonies demonstrated that in seven of eight cases, insertion into both the HMWl and HMW2 loci had occurred. One εuch mutant was selected for further studies. To confirm the intended phenotypes, the mutant strains were examined by Western blot analysis with a polyclonal antiserum against recombinant HMWl protein. The parental strain expressed both the 125-kD HMWl and the 120-kD HMW2 protein (Figure 16) . In contrast, the HMW2" mutant failed to express the 120-kD protein, and the HMWl mutant failed to express the 125-kD protein. The double mutant lacked expression of either protein. On the basis of whole cell lysates, outer membrane profiles, and colony morphology, the wild type strain and the mutants were otherwise identical with one another. Transmisεion electron microscopy demonstrated that none of the four strains expressed pili. The capacity of wild type strain 12 to adhere to Chang epithelial cells was examined. In such assays, bacteria were inoculated into broth and allowed to grow to a density of -2 x 10 5 cfu/ml. Approximately 2 x 10 7 cfu were inoculated onto epithelial cell monolayers, and plates were gently centrifuged at 165 x g for 5 minuteε to facilitate contact between bacteria and the epithelial surface. After incubation for 30 minutes at 37°C in 5% C0 2 , monolayers were rinsed 5 times with PBS to remove nonadherent organisms and were treated with trypsin-EDTA (0.05% trypsin, 0.5% EDTA) in PBS to release them from the plastic support. Well contents were agitated, and dilutions were plated on solid medium to yield the number of adherent bacteria per monolayer. Percent adherence was calculated by dividing the number of adherent cfu per monolayer by the number of inoculated cfu. As depicted in Table 1 below (the Tables appear at the end of the descriptive text) , this strain adhered quite efficiently, with nearly 90% of the inoculum binding to the monolayer. Adherence by the mutant expressing HMWl but not HMW2 (HMW2 * ) was also quite efficient and comparable to that by the wild type strain. In contrast, attachment by the strain expressing HMW2 but deficient in expression of HMWl (HMWl') was decreased about 15-fold relative to the wild type. Adherence by the double mutant (HMW1-/HMW2") was decreased even further, approximately 50-fold compared with the wild type and approximately 3-fold compared with the HMWl mutant. Considered together, these resultε εuggeεt that both the HMWl protein and the, HMW2 protein influence attachment to Chang epithelial cells. Interestingly, optimal adherence to thiε cell line appearε to require HMWl but not HMW2. Example 4: This Example illustrates the preparation and expression of HMW3 and HMW4 proteins and their function as adhesins. Using the plasmids pHMWl-16 and pHMWl-17 (see Example 3) and following a scheme similar to that employed with strain 12 as described in Example 3, three non-typeable Haemophilus strain 5 mutants were isolated, including one with the kanamycin gene inserted into the hmwl-like (designated hmw3_) locus, a second with an insertion in the hmw2-like (designated hmw4) locus, and a third with insertions in both loci. As predicted, Western immunoblot analysis demonstrated that the mutant with insertion of the kanamycin cassette into the hmwl- like locus had lost expresεion of the HMW3 125-kD protein, while the mutant with insertion into the hmw2- like locus failed to express the HMW4 123-kD protein. The mutant with a double insertion was unable to express either of the high molecular weight proteins. As shown in Table 1 below, wild type strain 5 demonstrated high level adherence, with almost 80% of the inoculum adhering per monolayer. Adherence by the mutant deficient in expression of the HMW2-like protein (i.e. HMW4 protein) was also quite high. In contrast. adherence by the mutant unable to express the HMWi-like protein (i.e. HMW3 protein) was reduced about 5-fold relative to the wild type, and attachment by the double mutant was diminished even further (approximately 25- fold) . Examination of Giemsa-εtained samples confirmed these observations (not shown) . Thus, the results with strain 5 for proteins HMW3 and HMW4 corroborate the findings with strain 12 and the HMWl and HMW2 proteins. Example 5: Thiε Example contains additional data concerning the adhesin properties of the HMWl and HMW2 proteins. To confirm an adherence function for the HMWl and HMW2 proteins and to examine the effect of HMWl and HMW2 independently of other H. influenzae surface structures, the hmwl and the hmw2 gene clusters were introduced into E. coli DH5α, using plasmids pHMWl-14 and pHMW2-21, respectively. As a control, the cloning vector, pT7-7, was also transformed into E. coli DH5α. Western blot analysis demonstrated that E. coli DH5α containing the hmwl genes expressed a 125 kDa protein, while the same strain harboring the hmw2 genes expressed a 120-kDa protein. E. coli DH5α containing pT7-7 failed to react with antiserum against recombinant HMWl. Transmisεion electron microεcopy revealed no pili or other surface appendages on any of the E. coli strains. Adherence by the E. coli strains was quantitated and compared with adherence by wild type non-typeable H. influenzae strain 12. As shown in Table 2 below, adherence by E. coli DH5α containing vector alone was lesε than 1% of that for εtrain 12. In contrast, E. coli DH5 harboring the hmwl gene cluεter demonεtrated adherence levels comparable to those for strain 12. Adherence by E. coli DH5α containing the hmw2 genes was approximately 6-fold lower than attachment by strain 12 but was increased 20-fold over adherence by E. coli DH5α with pT7-7 alone. These results indicate that the HMW l * and HMW2 proteins are capable of independently mediating attachment to Chang conjunctival cells. These results are consistent with the results with the H. influenzae mutants reported in Examples 3 and 4, providing further evidence that, with Chang epithelial cells, HMWl is a more efficient adhesin than is HMW2. Experiments with E. coli HB101 harboring pT7-7, pHMWl-14, or pHMW2-21 confirmed the reεults obtained with the DH5α derivatives (see Table 2). Example 6: This Example illustrates the copurification of HMWl and HMW2 proteinε from wild-type non-typeable H. influenzae strain. HMWl and HMW2 were isolated and purified from non- typeable H. influenzae (NTHI) strain 12 in the following manner. Non-typeable Haemophilus bacteria from frozen stock culture were streaked onto a chocolate plate and grown overnight at 37 β C in an incubator with 5% CO,. 50ml starter culture of brain heart infusion (BHI) broth, supplemented with 10 μg/ml each of hemin and NAD was inoculated with growth on chocolate plate. The starter culture was grown until the optical density (O.D. - 600nm) reached 0.6 to 0.8 and then the bacteria in the starter culture was used to inoculate six 500 ml flasks of supplemented BHI using 8 to 10 ml per flask. The bacteria were grown in 500 ml flasks for an additional 5 to 6 hours at which time the O.D. was 1.5 or greater. Cultures were centrifuged at 10,000 rpm for 10 minuteε. Bacterial pellets were resuspended in a total volume of 250 ml of an extraction solution comprising 0.5 M NaCl, 0.01 M Na 2 EDTA, 0.01 M Triε 50 μM 1,10- phenanthroline, pH 7.5. The cells were not sonicated or otherwise disrupted. The resuspended cells were allowed to sit on ice at 0°C for 60 minuteε. The resuspended cells were centrifuged at 10,000 rpm for 10 minutes at 4 β C to remove the majority of intact cells and cellular debris. The supernatant was collected and centrifuged at 100,000 x g for 60 minutes at 4°C. The supernatant again was collected and dialyzed overnight at 4 C C against 0.01 M sodium phosphate, pH 6.0. The sample was centrifuged at 10,000 rpm for 10 minutes at 4°C to remove insoluble debris precipitated from solution during dialysis. The supernatant was applied to a 10 ml CM Sepharose column which haε been pre-equilibrated with 0.01 M εodium phosphate, pH 6. Following application to thiε column, the column waε washed with 0.01 M sodium phosphate. Proteins were elevated from the column with a 0 - 0.5M KC1 gradient in 0.01 M Na phosphate, pH 6 and fractions were collected for gel examination. Coomassie gels of column fractions were carried out to identify those fractions containing high molecular weight proteins. The fractions containing high molecular weight proteins were pooled and concentrated to a 1 to 3 ml volume in preparation for application of sample to gel filtration column. A Sepharose CL-4B gel filtration column was equilibrated with phosphate-buffered saline, pH 7.5. The concentrated high molecular weight protein sample was applied to the gel filtration column and column fractions were collected. Coomassie gels were performed on the column fractions to identify those containing high molecular weight proteins. The column fractions containing high molecular weight proteins were pooled. Example 7: Thiε Example illustrates the use of specified HMWl and HMW2 proteins in immunization studies. The copurified HMWl and HMW2 proteins prepared as described in Example 6 were tested to determine whether they would protect against experimental otitis media caused by the homologous strain. Healthy adult chinchillas, l to 2 years of age with weights of 350 to 500g, received three monthly subcutaneous injections with 40 μg of an HMW1-HMW 2 protein mixture in Freund's adjuvant. Control animals received phosphate-buffered saline in Freunds' adjuvant. One month after the last injection, the animals were challenged by intrabullar inoculation with 300 cfu of NTHI strain 12. Middle ear infection developed in 5 of 5 control animals versus 5 of 10 immunized animals. Although only 5 of 10 chinchillas were protected in this test, the test conditions are very stringent, requiring bacteria to be injected directly into the middle ear space and to proliferate in what is in essence a small abscess cavity. As seen from the additional data below, complete protection of chinchillas can be achieved. The five HMWl/HMW2-immunized animals that did not develop otitis media demonstrated no signs of middle ear inflammation when examined by otoscopy nor were middle ear effusions detectable. Among the five HMWl/HMW2-immunized animals that became infected, the total duration of middle ear infection as assessed by the persistence of culture- positive middle ear fluid was not different from controls. However, the degree of inflammation of the tympanic membranes was subjectively lesε than in the HMWl/HMW2-immunized animals. When quantitative bacterial counts were performed on the middle ear fluid specimens recovered from infected animals, notable differences were apparent between the HMWl/HMW2-immunized and PBS- immunized animals (Figure 17) . Shown in Figure 17 are quantitative middle ear fluid bacterial counts from animals on day 7 post-challenge, a time point associated with the maximum colony counts in middle ear fluid. The data were log-transformed for purpose of statistical comparison. The data from the control animals are shown on the left and data from the high molecular weight protein immunized animals on the right. The two horizontal lines indicate the respective means and standard derivations of middle ear fluid colony counts for only the infected animals in each group. As can be seen from this Figure, the HMWl/HMW2-immunized animals had significantly lower middle ear fluid bacterial counts than the PBS-immunized controls, geometric means of 7.4 X 10 6 and 1.3 X 10 s , respectively (p=0.02. Students' t- teεt) Serum antibody titres following immunization were comparable in uninfected and infected animals. However, infection in immunized animals was uniformly associated with the appearance of bacteria down-regulated in expression of the HMW proteins, suggesting bacterial selection in response to immunologic pressure. Although this data showε that protection following immunization was not complete, this data suggests the HMW adhesin proteins are potentially important protective antigens which may comprise one component of a multi- component NTHI vaccine. In addition, complete protection has been achieved in the chinchilla model at lower dosage challenge, as set forth in Table 3 below. Groups of five animals were immunized with 20 μg of the HMW1-HMW2 mixture prepared as described in Example 6 on days 1, 28 and 42 in the presence of alum. Blood samples were collected on day 53 to monitor the antibody response. On day 56, the left ear of animals was challenged with about 10 cfu of H. influenzae strain 12. Ear infection was monitored on day 4. Four animals in Group 3 were infected previously by H. influenzae strain 12 and were recovered completely for at least one month before the second challenge. Example 8: This Example illustrates the provision of synthetic peptides corresponding to a portion only of the HMWl protein. A number of synthetic peptides were derived from HMWl. Antisera then were raised to these peptides. The anti-peptide antisera to peptide HMW1-P5 was shown to recognize HMWl. Peptide HMW1-P5 covers amino acids 1453 to 1481 of HMWl, has the sequence VDEVIEAKRILEKVKDLSDEEREALAKLG (SEQ ID No: 11) , and represents bases 1498 to 1576 in Figure 10. This finding demonstrates that the DNA sequence and the derived protein iε being interpreted in the correct reading frame and that peptides derived from the sequence can be produced which will be immunogenic. Example 9: This Example describes the generation of monoclonal antibodies to the high molecular weight proteins of non- typeable H. influenzae. Monoclonal antibodies were generated using standard techniques. In brief, female BALB/c mice (4 to 6 weeks old) were immunized by intraperitoneal injection with high molecular weight proteins purified from nontypable Haemophilus strain 5 or strain 12, as described in Example 6. The first injection of 40 to 50 μg of protein was administered with Freund's complete adjuvant and the second dose, received four to five weeks after the first, was administered with phosphate-buffered saline. Three days following the second injection, the mice were sacrificed and splenic lymphocytes were fused with SP2/0-Agl4 plasmacytoma cells. Two weeks following fusion, hybridoma supernatants were screened for the presence of high molecular weight protein specific antibodies by a dot-blot assay. Purified high molecular weight proteins at a concentration of 10 μg per ml in TRIS-buffered saline (TBS) , were used to senεitize nitrocellulose sheets (Bio- Rad Laboratories, Richmond, CA) by soaking for 20 minutes. Following a blocking step with TBS-3% gelatin, the nitrocellulose was incubated for 60 minutes at room temperature with individual hybridoma supernatants, at a 1:5 dilution in TBS-O. 1 % Tween, using a 96-well Bio-Dot micro-filtration apparatus (Bio-Rad) . After washing, the sheets were incubated for one hour with alkaline- phosphatase-conjugated affinity isolated goat-anti(mouse IgG + IgM) antibodies (Tago, Inc., Burlinga e, CA) . Following additional washeε, poεitive supernatants were identified by incubation of the nitrocellulose sheet in alkaline phosphatase buffer (0.10 M TRIS, 0.10 M NaCl, 0.005 M MgCl 2 ,) containing nitroblue tetrazolium (0.1 mg/ml) and 5-bromo-4-chloro-3-indoyl phosphate (BCIP) (0.05 mg/ml) . For the antibody isotyping and immunoelectron microεcopy εtudies to be described below, the monoclonal antibodies were purified from hybridoma supernatants. The antibodies recovered in this work were all of the IgG clasε. To purify the monoclonal antibodies, the hybridoma supernatants were first subjected to ammonium sulfate precipitation (50% final concentration at 0°C) . Following overnight incubation, the precipitate was recovered by centrifugation and resolubilized in phoεphate buffered εaline. The solution was then dialyzed overnight against 0.01 M sodium phosphate buffer, pH 6.0. The following day the sample was applied to a DEAE-Sephacel column preequilibrated with the same phosphate buffer and the proteins were subsequently eluted with a KC1 gradient. Column fractions containing the monoclonal antibodies were identified by examination of samples on Coomassie gels for protein bands typical of light and heavy chains. The isotype of each monoclonal antibody was determined by immunodiffusion using the Ouchterlony method. Immunodiffusion plates were prepared on glass slides with 10 ml of 1% DNA-grade agarose (FMC Bioproducts, Rockland, ME) in phospate-buffered saline. After the agarose solidified, 5-mm wells were punched into the agarose in a circular pattern. The center wel l contained a concentrated preparation of the monoclona l antibody being evaluated and the surrounding wells contained goat anti-mouse subclass-specific antibodies (Tago) . The plates were incubated for 48 hours in a humid chamber at 4 P C and then examined for white lines of immunoprecipitation. Hybridoma supernatants which were reactive in the dot-blot assay described above were examined by Western blot analysis, both to confirm the reactivity with the high molecular weight proteins of the homologous nontypable Haemophilus strain and to examine the cross- reactivity with similar proteins in heterologous strains. Nontypable Haemophilus influenzae cell sonicates containing 100 μg of total protein were solubilized in electrophoresiε sample buffer, subjected to SDS- polyacrylamide gel electrophoresis on 7.5% acrylamide gels, and transferred to nitrocellulose using a Genie electrophoretic blotter (Idea Scientific Company, Corvallis, OR) for 45 min at 24 V. After transfer, the nitrocellulose sheet waε blocked and then probed εequentially with the hybridoma εupernatant, with alkaline phoεphatase-conjugated goat-anti(mouse IgG + IgM) second antibody, and finally bound antibodies were detected by incubation with nitroblue tetrazolium/BCIP solution. Thiε same assay was employed to examine the reactivity of the monoclonals with recombinant fusion proteins expressed in E. coli (see below) . In preparation for immunoelectronmicroscopy, bacteria were grown overnight on supplemented chocolate agar and several colonies were suεpended in phoεphate- buffered-saline containing 1 % albumin. A 20-μl drop of thiε bacterial suspension was then applied to a carbon- coated grid and incubated for 2 min. Excess fluid was removed and the specimen was then incubated for 5 min with the purified high molecular weight protein-specific monoclonal antibody being analyzed. Following removal of excess liquid and a wash with phosphatebuffered saline, the specimen was incubated with anti-mouse IgG conjugated to 10-nm colloidal gold particles. following final washes with phosphate-buffered saline, the sample waε rinsed with distilled water. Staining of the bacterial cells was performed with 0.5% uranyl acetate for l min. Samples were then examined in a Phillips 20lc electron microscope. Fourteen different hybridomas were recovered which produced monoclonal antibodies reactive with the purified HMWl and HMW2 proteinε of nontypable Haemophiluε strain 12 in the immunoblot screening assay. Of the monoclonals screened by immunoelectron microscopy to date, aε described below, two were demonstrated to bind surface epitopes on prototype strain 12. These two monoclonal antibodies, designated AD6 (ATCC ) and 10C5 (ATCC ) , were both of the IgGl subclass. Example 10: This Example describes the identification of surface-exposed B-cell epitopes of high molecular weight proteins of non-typeable H. influenzae. To map epitopes recognized by the monoclonal antibodies, their reactivity with a panel of recombinant fusion proteins expressed by pGEMEX® recombinant plasmids was examined. These plasmids were constructed by cloning various segments of the hmwla or hmw2A structural genes into T7 expression vectors pGEMEX® -1 and GEMEX®-2 (Promega Corporation, Madison, WI) . Shown in Figures 18 and 19 are the schematic diagrams depicting the segments derived from the hmwl and hmw2 gene clusters cloned into the pGEMEX® expression plasmids. These segments were inserted such that in-frame fusions were created at each junction site. Thus, these plasmids encode recombinant fusion proteins containing pGEMEX®-encoded T7 gene 10 amino acids in the regions indicated by the hatched bars and hmwla or hmw2A encoded amino acids in the regions indicated by the black bars in these Figures. A stop codon iε preεent at the junction of the black and white segments of each bar. Four discrete sites within the hmwlA structural gene were selected as the 5' ends of the hmwl inserts. For each 5' end, a series of progressively smaller inserts was created by taking advantage of convenient downstream restriction sites. The first recombinant plasmid depicted in Figure 18 was constructed by isolating a 4.9 kbp BamHI-Hindlll fragment from pHMWl-i4 (Example l. Figure 5A) , which contains the entire hmwl gene cluster and inεerting it into BamHI-Hindlll digested pGEMEX®-l. The second recombinant plasmid in this set was constructed by digesting the "parent" plasmid with BstEII-Hindlll. recovering the 6.8 kbp larger fragment, blunt-ending with Klenow DNA polymerase, and religating. The third recombinant plasmid in this set was constructed by digesting the "parent" plasmid with Clal-Hindlll. recovering the 6.0 kbp larger fragment, blunt-ending, and religating. The next set of four hmwl recombinant plasmids was derived from a "parent" plasmid constructed by ligating a 2.2 kbp EcoRI fragment from the hmwl gene cluster into EcoRI-digested pGEMEX®-2. The other three recombinant plasmidε in thiε εecond set were constructed by digesting at downstream BstEII f EcoRV f and Clal sites, respectively, using techniques similar to those just described. The third set of three recombinant plasmids depicted was derived from a "parent" plasmid constructed by double-digesting the firεt recombinant plasmid described above (i.e. the one containing the 4.9 kbp BamHI-Hindlll fragment) with B_amHI and Clal. blunt- ending, and religating. This resulted in a construct encoding a recombinant protein with an in-frame fusion at the Clal site of the hmwlA gene. The remaining two plasmidε in thiε third set were constructed by digesting at downstream BstEII and EcoRV sites, respectively. Finally, the fourth set of two recombinant plasmids was derived from a "parent" plasmid constructed by double- digesting the original BamHI-HindlII construct with Hindi and EcoRV. then religating. This resulted in a construct encoding a recombinant protein with an in-frame fusion at the EcoRV site of the hmwlA gene. The remaining plaεmid in thiε fourth set was constructed by digesting at the downstream BstEII site. Three discrete sites with the hmw2A structural gene were selected as the 5' ends of the hmw2 inserts. The first recombinant plasmid depicted in Figure 19 was constructed by isolating a 6.0 kbp EcoRI-XhoI fragment from pHMW2-21, which contains the entire hmw2 gene cluster, and inserting it into EcoRI-Sail digested pGEMEXΦ-1. The second recombinant plasmid in thiε set was constructed by digesting at an Mlul site near the 3' end of the hmw2A gene. The second set of two hmw2 recombinant plasmids was derived from a "parent" plasmid constructed by isolating a 2.3 kbp Hindlll fragment from pHMW2-21 and inserting it into HindiII-digested pGEMEX®- 2. The remaining plasmid in this second set waε conεtructed by digeεting at the downstream Mlul site. Finally, the last plasmid depicted was constructed by isolating a 1.2 kbp HincII-Hindlll. fragment from the indicated location in the hmw2 gene cluster and inserting it into HincII-Hindlll digested pGEMEX®-l. Each of the recombinant plasmids was used to transform E. coli strain JM101. The resulting transformants were used to generate the recombinant fusion proteins employed in the mapping studies. To prepare recombinant proteins, the transformed E. coli strains were grown to an A^ of 0.5 in L broth containing 50 μg of ampicillin per ml. IPTG was then added to lmM and mGPl-2, the M13 phage containing the T7 RNA polymerase gene, was added at multiplicity of infection of 10. One hour later, cells were harvested, and a sonicate of the cells was prepared. The protein concentrations of the samples were determined and cell sonicates containing 100 μg of total protein were solubilized in electrophoresis sample buffer, subjected to SDS-polyacrylamide gel electrophoresis, and examined on Coomasεie gels to assess the expresεion level of recombinant fuεion proteinε. Once high levelε of expreεεion of the recombinant fusion proteins were confirmed, the cell sonicates were used in the Western blot analyseε deεcribed above. Shown in Figure 20 is an electron micrograph demonstrating surface binding of Mab AD6 to representative nontypable Haemophilus influenzae strains. In the upper left panel of the Figure iε nontypable Haemophilus strain 12 and in the upper right panel is a strain 12 derivative which no longer expressed the high molecular weight proteins. As can be seen, colloidal gold particles decorate the surface of strain 12, indicating bound AD6 antibody on the surface. In contrast, no gold particles are evident on the surface of the strain 12 mutant which no longer expresses the high molecular weight proteins. These resultε indicate that monoclonal antibody AD6 iε recognizing a surface-exposed epitope on the high molecular weight proteins of strain 12. Analogous studies were performed with monoclonal antibody 10C5 demonstrating it too bound to surface- acceεεible epitopes on the high molecular weight HMWl and HMW2 proteins of strain 12. Having identified two surface-binding onoclonalε, the epitope which each monoclonal recognized waε mapped. To accompliεh thiε task, the two sets of recombinant plasmids containing various portions of either the hmwla or hmw2A structural genes (Figureε 18 and 19) were employed. With theεe complementary sets of recombinant plasmidε, the epitopes recognized by the monoclonal antibodies were mapped to relatively small regions of the very large HMWl and HMW2 proteins. To localize epitopes recognized by Mab AD6, the pattern of reactivity of this monoclonal antibody with a large set of recombinant fusion protein waε examined. Figure 21 iε a Weεtern blot which demonεtrateε the pattern of reactivity of Mab AD6 with five recombinant fusion proteinε, a relevant subset of the larger number originally examined. From analysis of the pattern of reactivity of Mab AD6 with this set of proteins, one is able to map the epitope it recognizes to a very short segment of the HMWl and HMW2 proteins. A brief summary of this analysis follows. For reference, the relevant portions of the hmwlA or hmw2A structural genes which were expressed in the recombinant proteins being examined are indicated in the diagram at the top of the figure. As shown in lane 1, Mab AD6 recognizeε an epitope encoded by fragment l, a fragment which encompasses the distal one-fourth of the hmwlA gene. Reactivity is lost when only the portion of the gene comprising fragment 2 is expressed. This observation localizes the AD6 epitope somewhere within the last 180 amino acids at the carboxy- terminal end of the HMWl protein. Mab AD6 also recognizes an epitope encoded by fragment 3, derived from the hmw2A structural gene. This is a rather large fragment which encompasses nearly one-third of the gene. Reactivity iε lost when fragment 4 is expressed. The only difference between fragments 3 and 4 is that the last 225 base pairs at the 3' end of the hmw2A structural gene were deleted in the latter construct. This observation indicates that the AD6 epitope is encoded by this short terminal segment of the hmw2A gene. Strong support for this idea is provided by the demonstrated binding of Mab AD6 to the recombinant protein encoded by fragment 5, a fragment encompassing the distal one-tenth of the hmw2A structural gene. Taken together, these data identify the AD6 epitope as common to both the HMWl an d HMW2 proteins and place its location with 75 amino acids of the carboxy termini of the two proteins. Figure 22 is a Western blot demonstrating the pattern of reactivity of Mab 10C5 with the same five recombinant fusion proteins examined in Figure 21. As shown in lane 1, Mab 10C5 recognizes an epitope encoded by fragment 1. In contrast to Mab AD6, Mab 10C5 also recognizes an epitope encoded by fragment 2. Also in contrast to Mab AD6, Mab 10C5 does not recognize any of the hmw2A-derived recombinant fusion proteins. Thus, these data identify the 10C5 epitope as being unique to the HMWl protein and as being encoded by the fragment designated as fragment 2 in this figure. This fragment corresponds to a 155-amino acid segment encoded by the EcoRV-BstEII segment of the hmwlA structural gene. Having identified the approximate locations of the epitopes on HMWl and HMW2 recognized by the two monoclonalε, the extent to which theεe epitopes were shared by the high molecular weight proteinε of heterologous nontypable Haemophilus strainε was next determined. When examined in Western blot assays with bacterial cell sonicates, Mab AD6 was reactive with epitopes expresεed on the high molecular weight proteins of 75% of the inventor's collection of more than 125 nontypable Haemophilus influenzae strainε. In fact, thiε monoclonal appeared to recognize epitopeε expressed on high molecular weight proteins in virtually all nontypable Haemophilus strains which we previously identified as expressing HMW1/HMW2-like proteins. Figure 23 is an example of a Western blot demonstrating the reactivity of Mab AD6 with a representative panel of such heterologous strainε. As can be seen, the monoclonal antibody recognizes one or two bands in the 100 to 150 kDa range in each of these strains. For reference, the strain shown in lane 1 is prototype strain 12 and the two bands visualized represent HMWl and HMW2 as the upper and lower immunoreactive bands, respectively. In contrast to the broad cross-reactivity observed with Mab AD6, Mab 10C5 was much more limited in its ability to recognize high molecular weight proteins in heterologous strains. Mab 10C5 recognized high molecular weight proteins in approximately 40% of the strains which expressed HMWl/HMW2-like proteins. As was the case with Mab AD6, Mab 10C5 did not recognize proteins in any the nontypable Haemophilus strains which did not express HMWl/HMW2-like proteins. In a limited fashion, the reactivity of Mab AD6 with surface-exposed epitopes on the heterologous strains has been examined. In the bottom two panels of Figure 20 are electron micrographs demonstrating the reactivity of Mab AD6 with surface-accessible epitopes on nontypable Haemophilus strainε 5 and 15. As can be seen, abundant colloidal-gold particles are evident on the surfaces of each of these strains, confirming their surface expresεion of the AD6 epitope. Although limited in scope, these data suggest that the AD6 epitope may be a common surface-accessible epitope on the high molecular weight adhesion proteins of most nontypable Haemophilus influenzae which express HMWl/HMW2-like proteins. SUMMARY OF DISCLOSURE In summary of this disclosure, the present invention provides high molecular weight proteins of non-typeable Haemophilus f genes coding for the same and vaccines incorporating such proteins. Modifications are possible within the scope of this invention. TABLE 1: Effect of mutation of high molecular weight proteins on adherence to Chang epithelial cells by nontypable H. influenzae . * Numbers repreεent mean (± εtandard error of the mean) of measurements in triplicate or quadruplicate from representative experiments. t Adherence values for strain 12 derivatives are relative to strain 12 wild type; values for strain 5 derivatives are relative to strain 5 wild type. TABLE 2: Adherence by E. coli DH5α and HB101 harboring hmwl or hjmv2 gene clusters. * The plasmid pHMWl-14 contains the hmwl gene cluster, while pHMW2-21 contains the hmw2 gene cluster; pT7-7 is the cloning vector used in these constructs. t Numbers represent the mean (± standard error of the mean) of measurements made in triplicate from representative experiments. TABLE 3: Protective ability of HMW protein against non- typeable H. influenzae challenge in chinchilla model SEQUENCE LISTING (1) GENERAL INFORMATION: (i) APPLICANT: Baren amp, Stephen J (ii) TITLE OF INVENTION: High Molecular Weight Surface Proteins of Non-Typeable Haemophilus (iii) NUMBER OF SEQUENCES: 11 (iv) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: Shoemaker and Mattare, Ltd. (B) STREET: 2001 Jefferson Davis Hwy. , 1203 Crystal Plaza Bldg. 1 (C) CITY: Arlington (D) STATE: Virginia (E) COUNTRY: U.S.A. (F) ZIP: 22202-0286 (v) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: Patentln Release #1.0, Version #1.30 (vi) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: US 08/617,697 (B) FILING DATE: 01-APR-1996 (C) CLASSIFICATION: (vii) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: US 08/302,832 (B) FILING DATE: 05-OCT-1994 (vii) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: US PCT/US93/02166 (B) FILING DATE: 16-MAR-1993 (viii) ATTORNEY/AGENT INFORMATION: (A) NAME: Berkstresser, Jerry W (B) REGISTRATION NUMBER: 22,651 (C) REFERENCE/DOCKET NUMBER: 1038-557 (ix) TELECOMMUNICATION INFORMATION: (A) TELEPHONE: (703) 415-0810 (B) TELEFAX: (703) 415-0813 (2) INFORMATION FOR SEQ ID NO:l: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 5116 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:l: ACAGCGTTCT CTTAATACTA GTACAAACCC ACAATAAAAT ATGACAAACA ACAATTACAA 60 CACCTTTTTT GCAGTCTATA TGCAAATATT TTAAAAAATA GTATAAATCC GCCATATAAA 120 ATGGTATAAT CTTTCATCTT TCATCTTTCA TCTTTCATCT TTCATCTTTC ATCTTTCATC 180 TTTCATCTTT CATCTTTCAT CTTTCATCTT TCATCTTTCA TCTTTCATCT TTCATCTTTC 240 ACATGCCCTG ATGAACCGAG GGAAGGGAGG GAGGGGCAAG AATGAAGAGG GAGCTGAACG 300 AACGCAAATG ATAAAGTAAT TTAATTGTTC AACTAACCTT AGGAGAAAAT ATGAACAAGC 360 TATATCGTCT CAAATTCAGC AAACGCCTGA ATGCTTTGGT TGCTGTGTCT GAATTGGCAC 420 GGGGTTGTGA CCATTCCACA GAAAAAGGCA GCGAAAAACC TGCTCGCATG AAAGTGCGTC 480 ACTTAGCGTT AAAGCCACTT TCCGCTATGT TACTATCTTT AGGTGTAACA TCTATTCCAC 540 AATCTGTTTT AGCAAGCGGC TTACAAGGAA TGGATGTAGT ACACGGCACA GCCACTATGC 600 AAGTAGATGG TAATAAAACC ATTATCCGCA ACAGTGTTGA CGATATCATT AATTGGAAAC 660 AATTTAACAT CGACCAAAAT GAAATGGTGC AGTTTTTACA AGAAAACAAC AACTCCGCCG 720 TATTCAACCG TGTTACATCT AACCAAATCT CCCAATTAAA AGGGATTTTA GATTCTAACG 780 GACAAGTCTT TTTAATCAAC CCAAATGGTA TCACAATAGG TAAAGACGCA ATTATTAACA 840 CTAATGGCTT TACGGCTTCT ACGCTAGACA TTTCTAACGA AAACATCAAG GCGCGTAATT 900 TCACCTTCGA GCAAACCAAA GATAAAGCGC TCGCTGAAAT TGTGAATCAC GGTTTAATTA 960 CTGTCGGTAA AGACGGCAGT GTAAATCTTA TTGGTGGCAA AGTGAAAAAC GAGGGTGT A 1020 TTAGCGTAAA TGGTGGCAGC ATTTCTTTAC TCGCAGGGCA AAAAATCACC ATCAGCGATA 1080 TAATAAACCC AACCATTACT TACAGCATTG CCGCGCCTGA AAATGAAGCG GTCAATCTGG 1140 GCGATATTTT TGCCAAAGGC GGTAACATTA ATGTCCGTGC TGCCACTATT CGAAACCAAG 1200 GTAAACTTTC TGCTGATTCT GTAAGCAAAG ATAAAAGCGG CAATATTGTT CTTTCCGCCA 1260 AAGAGGGTGA AGCGGAAATT GGCGGTGTAA TTTCCGCTCA AAATCAGCAA GCTAAAGGCG 1320 GCAAGCTGAT GATTACAGGC GATAAAGTCA CATTAAAAAC AGGTGCAGTT ATCGACCTTT 1380 CAGGTAAAGA AGGGGGAGAA ACTTACCTTG GCGGTGACGA GCGCGGCGAA GGfAAAAAGG 1440 GCATTCAATT AGCAAAGAAA ACCTCTTTAG AAAAAGGCTC AACCATCAAT GTATCAGGCA 1500 AAGAAAAAGG CGGACGCGCT ATTGTGTGGG GCGATATTGC GTTAATTGAC GGCAATATTA 1560 ACQCTCAAGG TAGTGGTGAT ATCGCTAAAA a-^3TGGTTT TGTGGAGACG TCGGGGCATG 1620 ATTTATTCAT CAAAGACAAT βCAATTGTTG ACGCCAAAGA GTGGTTGTTA GACCCGGATA 1680 ATGTATCTAT TAATGCAGAA ACAGCAGGAC GCAGCAATAC TTCAGAAGAC GATGAATACA 1740 CGGGATCCGG GAATAGTGCC AGCACCCCAA AACGAAACAA AGAAAAGACA ACATTAACAA 1800 ACACAACTCT TGAGAGTATA CTAAAAAAAG GTACCTTTGT TAACATCACT GCTAATCAAC I860 GCATCTATGT CAATAGCTCC ATTAATTTAT CCAATGGCAG CTTAACTCTT TGGAGTGAGG 1920 GTCGGAGCGG TGGCGGCGTT GAGATTAACA ACGATATTAC CACCGGTGAT GATACCAGAG 1980 GTGCAAACTT AACAATTTAC TCAGGCGGCT GGGTTGATGT TCATAAAAAT ATCTCACTCG 20 0 GGGCGCAAGG TAACATAAAC ATTACAGCTA AACAAGATAT αSCCTTTGAG AAAGGAAGCA 2100 ACCAAGTCAT TACAGGTCAA GGGACTATTA CCTCAGGCAA TCAAAAAGGT TTTAGATTTA 2160 ATAATGTCTC TCTAAACGGC ACTGGCAGCG GACTGCAATT CACCACTAAA AGAACCAATA 2220 AATACGCTAT CACAAATAAA TTTGAAGGGA CTTTAAATAT TTCAGGGAAA GTGAACATCT 2280 CAATGGTTTT ACCTAAAAAT GAAAGTGGAT ATGATAAATT CAAAGGACGC ACTTACTGGA 2340 ATTTAACCTC CTTAAATGTT TCCGAGAGTG GCGAGTTTAA CCTCACTATT GACTCCAGAG 2400 GAAGCGATAG TGCAGGCACA CTTACCCAGC CTTATAATTT AAACGGTATA TCATTCAACA 2460 AAGACACTAC CTTTAATGTT GAACGAAATG CAAGAGTCAA CTTTGACATC AAGGCACCAA 2520 TAGGGATAAA TAAGTATTCT AGTTTGAATT ACGCATCATT TAATGGAAAC ATTTCAGTTT 2580 CGGGAGGGGG GAGTGTTGAT TTCACACTTC TCGCCTCATC CTCTAACGTC CAAACCCCCG 2640 GTGTAGTTAT AAATTCTAAA TACTTTAATG TTTCAACAGG GTCAAGTTTA AGATTTAAAA 2700 CTTCAGGCTC AACAAAAACT GGCTTCTCAA TAGAGAAAGA TTTAACTTTA AATGCCACCG 2760 GAGGCAACAT AACACTTTTG CAAGTTGAAG GCACCGATGG AATGATTGGT AAAGGCATTG 2820 TAGCCAAAAA AAACATAACC TTTGAAGGAG GTAACATCAC CTTTGGCTCC AGGAAAGCCG 2880 TAACAGAAAT CGAAGGCAAT GTTACTATCA ATAACAACGC TAACGTCACT CTTATCGGTT 2940 CGGATTTTGA CAACCATCAA AAACCTTTAA CTATTAAAAA AGATGTCATC ATTAATAGCG 3000 GCAACCTTAC CGCTGGAGGC AATATTGTCA ATATAGCCGG AAATCTTACC GTTGAAAGTA 3060 ACGCTAATTT CAAAGCTATC ACAAATTTCA CTTTTAATGT AGGCGGCTTG TTTGACAACA 3120 AAGGCAATTC AAATATTTCC ATTGCCAAAG GAGGGGCTCG CTTTAAAGAC ATTGATAATT 3180 CCAAGAATTT AAGCATCACC ACCAACTCCA GCTCCACTTA CCGCACTATT ATAAGCGGCA 3240 ATATAACCAA TAAAAACGGT GATTTAAATA TTACGAACGA AGGTAGTGAT ACTGAAATGC 3300 AAATTGGCGG CGATGTCTCG CAAAAAGAAG GTAATCTCAC GATTTCTTCT GACAAAATCA 3360 ATATTACCAA ACAGATAACA ATCAAGGCAG GTGTTGATGG GGAGAATTCC GATTCAGACG 3420 CGACAAACAA TGCCAATCTA ACCATTAAAA CCAAAGAATT GAAATTAACG CAAGACCTAA 3480 ATATTTCAGG TTTCAATAAA GCAGAGATTA CAGCTAAAGA TGGTAGTGAT TTAACTATTG 3540 GTAACACCAA TAGTGCTGAT GGTACTAATG CCAAAAAAGT AACCTTTAAC CAGGTTAAAG 3600 ATTCAAAAAT CTCTGCTGAC GGTCACAAGG TGACACTACA CAGCAAAGTG GAAACATCCG 3660 GTAGTAATAA CAACACTGAA GATAGCAGTG ACAATAATGC CGGCTTAACT ATCGATGCAA 3720 AAAATGTAAC AGTAAACAAC AATATTACTT CTCACAAAGC AGTGAGCATC TCTGCGACAA 3780 GTGGAGAAAT TACCACTAAA ACAGGTACAA CCATTAACGC AACCACTGGT AACGTGGAGA 3840 TAACCGCTCA AACAGGTAGT ATCCTAGGTG GAATTGAGTC CAGCTCTGGC TCTGTAACAC 3900 TTACTGCAAC CGAGGGCGCT CTTGCTGTAA GCAATATTTC GGGCAACACC GTTACTGTTA 3960 CTGCAAATAG CGGTGCATTA ACCACTTTGG CAGGCTCTAC AATTAAAGGA ACCGAGAGTG 4020 TAACCACTTC AAGTCAATCA GGCGATATCG GCGGTACGAT TTCTGGTGGC ACAGTAGAGG 4080 TTAAAGCAAC CGAAAGTTTA ACCACTCAAT CCAATTCAAA AATTAAAGCA ACAACAGGCG 4140 AGGCTAACGT AACAAGTGCA ACAGGTACAA TTGGTGGTAC GATTTCCGGT AATACGGTAA 4200 ATGTTACGGC AAACGCTGGC GATTTAACAG TTGGGAATGG CGCAGAAATT AATGCGACAG 4260 AAGGAGCTGC AACCTTAACT ACATCATCGG GCAAATTAAC TACC3AAGCT AGTTCACACA 4320 TTACTTCAGC CAAGGGTCAG GTAAATCTTT CAGCTCAGGA TGGTAGCGTT GCAGGAAGTA 4 380 TTAATGCCGC CAATGTGACA CTAAATACTA CAGGCACTTT AACTACCGTG AAGGGTTCAA 4440 ACATTAATGC AACCAGCGGT ACCTTGGTTA TTAACGCAAA AGACGCTGAG CTAAATGGCG 500 CAGCATTGGG TAACCACACA GTGGTAAATG CAACCAACGC AAATGGCTCC GGCAGCGTAA 4560 TCGCGACAAC CTCAAGCAGA GTGAACATCA CTGGGGATTT AATCACAATA AATGGATTAA 4620 ATATCATTTC AAAAAACGGT ATAAACACCG TACTGTTAAA AGGCGTTAAA ATTGATGTGA 4680 AATACATTCA ACCGGGTATA GCAAGCGTAG ATGAAGTAAT TGAAGCGAAA CGCATCCTTG 4740 AGAAGGTAAA AGATTTATCT GATGAAGAAA GAGAAGCGTT AGCTAAACTT GGAGTAAGTG 4800 CTGTACGTTT TATTGAGCCA AATAATACAA TTACAGTCGA TACACAAAAT GAATTTGCAA 4860 CCAGACCATT AAGTCGAATA GTGATTTCTG AAGGCAGGGC GTGTTTCTCA AACAGTGATG 4920 GCGCGACGGT GTGCGTTAAT ATCGCTGATA ACGGGCGGTA GCGGTCAGTA ATTGACAAGG 4980 TAGATTTCAT CCTGCAATGA AGTCATTTTA TTTTCGTATT ATTTACTGTG TGGGTTAAAG 5040 TTCAGTACGG GCTTTACCCA TCTTGTAAAA AATTACGGAG AATACAATAA AGTATTTTTA 5100 ACAGGTTATT ATTATG 5116 (2) INFORMATION FOR SEQ ID NO:2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1536 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2: Met Asn Lys lie Tyr Arg Leu Lys Phe Ser Lys Arg Leu Asn Ala Leu 1 5 10 15 Val Ala Val Ser Glu Leu Ala Arg Gly Cys Asp His Ser Thr Glu Lys 20 25 30 Gly Ser Glu Lys Pro Ala Arg Met Lys Val Arg His Leu Ala Leu Lys 35 40 45 Pro Leu Ser Ala Met Leu Leu Ser Leu Gly Val Thr Ser He Pro Gin 50 55 60 Ser Val Leu Ala Ser Gly Leu Gin Gly Met Asp Val Val His Gly Thr 65 70 75 80 Ala Thr Met Gin Val Asp Gly Asn Lys Thr He He Arg Asn Ser Val 85 90 95 Asp Ala He He Asn Trp Lys Gin Phe Asn He Asp Gin Asn Glu Met 100 105 110 Val Gin Phe Leu Gin Glu Asn Asn Asn Ser Ala Val Phe Asn Arg Val 115 120 125 Thr Ser Asn Gin He Ser Gin Leu Lys Gly He Leu Asp Ser Asn Gly 130 135 140 Gin Val Phe Leu He Asn Pro Asn Gly He Thr He Gly Lys Asp Ala 145 150 155 160 He He Asn Thr Asn Gly Phe Thr Ala Ser Thr Leu Asp He Ser Asn 165 170 175 Glu Asn He Lys Ala Arg Asn Phe Thr Phe Glu Gin Thr Lys Asp Lys 180 185 190 Ala Leu Ala Glu He Val Asn His Gly Leu He Thr Val Gly Lys Asp 195 200 205 Gly Ser Val Asn Leu He Gly Gly Lys Val Lys Asn Glu Gly Val He 210 215 220 Ser Val Asn Gly Gly Ser He Ser Leu Leu Ala Gly Gin Lys He Thr 225 230 235 240 He Ser Asp He He Asn Pro Thr He Thr Tyr Ser He Ala Ala Pro 245 250 255 Glu Asn Glu Ala Val Asn Leu Gly Asp He Phe Ala Lys Gly Gly Asn 260 265 270 He Asn Val Arg Ala Ala Thr He Arg Asn Gin Gly Lys Leu Ser Ala 275 280 285 Asp Ser Val Ser Lys Asp Lys Ser Gly Asn He Val Leu Ser Ala Lys 290 29S 300 Glu Gly Glu Ala Glu He Gly Gly Val He Ser Ala Gin Asn Gin Gin 305 310 315 320 Ala Lys Gly Gly Lys Leu Met He Thr Gly Asp Lys Val Thr Leu Lys 325 330 335 Thr Gly Ala Val He Asp Leu Ser Gly Lys Glu Gly Gly Glu Thr Tyr 340 345 350 Leu Gly Gly Asp Glu Arg Gly Glu Gly Lys Asn Gly He Gin Leu Ala 355 360 365 Lys Lys Thr Ser Leu Glu Lys Gly Ser Thr He Asn Val Ser Gly Lys 370 375 380 Glu Lys Gly Gly Arg Ala He Val Trp Gly Asp He Ala Leu He Asp 385 390 395 400 Gly Asn He Asn Ala Gin Gly Ser Gly Asp He Ala Lys Thr Gly Gly 405 410 415 Phe Val Glu Thr Ser Gly His Asp Leu Phe He Lys Asp Asn Ala He 420 425 430 Val Asp Ala Lys Glu Trp Leu Leu Asp Phe Asp Asn Val Ser He Asn 435 440 445 Ala Glu Thr Ala Gly Arg Ser Asn Thr Ser Glu Asp Asp Glu Tyr Thr 450 455 460 Gly Ser Gly Asn Ser Ala Ser Thr Pro Lys Arg Asn Lys Glu Lys Thr 465 470 475 480 Thr Leu Thr Asn Thr Thr Leu Glu Ser He Leu Lys Lys Gly Thr Phe 485 490 495 Val Asn He Thr Ala Asn Gin Arg He Tyr Val Asn Ser Ser He Asn 500 505 510 Leu Ser Asn Gly Ser Leu Thr Leu Trp Ser Glu Gly Arg Ser Gly Gly 515 520 525 Gly Val Glu He Asn Asn Asp He Thr Thr Gly Asp Asp Thr Arg Gly 530 535 540 Ala Asn Leu Thr He Tyr Ser Gly Gly Trp Val Asp Val His Lys Asn 545 550 555 560 He Ser Leu Gly Ala Gin Gly Asn He Asn He Thr Ala Lys Gin Asp 565 S70 575 He Ala Phe Glu Lys Gly Ser Asn Gin Val He Thr Gly Gin Gly Thr S80 585 590 He Thr Ser Gly Asn Gin Lys Gly Phe Arg Phe Asn Asn Val Ser Leu 595 600 605 Asn Gly Thr Gly Ser Gly Leu Gin Phe Thr Thr Lys Arg Thr Asn Lys 610 615 620 Tyr Ala He Thr Asn Lys Phe Glu Gly Thr Leu Asn He Ser Gly Lys 625 630 635 640 Val Asn He Ser Met Val Leu Pro Lys Asn Glu Ser Gly Tyr Asp Lys 645 650 655 Phe Lys Gly Arg Thr Tyr Trp Asn Leu Thr Ser Leu Asn Val Ser Glu 660 665 670 Ser Gly Glu Phe Asn Leu Thr He Asp Ser Arg Gly Ser Asp Ser Ala 675 680 685 Gly Thr Leu Thr Gin Pro Tyr Asn Leu Asn Gly He Ser Phe Asn Lys 690 695 700 Asp Thr Thr Phe Asn Val Glu Arg Asn Ala Arg Val Asn Phe Asp He 705 710 71S 720 Lys Ala Pro He Gly He Asn Lys Tyr Ser Ser Leu Asn Tyr Ala Ser 725 730 735 Phe Asn Gly Asn He Ser Val Ser Gly Gly Gly Ser Val Asp Phe Thr 740 745 750 Leu Leu Ala Ser Ser Ser Asn Val Gin Thr Pro Gly Val Val He Asn 755 760 765 Ser Lys Tyr Phe Asn Val Ser Thr Gly Ser Ser Leu Arg Phe Lys Thr 770 775 780 Ser Gly Ser Thr Lys Thr Gly Phe Ser He Glu Lys Asp Leu Thr Leu 785 790 795 800 Asn Ala Thr Gly Gly Asn He Thr Leu Leu Gin Val Glu Gly Thr Asp 805 810 815 Gly Met He Gly Lys Gly He Val Ala Lys Lys Asn He Thr Phe Glu 820 825 830 Gly Gly Asn He Thr Phe Gly Ser Arg Lys Ala Val Thr Glu He Glu 835 840 845 Gly Asn Val Thr He Asn Asn Asn Ala Asn Val Thr Leu He Gly Ser 850 855 860 Asp Phe Asp Asn His Gin Lys Pro Leu Thr He Lys Lys Asp Val He 865 870 875 880 He Asn Ser Gly Asn Leu Thr Ala Gly Gly Asn He Val Asn He Ala 885 890 895 Gly Asn Leu Thr Asn Phe Thr Phe Asn Val Gly Gly Leu Phe Asp Asn Lys Gly Asn Ser Asn 915 920 925 He Ser He Ala Lys Gly Gly Ala Arg Phe Lys Asp He Asp Asn Ser 930 935 940 Lys Asn Leu Ser He Thr Thr Asn Ser Ser Ser Thr Tyr Arg Thr He 945 950 955 960 He Ser Gly Asn He Thr Asn Lys Asn Gly Asp Leu Asn He Thr Asn 965 970 975 Glu Gly Ser Asp Thr Glu Met Gin He Gly Gly Asp Val Ser Gin Lys 980 985 990 Glu Gly Asn Leu Thr He Ser Ser Asp Lys .lie Asn He Thr Lys Gin 995 1000 1005 He Thr He Lys Ala Gly Val Asp Gly Glu Asn Ser Asp Ser Asp Ala 1010 1015 1020 Thr Asn Asn Ala Asn Leu Thr He Lys Thr Lys Glu Leu Lys Leu Thr 1025 1030 1035 1040 Gin Asp Leu Asn He Ser Gly Phe Asn Lys Ala Glu He Thr Ala Lys 1045 1050 1055 Asp Gly Ser Asp Leu Thr He Gly Asn Thr Asn Ser Ala Asp Gly Thr 1060 1065 1070 Asn Ala Lys Lys Val Thr Phe Asn Gin Val Lys Asp Ser Lys He Ser 1075 1080 1085 Ala Asp Gly His Lys Val Thr Leu His Ser Lys Val Glu Thr Ser Gly 1090 1095 1100 Ser Asn Asn Asn Thr Glu Asp Ser Ser Asp Asn Asn Ala Gly Leu Thr 1105 1110 1115 1120 He Asp Ala Lys Asn Val Thr Val Asn Asn Asn He Thr Ser His Lys 1125 1130 1135 Ala Val Ser He Ser Ala Thr Ser Gly Glu He Thr Thr Lys Thr Gly 1140 1145 11S0 Thr Thr He Asn Ala Thr Thr Gly Asn Val Glu He Thr Ala Gin Thr 1155 1160 1165 Gly Ser He Leu Gly Gly He Glu Ser Ser Ser Gly Ser Val Thr Leu 1170 1175 1180 Thr Ala Thr Glu Gly Ala Leu Ala Val Ser Asn He Ser Gly Asn Thr 1185 1190 1195 1200 Val Thr Val Thr Ala Asn Ser Gly Ala Leu Thr Thr Leu Ala Gly Ser 1205 1210 1215 Thr He Lys Gly Thr Glu Ser Val Thr Thr Ser Ser Gin Ser Gly Asp 1220 1225 1230 He Gly Gly Thr He Ser Gly Gly Thr Val Glu Val Lys Ala Thr Glu 1235 1240 1245 Ser Leu Thr Thr Gin Ser Asn Ser Lys He Lys Ala Thr Thr Gly Glu 1250 1255 1260 Ala Asn Val Thr Ser Ala Thr Gly Thr He Gly Gly Thr He Ser Gly 1265 1270 1275 1280 Asn Thr Val Asn Val Thr Ala Asn Ala Gly Asp Leu Thr Val Gly Asn 1285 1290 1295 Gly Ala Glu He Asn Ala Thr Glu Gly Ala Ala Thr Leu Thr Thr Ser 1300 1305 1310 Ser Gly Lys Leu Thr Thr Glu Ala Ser Ser His He Thr Ser Ala Lys 1315 1320 1325 Gly Gin Val Asn Leu Ser Ala Gin Asp Gly Ser Val Ala Gly Ser He 1330 1335 1340 Asn Ala Ala Asn Val Thr Leu Asn Thr Thr Gly Thr Leu Thr Thr Val 1345 1350 1355 1360 Lys Gly Ser Asn He Asn Ala Thr Ser Gly Thr Leu Val He Asn Ala 1365 1370 1375 Lys Asp Ala Glu Leu Asn Gly Ala Ala Leu Gly Asn His Thr Val Val 1380 1385 1390 Asn Ala Thr Asn Ala Asn Gly Ser Gly Ser Val He Ala Thr Thr Ser 1395 1400 1405 Ser Arg Val Asn He Thr Gly Asp Leu He Thr He Asn Gly Leu Asn 1410 1415 1420 He He Ser Lys Asn Gly He Asn Thr Val Leu Leu Lys Gly Val Lys 1425 1430 1435 1440 He Asp Val Lys Tyr He Gin Pro Gly He Ala Ser Val Asp Glu Val 1445 1450 1455 He Glu Ala Lys Arg He Leu Glu Lys Val Lys Asp Leu Ser Asp Glu 1460 1465 1470 Glu Arg Glu Ala Leu Ala Lys Leu Gly Val Ser Ala Val Arg Phe He 147S 1480 1485 Glu Pro Asn Asn Thr He Thr Val Asp Thr Gin Asn Glu Phe Ala Thr 1490 1495 1500 Arg Pro Leu Ser Arg He Val He Ser Glu Gly Arg Ala Cys Phe Ser 1505 1510 1515 1520 Asn Ser Asp Gly Ala Thr Val Cys Val Asn He Ala Asp Asn Gly Arg 1525 1530 1535 (2) INFORMATION FOR SEQ ID NO:3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 4937 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3: TAAATATACA AGATAATAAA AATAAATCAA GATTTTTGTG ATGACAAACA ACAATTACAA 60 CACCTTTTTT GCAGTCTATA TGCAAATATT TTAAAAAAAT AGTATAAATC CGCCATATAA 120 AATGGTATAA TCTTTCATCT TTCATCTTTA ATCTTTCATC TTTCATCTTT CATCTTTCAT 180 CTTTCATCTT TCATCTTTCA TCTTTCATCT TTCATCTTTC ATCTTTCATC TTTCATCTTT 240 CACATGAAAT GATGAACCGA GGGAAGGGAG GGAGGGGCAA GAATGAAGAG GGAGCTGAAC 300 GAACGCAAAT GATAAAGTAA TTTAATTGTT CAACTAACCT TAGGAGAAAA TATGAACAAG 360 ATATATCGTC TCAAATTCAG CAAACGCCTG AATGCTTTGG TTGCTGTGTC TGAATTGGCA 420 CGGGGTTGTG ACCATTCCAC AGAAAAAGGC TTCCGCTATG TTACTATCTT TAGGTGTAAC 480 CACTTAGCGT TAAAGCCACT TTCCGCTATG TTACTATCTT TAGGTGTAAC ATCTATTCCA 540 CAATCTGTTT TAGCAAGCGG CTTACAAGGA ATGGATGTAG TACACGGCAC AGCCACTATG 600 CAAGTAGATG GTAATAAAAC CATTATCCGC AACAGTGTTG ACGCTATCAT TAATTGGAAA 660 CAATTTAACA TCGACCAAAA TGAAATGGTG CΛGTTTTTAC AAGAAAACAA CAACTCCGCC 720 GTATTCAACC GTGTTACATC TAACCAAATC TCCCAATTAA AAGGGATTTT AGATTCTAAC 780 GGACAAGTCT TTTTAATCAA CCCAAATGGT ATCACAATAG GTAAAGACGC AATTATTAAC 840 ACTAATGGCT TTACGGCTTC TACGCTAGAC ATTTCTAACG AAAACATCAA GGCGCGTAAT 900 TTCACCTTCG AGCAAACCAA AGATAAAGCG CTCGCTGAAA TTGTGAATCA CGGTTTAATT 960 ACTGTCGGTA AAGACGGCAG TGTAAATCTT ATTGGTGGCA AAGTGAAAAA CGAGGGTGTG 1020 ATTAGCGTAA ATGGTGGCAG CATTTCTTTA CTCGCAGGGC AAAAAATCAC CATCAGCGAT 1080 ATAATAAACC CAACCATTAC TTACAGCATT GCCGCGCCTG AAAATGAAGC GGTCAATCTG 1140 GGCGATATTT TTGCCAAAGG CGGTAACATT AATGTCCGTG CTGCCACTAT TCGAAACCAA 1200 GGTAAACTTT CTGCTGATTC TGTAAGCAAA GATAAAAGCG GCAATATTGT TCTTTCCGCC 1260 AAAGAGGGTG AAGCGGAAAT TGGCGGTGTA ATTTCCGCTC AAAATCAGCA AGCTAAAGGC 1320 GGCAAGCTGA TGATTACAGG CGATAAAGTC ACATTAAAAA CAGGTGCAGT TATCGACCTT 1380 TCAGGTAAAG AAGGGGGAGA AACTTACCTT GGCGGTGACG AGCGCGGCGA AGGTAAAAAC 1440 GGCATTCAAT TAGCAAAGAA AACCTCTTTA GAAAAAGGCT CAACCATCAA TGTATCAGGC 1500 AAAGAAAAAG GCGGACGCGC TATTGTGTGG GGCGATATTG CGTTAATTGA CGGCAATATT 1S60 AACGCTCAAG GTAGTGGTGA TATCGCTAAA ACCGGTGGTT TTGTGGAGAC ATCGGGGCAT 1620 TATTTATCCA TTGACAGCAA TGCAATTGTT AAAACAAAAG AGTGGTTGCT AGACCCTGAT 1680 GATGTAACAA TTGAAGCCGA AGACCCCCTT CGCAATAATA CCAACAGGCA CCGGTGAAGC AAGCGACCCT AAAAAAAATA ACCAATACAA CTATTTCAAA TTATCTGAAA AACGCCTGGA AGAAAACTTA CCGTTAATAG CTCAATCAAC ATCGGAAGCA AGTAAAGGTC AGCGTGGCGG AGGCGTTCAG ATTGATGGAG AATTTAACCA TTTATTCTGG CGGATGGGTT GATGTTCATA GGTTTTTTAA ATATTACCGC CGCTTCCGTA GCTTTTGAAG GACGCGGCAA ATGCTAAAAT TGTCGCCCAG GGCACTGTAA GATTTCAGGG CTAACAACGT ATCTTTAAAC GGAACGGGTA TCAGTGAATA ATTTAACCCA CAATCTTAGT GGCACAATTA ATTAACCAAA CTACGAGAAA GAACACCTCG TATTGGCAAA AACGTCAGTG CTCTTAATCT AGAGACAGGC GCAAATTTTA AGCAATAGCA AAGGCTTAAC AACACAGTAT AGAAGCTCTG GTAAATGGCA ACATGTCATT CAATCTCAAA GAAGGAGCGA CCAAACGAGA ACATGAACAC AAGCAAACCT TTACCAATTC GCCACTGGTG GGGGCTCTGT TTTTTTTGAT ATATATGCCA GAGTTAAAAA TGAGTGAAAT TAATATCTCT AACGGCGCTA GTTCGCGGCG ATGACGCTTT TAAAATCAAC AAAGACTTAA AATTTCAGCC TCAGACAGAC GAAAGATGAT TTTTATGACG AATTCAACCT ACAACATATC CATTCTGGGC GGTAATGTCA AGCAGCAGCA TTACGGGGAA TATTACTATC GAGAAAGCAG AATAACGCCC CTAATCAGCA AAACATAAGG GATAGAGTTA GTTAATGGGA GTTTAAGTTT AACTGGCGAA AATGCAGATA TCAGAAAGCG CCACTTTTAA AGGAAAGACT AGAGATACCC ACCAATAATG GCACTGCCGA AATTAATATA ACACAAGGAG ACCAATGATG GTGATTTAAA CATTACCACT CACGCTAAAC GGCGGAGATA TAATCAACAA AAAAGGAAGC TTAAATATTA GAAATCCAAA TTGGCGGCAA TATCTCGCAA AAAGAAGGCA AAAATTAATA TCACCAAACA GATAACAATC AAAAAGGGTA TCAGATGCGA CAAGTAATGC CAACCTAACT ATTAAAACCA GACCTAAGTA TTTCAGGTTT CAATAAAGCA GAGATTACAG ACTATTGGCA ACAGTAATGA CGGTAACAGC GGTGCCGAAG AATGTTAAAG ATTCAAAAAT CΓCTGCTGAC GGTCACAATG AAAACATCTA GCAGCAATGG CGGACGTGAA AGCAATAGCG ATTACTGCAA AAAATGTAGA AGTAAACAAA GATATTACTT ACCGCGTCGG AAAAGGTTAC CACCACAGCA GGCTCGACCA GCAAGTATTA CAACCAAAAC AGGTGATATC AGCGGTACGA GTTAGCGCGA CTGGTGATTT AACCACTAAA TCCGGCTCAA GAGGCTAATG TAACAAGTGC AACAGGTACA ATTGGCGGTA AATGTTACGG CAAACGCTGG CGATTTAACA GTTGGGAATG GAAGGAGCTG CAACCTTAAC CGCAACAGGG AATACCTTGA ATCACTTCAA CTAAGGGTCA GGTAGACCTC TTGGCTCAGA ATTAATGCTG CTAATGTGAC ATTAAATACT ACAGGCACCT GATATTAAAG CAACCAGCGG CACCTTGGTT ATTAACGCAA GATGCATCAG GTGATAGTAC AGAAGTGAAT GCAGTCAACG ACTGCGGCAA CCTCAAGCAG TGTGAATATC ACTGGGGATT AATATCATTT CGAAAGATGG TAGAAACACT GTGCGCTTAA AAATATATCC AGCCAGGTGT AGCAAGTGTA GAAGAAGTAA GAAAAAGTAA AAGATTTATC TGATGAAGAA AGAGAAACAT GCTGTACGTT TTGTTGAGCC AAATAATACA ATTACAGTCA ACCAGACCGT CAAGTCAAGT GATAATTTCT GAAGGTAAGG GGCGCACGAG TATGTACCAA TGTTGCTGAC GATGGACAGC GTAGATTTCA TCCTGCAATG AAGTCATTTT ATTTTCGTAT GTTCAGTACG GGCTTTACCC ATCTTGTAAA AAATTACGGA AACAGGTTAT TATTATG (2 ) INFORMATION FOR SEQ ID NO : 4 : ( i ) SEQUENCE CHARACTERISTICS : (A) LENGTH : 1477 amino acids (B) TYPE : amino acid (C) STRANDEDNESS : single (D) TOPOLOGY* linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4: Met Asn Lys He Tyr Arg Leu Lys Phe Ser Lys Arg Leu Asn Ala Leu 1 5 10 15 Val Ala Val Ser Glu Leu Ala Arg Gly Cys Asp His Ser Thr Glu Lys 20 25 30 Gly Ser Glu Lys Pro Ala Arg Met Lys Val Arg His Leu Ala Leu Lys 35 40 45 Pro Leu Ser Ala Met Leu Leu Ser Leu Gly Val Thr Ser He Pro Gin 50 55 60 Ser Val Leu Ala Ser Gly Leu Gin Gly Met Asp Val Val His Gly Thr 65 70 75 80 Ala Thr Met Gin Val Asp Gly Asn Lys Thr He He Arg Asn Ser Val 85 90 95 Asp Ala He He Asn Trp Lys Gin Phe Asn He Asp Gin Asn Glu Met 100 105 no Val Gin Phe Leu Gin Glu Asn Asn Asn Ser Ala Val Phe Asn Arg Val 115 120 125 Thr Ser Asn Gin He Ser Gin Leu Lys Gly He Leu Asp Ser Asn Gly 130 135 140 Gin Val Phe Leu He Asn Pro Asn Gly He Thr He Gly Lys Asp Ala 145 150 155 160 He He Asn Thr Asn Gly Phe Thr Ala Ser Thr Leu Asp He Ser Asn 165 170 175 Glu Asn He Lys Ala Arg Asn Phe Thr Phe Glu Gin Thr Lys Asp Lys 180 185 190 Ala Leu Ala Glu He Val Asn His Gly Leu He Thr Val Gly Lys Asp 195 200 205 Gly Ser Val Asn Leu He Gly Gly Lys Val Lys Asn Glu Gly Val He 210 215 220 Ser Val Asn Gly Gly Ser He Ser Leu Leu Ala Gly Gin Lys He Thr 225 230 235 240 He Ser Asp He He Asn Pro Thr He Thr Tyr Ser He Ala Ala Pro 245 250 255 Glu Asn Glu Ala Val Asn Leu Gly Asp He Phe Ala Lys Gly Gly Asn 260 265 270 He Asn Val Arg Ala Ala Thr He Arg Asn Gin Gly Lys Leu Ser Ala 275 280 285 ' . Asp Ser Val Ser Lys Asp Lys Ser Gly Asn He Val Leu Ser Ala Lys 290 295 300 Glu Gly Glu Ala Glu He Gly Gly Val He Ser Ala Gin Asn Gin Gin 305 310 31S 320 Ala Lys Gly Gly Lys Leu Met He Thr Gly Asp Lys Val Thr Leu Lys 325 330 335 Thr Gly Ala Val He Asp Leu Ser Gly Lys Glu Gly Gly Glu Thr Tyr 340 345 350 Leu Gly Gly Asp Glu Arg Gly Glu Gly Lys Asn Gly He Gin Leu Ala 355 360 365 Lys Lys Thr Ser Leu Glu Lys Gly Ser Thr He Asn Val Ser Gly Lys 370 375 380 Glu Lys Gly Gly Phe Ala He Val Trp Gly Asp He Ala Leu He Asp 385 390 395 400 Gly Asn He Asn Ala Gin Gly Ser Gly Asp He Ala Lys Thr Gly Gly 40S 410 415 Phe Val Glu Thr Ser Gly His Asp Leu Phe He Lys Asp Asn Ala He 420 425 430 Val Asp Ala Lys Glu Trp Leu Leu Asp Phe Asp Asn Val Ser He Asn 435 440 445 Ala Glu Asp Pro Leu Phe Asn Asn Thr Gly He Asn Asp Glu Phe Pro 450 455 460 Thr Gly Thr Gly Glu Ala Ser Asp Pro Lys Lys Asn Ser Glu Leu Lys 465 470 475 480 Thr Thr Leu Thr Asn Thr Thr He Ser Asn Tyr Leu Lys Asn Ala Trp 485 490 495 Thr Met Asn He Thr Ala Ser Arg Lys Leu Thr Val Asn Ser Ser He 500 505 510 Asn He Gly Ser Asn Ser His Leu He Leu His Ser Lys Gly Gin Arg 515 520 525 Gly Gly Gly Val Gin He Asp Gly Asp He Thr Ser Lys Gly Gly Asn 530 535 540 Leu Thr. He Tyr Ser Gly Gly Trp Val Asp Val His Lys Asn He Thr 545 550 555 560 Leu Asp Gin Gly Phe Leu Asn He Thr Ala Ala Ser Val Ala Phe Glu 565 570 575 Gly Gly Asn Asn Lys Ala Arg Asp Ala Ala Asn Ala Lys He Val Ala 580 S85 590 Gin Gly Thr Val Thr He Thr Gly Glu Gly Lys Asp Phe Arg Ala Asn 595 600 605 Asn Val Ser Leu Asn Gly Thr Gly Lys Gly Leu Asn He He Ser Ser 610 615 620 Val Asn Asn Leu Thr His Asn Leu Ser Gly Thr He Asn He Ser Gly 625 630 635 640 Asn He Thr He Asn Gin Thr Thr Arg Lys Asn Thr Ser Tyr Trp Gin 645 650 655 Thr Ser His Asp Ser His Trp Asn Val Ser Ala Leu Asn Leu Glu Thr 660 665 670 * Gly Ala Asn Phe Thr Phe He Lys Tyr He Ser Ser Asn Ser Lys Gly 675 680 685 Leu Thr Thr Gin Tyr Arg Ser Ser Ala Gly Val Asn Phe Asn Gly Val 690 695 700 Asn Gly Asn Met Ser Phe Asn Leu Lys Glu Gly Ala Lys Val Asn Phe 705 710 715 720 Lys Leu Lys Pro Asn Glu Asn Met Asn Thr Ser Lys Pro Leu Pro He 725 730 735 Arg Phe Leu Ala Asn He Thr Ala Thr Gly Gly Gly Ser Val Phe Phe 740 745 750 Asp He Tyr Ala Asn His Ser Gly Arg Gly Ala Glu Leu Lys Met Ser 7SS 760 765 Glu He Asn He Ser Asn Gly Ala Asn Phe Thr Leu Asn Ser His Val 770 775 780 Arg Gly Asp Asp Ala Phe Lys He Asn Lys Asp Leu Thr He Asn Ala 785 790 795 800 Thr Asn Ser Asn Phe Ser Leu Arg Gin Thr Lys Asp Asp Phe Tyr Asp 805 810 815 Gly Tyr Ala Arg Asn Ala He Asn Ser Thr Tyr Asn He Ser He Leu 820 825 830 Gly Gly Asn Val Thr Leu Gly Gly Gin Asn Ser Ser Ser Ser He Thr 835 840 845 Gly Asn He Thr He Glu Lys Ala Ala Asn Val Thr Leu Glu Ala Asn 850 855 860 Asn Ala Pro Asn Gin Gin Asn He Arg Asp Arg Val He Lys Leu Gly 865 870 875 880 Ser Leu Leu Val Asn Gly Ser Leu Ser Leu Thr Gly Glu Asn Ala Asp 885 890 895 He Lys Gly Asn Leu Thr He Ser Glu Ser Ala Thr Phe Lys Gly Lys 900 905 910 Thr Arg Asp Thr Leu Asn He Thr Gly Asn Phe Thr Asn Asn Gly Thr 915 920 925 Ala Glu He Asn He Thr Gin Gly Val Val Lys Leu Gly Asn Val Thr 930 935 940 Asn Asp Gly Asp Leu Asn He Thr Thr His Ala Lys Arg Asn Gin Arg 945 950 9S5 960 Ser He He Gly Gly Asp He He Asn Lys Lys Gly Ser Leu Asn He 965 970 975 Thr Asp Ser Asn Asn Asp Ala Glu He Gin He Gly Gly Asn He Ser 980 985 990 Gin Lys Glu Gly Asn Leu Thr He Ser Ser Asp Lys He Asn He Thr 995 1000 1005 Lys Gin He Thr He Lys Lys Gly He Asp Gly Glu Asp Ser Ser Ser 1010 1015 1020 Asp Ala Thr Ser Asn Ala Asn Leu Thr He Lys Thr Lys Glu Leu Lys 1025 1030 103S 1040 Leu Thr Glu Asp Leu Ser He Ser Gly Phe Asn Lys Ala Glu He Thr 1045 1050 1055 Ala Lys Asp Gly Arg Asp Leu Thr He Gly Asn Ser Asn Asp Gly Asn 1060 . 1065 1070 Ser Gly Ala Glu Ala Lys Thr Val Thr Phe Asn Asn Val Lys Asp Ser 1075 1O80 1085 Lys He Ser Ala Asp Gly His Asn Val Thr Leu Asn Ser Lys Val Lys 1090 1095 1100 Thr Ser Ser Ser Asn Gly Gly Arg Glu Ser Asn Ser Asp Asn Asp Thr 1105 1110 1115 1120 Gly Leu Thr He Thr Ala Lys Asn Val Glu Val Asn Lys Asp He Thr 1125 1130 1135 Ser Leu Lys Thr Val Asn He Thr Ala Ser Glu Lys Val Thr Thr Thr 1140 1145 1150 Ala Gly Ser Thr He Asn Ala Thr Asn Gly Lys Ala Ser He Thr Thr 1155 1160 1165 Lys Thr Gly Asp He Ser Gly Thr He Ser Gly Asn Thr Val Ser Val 1170 1175 1180 Ser Ala Thr Val Asp Leu Thr Thr Lys Ser Gly Ser Lys He Glu Ala 1185 1190 1195 1200 Lys Ser Gly Glu Ala Asn Val Thr Ser Ala Thr Gly Thr He Gly Gly 1205 1210 1215 Thr He Ser Gly Asn Thr Val Asn Val Thr Ala Asn Ala Gly Asp Leu 1220 1225 1230 Thr Val Gly Asn Gly Ala Glu He Asn Ala Thr Glu Gly Ala Ala Thr 1235 1240 1245 Leu Thr Ala Thr Gly Asn Thr Leu Thr Thr Glu Ala Gly Ser Ser He 1250 1255 1260 Thr Ser Thr Lys Gly Gin Val Asp Leu Leu Ala Gin Asn Gly Ser He 1265 1270 1275 1280 Ala Gly Ser He Asn Ala Ala Asn Val Thr Leu Asn Thr Thr Gly Thr 1285 1290 1295 Leu Thr Thr Val Ala Gly Ser Asp He Lys Ala Thr Ser Gly Thr Leu 1300 1305 1310 Val He Asn Ala Lys Asp Ala Lys Leu Asn Gly Asp Ala Ser Gly Asp 1315 1320 1325 Ser Thr Glu Val Asn Ala Val Asn Ala Ser Gly Ser Gly Ser Val Thr 1330 1335 1340 Ala Ala Thr Ser Ser Ser Val Asn He Thr Gly Asp Leu Asn Thr Val 1345 1350 1355 1360 Asn Gly Leu Asn He He Ser Lys Asp Gly Arg Asn Thr Val Arg Leu 1365 1370 1375 Arg Gly Lys Glu lie Glu Val Lys Tyr He Gin Pro Gly Val Ala Ser 1380 1385 1390 Val Glu Glu Val He Glu Ala Lys Arg Val Leu Glu Lys Val Lys Asp 1395 1400 1405 Leu Ser Asp Glu Glu Arg Glu Thr Leu Ala Lys Leu Gly Val Ser Ala 1410 1415 1420 Val Arg Phe Val Glu Pro Asn Asn Thr He Thr Val Asn Thr Gin Asn 1425 1430 1435 1440 Glu Phe Thr Thr Arg Pro Ser Ser Gin val He He Ser Glu Gly Lys 1445 1450 1455 Ala Cys Phe Ser Ser Gly Asn Gly Ala Arg Val Cys Thr Asn Val Ala 1460 1465 1470 Asp Asp Gly Gin Pro 1475 (2) INFORMATION FOR SEQ ID NO:5: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 9171 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5: GGCAATATTA ACGCTCAAGG TAGTGGTGAT ATCGCTAAAA CCGGTGGTTT TGTGGAGACG 1560 TCGGGGCATG ATTTATTCAT CAAAGACAAT GCAATTGTTG ACGCCAAAGA GTGGTTGTTA 1620 GACCCGGATA ATGTATCTAT TAATGCAGAA ACAGCAGGAC GCAGCAATAC TTCAGAAGAC 1680 GATGAATACA CGGGATCCGG GAATAGTGCC AGCACCCCAA AACGAAACAA AGAAAAGACA 1740 ACATTAACAA ACACAACTCT TGAGAGTATA CTAAAAAAAG GTACCTTTGT TAACATCACT 1800 GCTAATCAAC GCATCTATGT CAATAGCTCC ATTAATTTAT CCAATGGCAG CTTAACTCTT 1860 TGGAGTGAGG GTCGGAGCGG TGGCGGCGTT GAGATTAACA ACGATATTAC CACCGGTGAT 1920 GATACCAGAG GTGCAAACTT AACAATTTAC TCAGGCGGCT GGGTTGATGT TCATAAAAAT 1980 ATCTCACTCG GGGCGCAAGG TAACATAAAC ATTACAGCTA AACAAGATAT CGCCTTTGAG 2040 AAAGGAAGCA ACCAAGTCAT TACAGGTCAA GGGACTATTA CCTCAGGCAA TCAAAAAGGT 2100 TTTAGATTTA ATAATGTCTC TCTAAACGGC ACTGGCAGCG GACTGCAATT CACCACTAAA 2160 AGAACCAATA AATACGCTAT CACAAATAAA TTTGAAGGGA CTTTAAATAT TTCAGGGAAA 2220 GTGAACATCT CAATGGTTTT ACCTAAAAAT GAAAGTGGAT ATGATAAATT CAAAGGACGC 2280 ACTTACTGGA ATTTAACCTC GAAAGTGGAT ATGATAAATT CAAAGGACGC CCTCACTATT 2340 GACTCCAGAG GAAGCGATAG TGCAGGCACA CTTACCCAGC CTTATAATTT AAACGGTATA 2400 TCATTCAACA AAGACACTAC CTTTAATGTT GAACGAAATG CAAGAGTCAA CTTTGACATC 2460 AAGGCACCAA TAGGGATAAA TAAGTATTCT AGTTTGAATT ACGCATCATT TAATGGAAAC 2520 ATTTCAGTTT CGGGAGGGGG GAGTGTTGAT TTCACACTTC TCGCCTCATC CTCTAACGTC 2580 CAAACCCCCG GTGTAGTTAT AAATTCTAAA TACTTTAATG TTTCAACAGG GTCAAGTTTA 2640 AGATTTAAAA CTTCAGGCTC AACAAAAACT GGCTTCTCAA TAGAGAAAGA TTTAACTTTA 2700 AATGCCACCG GAGGCAACAT AACACTTTTG CAAGTTGAAG GCACCGATGG AATGATTGGT 2760 AAAGGCATTG TAGCCAAAAA AAACATAACC TTTGAAGGAG GTAAGATGAG GTTTGGCTCC 2820 AGGAAAGCCG TAACAGAAAT CGAAGGCAAT GTTACTATCA ATAACAACGC TAACGTCACT 2880 CTTATCGGTT CGGATTTTGA CAACCATCAA AAACCTTTAA CTATTAAAAA AGATGTCATC 2940 ATTAATAGCG GCAACCTTAC CGCTGGAGGC AATATTGTCA ATATAGCCGG AAATCTTACC 3000 GTTGAAAGTA ACGCTAATTT CAAAGCTATC ACAAATTTCA CTTTTAATGT AGGCGGCTTG 3060 TTTGACAACA AAGGCAATTC AAATATTTCC ATTGCCAAAG GAGGGGCTCG CTTTAAAGAC 3120 ATTGATAATT CCAAGAATTT AAGCATCACC ACCAACTCCA GCTCCACTTA CCGCACTATT 3180 ATAAGCGGCA ATATAACCAA TAAAAACGGT GATTTAAATA TTACGAACGA AGGTAGTGAT 3240 ACTGAAATGC AAATTGGCGG CGATGTCTCG CAAAAAGAAG GTAATCTCAC GATTTCTTCT 3300 GACAAAATCA ATATTACCAA ACAGATAACA ATCAAGGCAG GTGTTGATGG GGAGAATTCC 3360 GATTCAGACG CGACAAACAA TGCCAATCTA ACCATTAAAA CCAAAGAATT GAAATTAACG 3420 CAAGACCTAA ATATTTCAGG TTTCAATAAA GCAGAGATTA CAGCTAAAGA TGGTAGTGAT 3 80 TTAACTATTG GTAACACCAA TAGTGCTGAT GGTACTAATG CCAAAAAAGT AACCTTTAAC 3540 CAGGTTAAAG ATTCAAAAAT CTCTGCTGAC GGTCACAAGG TGACACTACA GAAACATCCG GTAGTAATAA CAACACTGAA GATAGCAGTG ACAATAATGC ATCGATGCAA AAAATGTAAC AGTAAACAAC AATATTACTT CTCACAAAGC TCTGCGACAA GTGGAGAAAT TACCACTAAA ACAGGTACAA CCATTAACGC AACGTGGAGA TAACCGCTCA AACAGGTAGT ATCCTAGGTG GAATTGAGTC TCTGTAACAC TTACTGCAAC CGAGGGCGCT CTTGCTGTAA GCAATATTTC GTTACTGTTA CTGCAAATAG CGGTGCATTA ACCACTTTGG CAGGCTCTAC ACCGAGAGTG TAACCACTTC AAGTCAATCA GGCGATATCG GCGGTACGAT ACAGTAGAGG TTAAAGCAAC CGAAAGTTTA ACCACTCAAT CCAATTCAAA ACAACAGGCG AGGCTAACGT AACAAGTGCA ACAGGTACAA TTGGTGGTAC AATACGGTAA ATGTTACGGC AAACGCTGGC GATTTAACAG TTGGGAATGG AATGCGACAG AAGGAGCTGC AACCTTAACT ACATCATCGG GCAAATTAAC AGTTCACACA TTACTTCAGC CAAGGGTCAG GTAAATCTTT CAGCTCAGGA GCAGGAAGTA TTAATGCCGC CAATGTGACA CTAAATACTA CAGGCACTTT AAGGGTTCAA ACATTAATGC AACCAGCGGT ACCTTGGTTA TTAACGCAAA CTAAATGGCG CAGCATTGGG TAACCACACA GTGGTAAATG CAACCAACGC GGCAGCGTAA TCGCGACAAC CTCAAGCAGA GTGAACATCA CTGGGGATTT AATGGATTAA ATATCATTTC AAAAAACGGT ATAAACACCG TACTGTTAAA ATTGATGTGA AATACATTCA ACCGGGTATA GCAAGCGTAG ATGAAGTAAT CGCATCCTTG AGAAGGTAAA AGATTTATCT GATGAAGAAA GAGAAGCGTT GGCGTAAGTG CTGTACGTTT TATTGAGCCA AATAATACAA TTACAGTCGA GAATTTGCAA CCAGACCATT AAGTCGAATA GTGATTTCTG AAGGCAGGGC AACAGTGATG GCGCGACGGT GTGCGTTAAT ATCGCTGATA ACGGGCGGTA ATTGACAAGG TAGATTTCAT CCTGCAATGA AGTCATTTTA TTTTCGTATT TGGGTTAAAG TTCAGTACGG GCTTTACCCA TCTTGTAAAA AATTACGGAG AGTATTTTTA ACAGGTTATT ATTATGAAAA ATATAAAAAG CAGATTAAAA TATCAGTATT GCTTGGCCTG GCTTCTTCAT CATTGTATGC AGAAGAAGCG AAGGCTTTCA GTTATCTGGT GCACTTGAAA CTTTAAGTGA AGACGCCCAA CAAAATCTTT ATCTAAATAC CAAGGCTCGC AAACTTTAAC AAACCTAAAA TTGAATTACA GGCTGTGCTA GATAAGATTG AGCCAAATAA GTTTGATGTG AACAAACCAT TACGGATGGC AATATTATGT TTGAGCTAGT CTCGAAATCA GCCAAGTTTT TTATAAGGCG AGCCAGGGTT ATAGTGAAGA AAATATCGCT C-ATCTTTGAA ACAAGGAAAA GTGTATGAAG ATGGTCGTCA GTGGTTCGAT TCAATATGGC AAAAGAAAAT CCACTTAAAG TCACTCGCGT GCATTACGAG AAAACAAAAC CTCTGATTTG GTAGTTGCAG GTTTTTCGCC TTTTGGCAAA ACGCGTAGCT 5640 TTGTTTCCTA TGATAATTTC GGCGCAAGGG AGTTTAACTA TCAACGTGTA AGTCTAGGTT S700 TTGTAAATGC αΛTTTGACC GGACATGATG ATGTΛTTAAA TCTAAACGCA TTGACCAATG 5760 TAAAAGCACC ATCAAAATCT TATGCGGTAG GCATAGGATA TACTTATCCG TTTTATGATA 5820 AACACCAATC CTTAAGTCTT TATACCAGCA TGAGTTATGC TGATTCTAAT GATATCGACG 5880 GCTTACCAAG TGCGATTAAT CGTAAATTAT CAAAAGGTCA ATCTATCTCT GCGAATCTGA 5940 AATGGAGTTA TTATCTCCCG ACATTTAACC TTGGAATGGA AGACCAGTTT AAAATTAATT 6000 TAGGCTACAA CTACCGCCAT ATTAATCAAA CATCCGAGTT AAACACCCTG GGTGCAACGA 6060 AGAAAAAATT TGCAGTATCA GGCGTAAGTG CAGGCATTGA TGGACATATC CAATTTACCC 6120 CTAAAACAAT CTTTAATATT GATTTAACTC ATCATTATTA CGCGAGTAAA TTACCAGGCT 6180 CTTTTGGAAT GGAGCGCATT GGCGAAACAT TTAATCGCAG CTATCACATT AGCACAGCCA 6240 GTTTAGGGTT GAGTCAAGAG TTTGCTCAAG GTTGGCATTT TAGCAGTCAA TTATCGGGTC 6300 AGTTTACTCT ACAAGATATA AGTAGCATAG ATTTATTCTC TGTAACAGGT ACTTATGGCG 6360 TCAGAGGCTT TAAATACGGC GGTGCAAGTG GTGAGCGCGG TCTTGTATGG CGTAATGAAT 6420 TAAGTATGCC AAAATACACC CGCTTTCAAA TCAGCCCTTA TGCGTTTTAT GATGCAGGTC 6480 AGTTCCGTTA TAATAGCGAA AATGCTAAAA CTTACGGCGA AGATATGCAC ACGGTATCCT 6540 CTGCGGGTTT AGGCATTAAA ACCTCTCCTA CACAAAACTT AAGCTTAGAT GCTTTTGTTG 6600 CTCGTCGCTT TGCAAATGCC AATAGTGACA ATTTGAATGG CAACAAAAAA CGCACAAGCT 6660 CACCTACAAC CTTCTGGGGT AGATTAACAT TCAGTTTCTA ACCCTGAAAT TTAATCAACT 6720 GGTAAGCGTT CCGCCTACCA GTTTATAACT ATATGCTTTA CCCGCCAATT TACAGTCTAT 6780 ACGCAACCCT GTTTTCATCC TTATATATCA AACAAACTAA GCAAACCAAG CAAACCAAGC 6840 AAACCAAGCA AACCAAGCAA ACCAAGCAAA CCAAGCAAAC CAAGCAAACC AAGCAAACCA 6900 AGCAAACCAA GCAAACCAAG CAAACCAAGC AAACCAAGCA ATGCTAAAAA ACAATTTATA 6960 TGATAAACTA AAACATACTC CATACCATGG CAATACAAGG GATTTAATAA TATGACAAAA 7020 GAAAATTTAC AAAGTGTTCC ACAAAATACG ACCGCTTCAC TTGTAGAATC AAACAACGAC 7080 CAAACTTCCC TGCAAATACT TAAACAACCA CCCAAACCCA ACCTATTACG CCTGGAACAA 7140 CATGTCGCCA AAAAAGATTA TGAGCTTGCT TGCCGCGAAT TAATGGCGAT TTTGGAAAAA 7200 ATGGACGCTA ATTTTGGAGG CGTTCACGAT ATTGAATTTG ACGCACCTGC TCAGCTGGCA 7260 TATCTACCCG AAAAACTACT AATTCATTTT GCCACTCGTC TCGCTAATGC AATTACAACA 7320 CKTΓTTTCCG ACCCCGAATT GGCAATTTCC GAAGAAGGGG CATTAAAGAT GATTAGCCTG 7380 CAACGCTGGT TGACGCTGAT TTTTGCCTCT TCCCCCTACG TTAACGCAGA CCATATTCTC 7440 AATAAATATA ATATCAACCC AGATTCCGAA GGTGGCTTTC ATTTAGCAAC AGACAACTCT 7S00 TCTATTGCTA AATTCTGTAT TTTTTACTTA CCCGAATCCA ATGTCAATAT GAGTTTAGAT 7560 GCGTTATGGG CAGGGAATCA ACAACTTTGT GCTTCATTGT GTTTTGCGTT GCAGTCTTCA 7620 CGTTTTATTG GTACTGCATC TGCGTTTCAT AAAAGAGCGG TGGTTTTACA GTGGTTTCCT 7680 AAAAAACTCG CCGAAATTGC TAATTTAGAT GAATTGCCTG CAAATATCCT TCATGATGTA 7740 TATATGCACT GCAGTTATGA TTTAGCAAAA AACAAGCACG ATGTTAAGCG TCCATTAAAC 7800 GAACTTGTCC GCAAGCATAT CCTCACGCAA GGATGGCAAG ACCGCTACCT TTACACCTTA 7860 GGTAAAAAGG ACGGCAAACC TGTGATGATG GTACTGCTTG AACATTTTAA TTCGGGACAT 7920 TCGATTTATC GCACGCATTC AACTTCAATG ATTGCTGCTC GAGAAAAATT CTATTTAGTC 7980 GGCTTAGGCC ATGAGGGCGT TGATAACATA GGTCGAGAAG TGTTTGACGA GTTCTTTGAA 8040 ATCAGTAGCA ATAATATAAT GGAGAGACTG TTTTTTATCC GTAAACAGTG CGAAACTTTC 8100 CAACCCGCAG TGTTCTATAT GCCAAGCATT GGCATGGATA TTACCACGAT TTTTGTGAGC B160 AACACTCGGC TTGCCCCTAT TCAAGCTGTA GCCTTGGGTC ATCCTGCCAC TACGCATTCT 8220 GAATTTATTG ATTATGTCAT CGTAGAAGAT GATTATGTGG GCAGTGAAGA TTGTTTTAGC 8280 GAAACCCTTT TACGCTTACC CAAAGATGCC CTACCTTATG TACCATCTGC ACTCGCCCCA 83 0 CAAAAAGTGG ATTATGTACT CAGGGAAAAC CCTGAAGTAG TCAATATCGG TATTGCCGCT 8400 ACCACAATGA AATTAAACCC TGAATTTTTG CTAACATTGC AAGAAATCAG AGATAAAGCT 8 60 AAAGTCAAAA TACATTTTCA TTTCGCACTT GGACAATCAA CAGGCTTGAC ACACCCTTAT 8520 GTCAAATGGT TTATCGAAAG CTATTTAGGT GACGATGCCA CTGCACATCC CCACGCACCT 8580 TATCACGATT ATCTGGCAAT ATTGCGTGAT TGCGATATGC TACTAAATCC GTTTCCTTTC 8640 GGTAATACTA ACGGCATAAT TαATATGGTT ACATTAGGTT TAGTTGGTGT ATGCAAAACG 8700 GGGGATGAAG TACATGAACA TATTGATGAA GGTCTGTTTA AACGCTTAGG ACTACCAGAA 8760 TGGCTGATAG CCGACACACG AGAAACATAT ATTGAATGTG CTTTGCGTCT AGCAGAAAAC 8820 CATCAAGAAC GCCTTGAACT CCGTCGTTAC ATCATAGAAA ACAACGGCTT ACAAAAGCTT 8880 TTTACAGGCG ACCCTCGTCC ATTGGGCAAA ATACTGCTTA AGAAAACAAA TGAATGGAAG 8940 CGGAAGCACT TGAGTAAAAA ATAACGGTTT TTTAAAGTAA AAGTGCGGTT AATTTTCAAA 9000 GCGTTTTAAA AACCTCTCAA AAATCAACCG CACTTTTATC TTTATAACGC TCCCGCGCGC 9060 TGACAGTTTA TCTCTTTCTT AAAATACCCA TAAAATTGTG GCAATAGTTG GGTAATCAAA 9120 TTCAATTGTT GATACGGCAA ACTAAAGACG GCGCGTTCTT CGGCAGTCAT C 9171 (2) INFORMATION FOR SEQ ID NO:6: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 9323 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6: CGCCACTTCA ATTTTGGATT GTTGAAATTC AACTAACCAA AAAGTGCGGT TAAAATCTGT 60 GGAGAAAATA GGTTGTAGTG AAGAACGAGG TAATTGTTCA AAAGGATAAA GCTCTCTTAA 120 TTGGGCATTG GTTGGCGTTT CTTTTTCGGT TAATAGTAAA TTATATTCTG GACGACTATG 180 CAATCCACCA ACAACTTTAC CGTTGGTTTT AAGCGTTAAT GTAAGTTCTT GCTCTTCTTG 240 GCGAATACGT AATCCCATTT TTTGTTTAGC AAGAAAATGA TCGGGATAAT CATAATAGGT 300 GTTGCCCAAA AATAAATTTT GATGTTCTAA AATCATAAAT TTTGCAAGAT ATTGTGGCAA 360 TTCAATACCT ATTTGTGGCG AAATCGCCAA TTTTAATTCA ATTTCTTGTA GCATAATATT 420 TCCCACTCAA ATCAACTGGT TAAATATACA AGATAATAAA AATAAATCAA GATTTTTGTG 480 ATGACAAACA ACAATTACAA C-ACCTTTTTT GCAGTCTATA TGCAAATATT TTAAAAAAAT 540 AGTATAAATC CGCCATATAA AATGGTATAA TCTTTCATCT TTCATCTTTC ATCTTTCATC 600 TTTCATCTTT CATCTTTCAT CTTTCATCTT TCATCTTTCA TCTTTCATCT TTCATCTTTC 660 ATCTTTCATC TTTCATCTTT CACATGAAAT GATGAACCGA GGGAAGGGAG GGAGGGGCAA 720 GAATGAAGAG GGAGCTGAAC GAACGCAAAT GATAAAGTAA TTTAATTGTT CAACTAACCT 780 TAGGAGAAAA TATGAACAAG ATATATCGTC TCAAATTCAG CAAACGCCTG AATGCTTTGG 840 TTGCTGTGTC TGAATTGGCA CGGGGTTGTG ACCATTCCAC AGAAAAAGGC AGCGAAAAAC 900 CTGCTCGCAT GAAAGTGCGT CACTTAGCGT TAAAGCCACT TTCCGCTATG TTACTATCTT 960 TAGGTGTAAC ATCTATTCCA CAATCTGTTT TAGCAAGCGG CAATTTAACA TCGACCAAAA 1020 TGAAATGGTG CAGTTTTTAC AAGAAAACAA GTAATAAAAC CATTATCCGC AACAGTGTTG 1080 ACGCTATCAT TAATTGGAAA CAATTTAACA TCGACCAAAA TGAAATGGTG CAGTTTTTAC 1140 AAGAAAACAA CAACTCCGCC GTATTCAACC GTGTTACATC TAACCAAATC TCCCAATTAA 1200 AAGGGATTTT AGATTCTAAC GGACAAGTCT TTTTAATCAA CCCAAATGGT ATCACAATAG 1260 GTAAAGACGC AATTATTAAC ACTAATGGCT TTACGGCTTC TACGCTAGAC ATTTCTAACG 1320 AAAACATCAA GGCGCGTAAT TTCACCTTCG AGCAAACCAA AGATAAAGCG CTCGCTGAAA 1380 TTGTGAATCA CGGTTTAATT ACTGTCGGTA AAGACGGCAG TGTAAATCTT ATTGGTGGCA 1440 AAGTGAAAAA CGAGGGTGTG ATTAGCGTAA ATGGTGGCAG CATTTCTTTA CTCGCAGGGC 1500 AAAAAATCAC CATCAGCGAT ATAATAAACC CAACCATTAC TTACAGCATT GCCGCGCCTG 1560 AAAATGAAGC GGTCAATCTG GGCGATATTT TTGCCAAAGG CGGTAACATT AATGTCCGTG 1620 CTGCCACTAT TCGAAACCAA GGTAAACTTT CTGCTGATTC TGTAAGCAAA GATAAAAGCG 1680 GCAATATTGT TCTTTCCGCC AAAGAGGGTG AAGCGGAAAT TGGCGGTGTA ATTTCCGCTC 1740 AAAATCAGCA AGCTAAAGGC GGCAAGCTGA TGATAAAGTC CGATAAAGTC ACATTAAAAA 1800 CAGGTGCAGT TATCGACCTT TCAGGTAAAG AAGGGGGAGA AACTTACCTT GGCGGTGACG 1860 AGCGCGGCGA AGGTAAAAAC GGCATTCAAT TAGCAAAGAA AACCTCTTTA GAAAAAGGCT 1920 CAACCATCAA TGTATCAGGC AAAGAAAAAG GCGGACGCGC TATTGTGTGG GGCGATATTG 1980 CGTTAATTGA CGGCAATATT AACGCTCAAG GTAGTGGTGA TATCGCTAAA ACCGGTGGTT 2040 TTGTGGAGAC ATCGGGGCAT TATTTATCCA TTGACAGCAA TGCAATTGTT AAAACAAAAG 2100 AGTGGTTGCT AGACCCTGAT GATGTAACAA TTGAAGCCGA AGACCCCCTT CGCAATAATA 2160 CCGGTATAAA TGATGAATTC CCAACAGGCA CCGGTGAAGC AAGCGACCCT AAAAAAAATA 22 20 GCGAACTCAA AACAACGCTA ACCAATACAA CTATTTCAAA TTATCTGAAA AACGCCTGGA 22 80 CAATGAATAT AACGGCATCA AGAAAACTTA CCGTTAATAG CTCAATCAAC ATCGGAAGCA 234 0 ACTCCCACTT AATTCTCCAT AGTAAAGGTC AGCGTGGCGG AGGCGTTCAG ATTGATGGAG 2 00 ATATTACTTC TAAAGGCGGA AATTTAACCA TTTATTCTGG CGGATGGGTT GATGTTCATA 2 460 AAAATATTAC GCTTGATCAG GGTTTTTTAA ATATTACCGC CGCTTCCGTA GCTTTTGAAG 2S 2 0 GTGGAAATAA CAAAGCACGC GACGCGGCAA ATGCTAAAAT TGTCGCCCAG GGCAGTGTAA 2580 CCATTACAGG AGAGGGAAAA GATTTCAGGG CTAACAACGT ATCTTTAAAC GGAACGGGTA 26 4 0 AAGGTCTGAA TATCATTTCA TCAGTGAATA ATTTAACCCA CAATCTTAGT GGCACAATTA 2700 ACATATCTGG GAATATAACA ATTAACCAAA CTACGAGAAA GAACACCTCG TATTGGCAAA 2760 CCAGCCATGA TTCGCACTGG AACGTCAGTG CTCTTAATCT AGAGACAGGC GCAAATTTTA 2820 CCTTTATTAA ATACATTTCA AGCAATAGCA AAGGCTTAAC AACACAGTAT AGAAGCTCTG 2880 CAGGGGTGAA TTTTAACGGC GTAAATGGCA ACATGTCATT CAATCTCAAA GAAGGAGCGA 2940 AAGTTAATTT CAAATTAAAA CCAAACGAGA ACATGAACAC AAGCAAACCT TTACCAATTC 3000 GGTTTTTAGC CAATATCACA GCCACTGGTG GGGGCTCTGT TTTTTTTGAT ATATATGCCA 3060 ACCATTCTGG CAGAGGGGCT GAGTTAAAAA TGAGTGAAAT TAATATCTCT AACGGCGCTA 3120 ATTTTACCTT AAATTCCCAT GTTCGCGGCG ATGACGCTTT TAAAATCAAC AAAGACTTAA 3180 CCATAAATGC AACCAATTCA AATTTCAGCC TCAGACAGAC GAAAGATGAT TTTTATGACG 3240 GGTACGCACG CAATGCCATC AATTCAACCT ACAACATATC CATTCTGGGC GGTAATGTCA 3300 CCCTTGGTGG ACAAAACTCA AGCAGCAGCA TTACGGGGAA TATTACTATC GAGAAAGCAG 3360 CAAATGTTAC GCTAGAAGCC AATAACGCCC CTAATCAGCA AAACATAAGG GATAGAGTTA 3420 TAAAACTTGG C-AGCTTGCTC GTTAATGGGA GTTTAAGTTT AACTGGCGAA AATGCAGATA 3480 TTAAAGGCAA TCTCACTATT TCAGAAAGCG CCACTTTTAA AGGAAAGACT AGAGATACCC 3540 TAAATATCAC CGGCAATTTT ACCAATAATG GCACTGCCGA AATTAATATA ACACAAGGAG 3600 TGGTAAAACT TGGCAATGTT ACCAATGATG GTGATTTAAA CATTACCACT CACGCTAAAC 3660 GCAACCAAAG AAGCATCATC GGCGGAGATA TAATCAACAA AAAAGGAAGC TTAAATATTA 3720 CAGACAGTAA TAATGATGCT GAAATCCAAA TTGGCGGCAA TATCTCGCAA AAAGAAGGCA 3780 ACCTCACGAT TTCTTCCGAT AAAATTAATA TCACCAAACA GATAACAATC AAAAAGGGTA 3840 TTGATGGAGA GGACTCTAGT TCAGATGCGA CAAGTAATGC CAACCTAACT ATTAAAACCA 3900 AAGAATTGAA ATTGACAGAA GACCTAAGTA TTTCAGGTTT CAATAAAGCA GAGATTACAG 3960 CCAAAGATGG TAGAGATTTA ACTATTGGCA ACAGTAATGA CGGTAACAGC GGTGCCGAAG 4020 CCAAAACAGT AACTTTTAAC AATGTTAAAG ATTCAAAAAT CTCTGCTGAC GGTCACAATG 4080 TGACACTAAA TAGCAAAGTG AAAACATCTA GCAGCAATGG CGGACGTGAA AGCAATAGCG 4140 ACAACGATAC CGGCTTAACT ATTACTGCAA AAAATGTAGA AGTAAACAAA GATATTACTT 4200 CTCTCAAAAC AGTAAATATC ACCGCGTCGG AAAAGGTTAC CACCACAGCA GGCTCGACCA 4260 TTAACGCAAC AAATGGCAAA GCAAGTATTA CAACCAAAAC AGGTGATATC AGCGGTACGA 4320 TTTCCGGTAA CACGGTAAGT GTTAGCGCGA CTGGTGATTT AACCACTAAA TCCGGCTCAA 4380 AAATTGAAGC GAAATCGGGT GAGGCTAATG TAACAAGTGC AACAGGTACA ATTGGCGGTA 4440 CAATTTCCGG TAATACGGTA AATGTTACGG CAAACGCTGG CGATTTAACA GTTGGGAATG 4500 GCGCAGAAAT TAATGCGACA GAAGGAGCTG CAACCTTAAC CGCAACAGGG AATACCTTGA 4560 CTACTGAAGC CGGTTCTAGC ATCACTTCAA CTAAGGGTCA GGTAGACCTC TTGGCTCAGA 4620 ATGGTAGCAT CGCAGGAAGC ATTAATGCTG CTAATGTGAC ATTAAATACT ACAGGCACCT 4680 TAACCACCGT GGCAGGCTCG GATATTAAAG CAACCAGCGG CACCTTGGTT ATTAACGCAA 4740 AAGATGCTAA GCTAAATGGT GATGCATCAG GTGATAGTAC AGAAGTGAAT GCAGTCAACG 4800 ACTGGGGATT TGGTAGTGTG ACTGCGGCAA CCTCAAGCAG TGTGAATATC ACTGGGGATT 4860 TAAACACAGT AAATGGGTTA AATATCATTT CGAAAGATGG TAGAAACACT GTGCGCTTAA 4920 GAGGCAAGGA AATTGAGGTG AAATATATCC AGCCAGGTGT AGCAAGTGTA GAAGAAGTAA 4980 TTGAAGCGAA ACGCGTCCTT GAAAAAGTAA AAGATTTATC TGATGAAGAA AGAGAAACAT 5040 TAGCTAAACT TGGTGTAAGT GCTGTACGTT TTGTTGAGCC AAATAATACA ATTACAGTCA 5100 ATACACAAAA TGAATTTACA ACCAGACCGT CAAGTCAAGT GATAATTTCT GAAGGTAAGG 5160 CGTGTTTCTC AAGTGGTAAT GGCGCACGAG TATGTACCAA TGTTGCTGAC GATGGACAGC S220 CGTAGTCAGT AATTGACAAG GTAGATTTCA TCCTGCAATG AAGTCATTTT ATTTTCGTAT 5280 TATTTACTGT GTGGGTTAAA GTTCAGTACG GGCTTTACCC ATCTTGTAAA AAATTACGGA 5340 GAATACAATA AAGTATTTTT AACAGGTTAT TATTATGAAA AATATAAAAA GCAGATTAAA 5400 ACTCAGTGCA ATATCAGTAT TGCTTGGCCT GGCTTCTTCA TCATTGTATG CAGAAGAAGC 5460 GTTTTTAGTA AAAGGCTTTC AGTTATCTGG TGCACTTGAA ACTTTAAGTG AAGACGCCCA 5520 ACTGTCTGTA GCAAAATCTT TATCTAAATA CCAAGGCTCG CAAACTTTAA CAAACCTAAA 5580 AACAGCACAG CTTGAATTAC AGGCTGTGCT AGATAAGATT GAGCCAAATA AATTTGATGT 5640 GATATTGCCG CAACAAACCA TTACGGATGG CAATATCATG TTTGAGCTAG TCTCGAAATC 5700 AGCCGCAGAA AGCCAAGTTT TTTATAAGGC GAGCCAGGGT TATAGTGAAG AAAATATCGC 5760 TCGTAGCCTG CCATCTTTGA AACAAGGAAA AGTGTATGAA GATGGTCGTC AGTGGTTCGA 5820 TTTGCGTGAA TTTAATATGG CAAAAGAAAA COCGCTTAAG GTTACCCGTG TACATTACGA 5880 ACTAAACCCT AAAAACAAAA CCTCTAATTT GATAATTGCG QGTT TCG CTTTTGGTAA 5940 AACGCGTAGC TTTATTTCTT ATGATAATTT 0«X33CGAGA GAGTTTAACT ACCAACGTGT 6000 AAGCTTGGGT TTTGTTAATG CCAATTTAAC TGGTCATGAT GATGTGTTAA TTATACCAGT 6060 ATGAGTTATG CTGATTCTAA TGATATCGAC GGCTTACCAA GTGCGATTAA TCGTAAATTA 6120 TCAAAAGGTC AATCTATCTC TGCGAATCTG AAATGGAGTT ATTATCTCCC AACATTTAAC 6180 CTTGGCATGG AAGACCAATT TAAAATTAAT TTAGGCTACA ACTACCGCCA TATTAATCAA 6240 ACCTCCGCGT TAAATCGCTT GGGTGAAACG AAGAAAAAAT TTGCAGTATC AGGCGTAAGT 6300 GCAGGCATTG ATGGACATAT CCAATTTACC CCTAAAACAA TCTTTAATAT TGATTTAACT 6360 CATCATTATT ACGCGAGTAA ATTACCAGGC TCTTTTGGAA TGGAGCGCAT TGGCGAAACA 6 20 TTTAATCGCA GCTATCACAT TAGCACAGCC AGTTTAGGGT TGAGTCAAGA GTTTGCTCAA 6480 GGTTGGCATT TTAGCAGTCA ATTATCAGGT CAATTTACTC TACAAGATAT TAGCAGTATA 6540 GATTTATTCT CTGTAACAGG TACTTATGGC GTCAGAGGCT TTAAATACGG CGGTGCAAGT 6600 GGTGAGCGCG GTCTTGTATG GCGTAATGAA TTAAGTATGC CAAAATACAC CCGCTTCCAA 6660 ATCAGCCCTT ATGCGTTTTA TGATGCAGGT CAGTTCCGTT ATAATAGCGA AAATGCTAAA 6720 ACTTACGGCG AAGATATGCA CACGGTATCC TCTGCGGGTT TAGGCATTAA AACCTCTCCT 6780 ACACAAAACT TAAGCCTAGA TGCTTTTGTT GCTCGTCGCT TTGCAAATGC CAATAGTGAC 6840 AATTTGAATG GCAACAAAAA ACGCACAAGC TCACCTACAA CCTTCTGGGG GAGATTAACA 6900 TTCAGTTTCT AACCCTGAAA TTTAATCAAC TGGTAAGCGT TCCGCCTACC AGTTTATAAC 6960 TATATGCTTT ACCCGCCAAT TTACAGTCTA TAGGCAACCC TGTTTTTACC CTTATATATC 7020 AAATAAACAA GCTAAGCTGA GCTAAGCAAA CCAAGCAAAC TCAAGCAAGC CAAGTAATAC 7080 TAAAAAAACA ATTTATATGA TAAACTAAAG TATACTCCAT GCCATGGCGA TACAAGGGAT 7140 TTAATAATAT GACAAAAGAA AATTTGCAAA ACGCTCCTCA AGATGCGACC GCTTTACTTG 7200 CGGAATTAAG CAACAATCAA ACTCCCCTGC GAATATTTAA ACAACCACGC AAGCCCAGCC 7260 TATTACGCTT GGAACAACAT ATCGCAAAAA AAGATTATGA GTTTGCTTGT CGTGAATTAA 7320 TGGTGATTCT GGAAAAAATG GACGCTAATT TTGGAGGCGT TCACGATATT GAATTTGACG 7380 CACCCGCTCA GCTGGCATAT CTACCCGAAA AATTACTAAT TTATTTTGCC ACTCGTCTCG 7440 CTAATGCAAT TACAACACTC TTTTCCGACC CCGAATTGGC AATTTCTGAA GAAGGGGCGT 7500 TAAAGATGAT TAGCCTGCAA CX-CTGGTTGA CGCTGATTTT TGCCTCTTCC CCCTACGTTA 7560 ACGCAGACCA TATTCTCAAT AAATATAATA TCAACCCAGA TTCCGAAGGT GGCTTTCATT 7620 TAGCAACAGA CAACTCTTCT ATTGCTAAAT TCTGTATTTT TTACTTACCC GAATCCAATG 7680 TCAATATGAG TTTAGATGCG TTATGGGCAG GGAATCAACA ACTTTGTGCT TCATTGTGTT 7740 TTGCGTTGCA GTCTTCACGT TTTATTGGTA CCGCATCTGC GTTTCATAAA AGAGCGGTGG 7800 TTTTACAGTG GTTTCCTAAA AAACTCGCCG AAATTGCTAA TTTAGATGAA TTGCCTGCAA 7860 ATATCCTTCA TGATGTATAT ATGCACTGCA GTTATGATTT AGCAAAAAAC AAGCACGATG 7920 TTAAGCGTCC ATTAAACGAA CTTGTCCGCA AGCATATCCT CACGCAAGGA TGGCAAGACC 7980 GCTACCTTTA CACCTTAGGT AAAAAGGACG GCAAACCTGT GATGATGGTA CTGCTTGAAC 8040 ATTTTAATTC GGGACATTCG ATTTATCGTA CACATTCAAC TTCAATGATT GCTGCTCGAG 8100 AAAAATTCTA TTTAGTCGGC TTAGGCCATG AGGGCGTTGA TAAAATAGGT CGAGAAGTGT 8160 TTGACGAGTT CTTTGAAATC AGTAGCAATA ATATAATGGA GAGACTGTTT TTTATCCGTA 8220 AACAGTGCGA AACTTTCCAA CCCGCAGTGT TCTATATGCC AAGCATTGGC ATGGATATTA 8280 CCACGATTTT TGTGAGCAAC ACTCGGCTTG CCCCTATTCA AGCTGTAGCC CTGGGTCATC 8340 CTGCCACTAC GCATTCTGAA TTTATTGATT ATGTCATCGT AGAAGATGAT TATGTGGGCA 8400 GTGAAGATTG TTTCAGCGAA ACCCTTTTAC GCTTACCCAA AGATGCCCTA CCTTATGTAC 8460 CTTCTGCACT CGCCCCACAA AAAGTGGATT ATGTACTCAG GGAAAACCCT GAAGTAGTCA 8520 ATATCGGTAT TGCCGCTACC ACAATGAAAT TAAACCCTGA ATTTTTGCTA ACATTGCAAG 8580 AAATCAGAGA TAAAGCTAAA GTCAAAATAC ATTTTCATTT CGCACTTGGA CAATCAACAG 8640 GCTTGACACA CCCTTATGTC AAATGGTTTA TCGAAAGCTA TTTAGGTGAC GATGCCACTG 8700 CACATCCCCA CGCACCTTAT CACGATTATC TGGCAATATT GCGTGATTGC GATATGCTAC 8760 TAAATCCGTT TCCTTTCGGT AATACTAACG GCATAATTGA TATGGTTACA TTAGGTTTAG 8820 TTGGTGTATG CAAAACGGGG GATGAAGTAC ATGAACATAT TGATGAAGGT CTGTTTAAAC 8880 GCTTAGGACT ACCAGAATGG CTGATAGCCG ACACACGAGA AACATATATT GAATGTGCTT 8940 TGCGTCTAGC AGAAAACCAT CAAGAACGCC TTGAACTCCG TCGTTACATC ATAGAAAACA 9000 ACGGCTTACA AAAGCTTTTT ACAGGCGACC CTCGTCCATT GGGCAAAATA CTGCTTAAGA 9060 AAACAAATGA ATGGAAGCGG AAGCACTTGA GTAAAAAATA ACGGTTTTTT AAAGTAAAAG 9120 TGCGGTTAAT TTTCAAAGCG TTTTAAAAAC CTCTCAAAAA TCAACCGCAC TTTTATCTTT 9180 ATAACGATCC CGCACGCTGA CAGTTTATCA GCCTCCCGCC ATAAAACTCC GCCTTTCATG 9240 GCGGAGATTT TAGCCAAAAC TGGCAGAAAT TAAAGGCTAA AATCACCAAA TTGCACCACA 9300 AAATCACCAA TACCCACAAA AAA 9323 (21 INFORMATION FOR SEQ ID NO:7: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 4794 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7: ATGAACAAGA TATATCGTCT CAAATTCAGC AAACGCCTGA ATGCTTTGGT TGCTGTGTCT 60 GAATTGACAC GGGGTTGTGA CCATTCCACA GAAAAAGGCA GTGAAAAACC TβTTCGTACG 120 AAAGTACGCC ACTTGGCGTT AAAGCCACTT TCCGCTATAT TGCTATCTTT GGGCATGGCA 180 TCCATTCCGC AATCTGTTTT AGCGAGOGGT TTACAGGQAA TGAGCGTCGT ACACGGTACA 240 GCAACCATGC AAGTAGACGG CAATAAAACC ACTATCCGTA ATAGCGTCAA TGCTATCATC 300 AATTGGAAAC AATTTAACAT TGACCAAAAT GAAATGGTGC AGTTTTTACA AGAAAGCAGC 360 AACTCTGCCG TTTTCAACCG TGTTACATCT GACCAAATCT CCCAATTAAA AGGGATTTTA 420 GATTCTAACG GACAAGTCTT TTTAATCAAC CCAAATGGTA TCACAATAGG TAAAGACGCA 4 80 ATTATTAACA CTAATGGCTT TACTGCTTCT ACGCTAGACA TTTCTAACGA AAACATCAAG 5 0 GCGCGTAATT TCACCCTTGA GCAAACCAAG GATAAAGCAC TCGCTGAAAT CGTGAATCAC 6 00 GGTTTAATTA CCGTTGGTAA AGACGGTAGC GTAAACCTTA TTGGTGGCAA AGTGAAAAAC 66 0 GAGGGCGTGA TTAGCGTAAA TGGCGGTAGT ATTTCTTTAC TTGCAGGGCA AAAAATCACC 720 ATCAGCGATA TAATAAATCC AACCATCACT TACAGCATTG CTGCACCTGA AAACGAAGCG 780 ATCAATCTGG GCGATATTTT TGCCAAAGGT GGTAACATTA ATGTCCGCGC TGCCACTATT 8 4 0 CGCAATAAAG GTAAACTTTC TGCCGACTCT GTAAGCAAAG ATAAAAGTGG TAACATTGTT 900 CTCTCTGCCA AAGAAGGTGA AGCGGAAATT GGCGGTGTAA TTTCCGCTCA AAATCAGCAA 960 GCCAAAGGTG GTAAGTTGAT GATTACAGGC GATAAAGTTA CATTGAAAAC GGGTGCAGTT 1020 ATCGACCTTT CGGGTAAAGA AGGGGGAGAA ACTTATCTTG GCGGTGACGA GCGTGGCGAA 1 080 GGTAAAAACG GCATTCAATT AGCAAAGAAA ACCACTTTAG AAAAAGGCTC AACAATTAAT 1 140 GTGTCAGGTA AAGAAAAAGG TGGGCGCGCT ATTGTATGGG GCGATATTGC GTTAATTGAC 1200 GGCAATATTA ATGCCCAAGG TAAAGATATC GCTAAAACTG GTGGTTTTGT GGAGACGTCG 1260 GGGCATTACT TATCCATTGA TGATAACGCA ATTGTTAAAA CAAAAGAATG GCTACTAGAC 1320 CCAGAGAATG TGACTATTGA AGCTCCTTCC GCTTCTCGCG TCGAGCTGGG TGCCGATAGG 1380 AATTCCCACT CGGCAGAGGT GATAAAAGTG ACCCTAAAAA AAAATAACAC CTCCTTGACA 1440 ACACTAACCA ATACAACCAT TTCAAATCTT CTGAAAAGTG CCCACGTGGT GAACATAACG 1S00 GCAAGGAGAA AACTTACCGT TAATAGCTCT ATCAGTATAG AAAGAGGCTC CCACTTAATT 1560 CTCCACAGTG AAGGTCAGGG CGGTCAAGGT GTTCAGATTG ATAAAGATAT TACTTCTGAA 1620 GGCGGAAATT TAACCATTTA TTCTGGCGGA TGGGTTGATG TTCATAAAAA TATTACGCTT 1680 GGTAGCGGCT TTTTAAACAT CACAACTAAA GAAGGAGATA TCGCCTTCGA AGACAAGTCT 1740 GGACGGAACA ACCTAACCAT TACAGCCCAA GGGACCATCA CCTCAGGTAA TAGTAACGGC 1800 TTTAGATTTA ACAACGTCTC TCTAAACAGC CTTGGCGGAA AGCTGAGCTT TACTGACAGC 1860 AGAGAGGACA GAGGTAGAAG AACTAAGGGT AATATCTCAA ACAAATTTGA CGGAACGTTA 1920 AACATTTCCG GAACTGTAGA TATCTCAATG AAAGCACCCA AAGTCAGCTG GTTTTACAGA 1980 GACAAAGGAC GCACCTACTG GAACGTAACC ACTTTAAATG TTACCTCGGG TAGTAAATTT 2040 AACCTCTCCA TTGACAGCAC AGGAAGTGGC TCAACAGGTC CAAGCATACG CAATGCAGAA 2100 TTAAATGGCA TAACATTTAA TAAAGCCACT TTTAATATCG CACAAGGCTC AACAGCTAAC 2160 TTTAGCATCA AGGCATCAAT AATGCCCTTT AAGAGTAACG CTAACTACGC ATTATTTAAT 2220 GAAGATATTT CAGTCTCAGG GGGGGGTAGC CTTAATTTCA AACTTAACGC CTCATCTAGC 2280 AACATACAAA CCCCTGGCGT AATTATAAAA TCTCAAAACT TTAATGTCTC AGGAGGGTCA 23 0 ACTTTAAATC TCAAGGCTGA AGGTTCAACA GAAACCGCTT TTTCAATAGA AAATGATTTA 2400 AACTTAAACG CCACCGGTGG CAATATAACA ATCAGACAAG TCGAGGGTAC CGATTCACGC 2460 GTCAACAAAG GTGTCGCAGC CAAAAAAAAC ATAACTTTTA AAGGGGGTAA TATCACCTTC 2520 GGCTCTCAAA AAGCCACAAC AGAAATCAAA GGCAATGTTA CCATCAATAA AAACACTAAC 2580 GCTACTCTTT GTGGTGCGAA TTTTGCCGAA AACAAATCGC CTTTAAATAT AGCAGGAAAT 2640 GTTATTAATA ATGGCAACCT TACCACTGCC GGCTCCATTA TCAATATAGC CGGAAATCTT 2700 ACTGTTTCAA AAGGCGCTAA CCTTCAAGCT ATAACAAATT ACACTTTTAA TGTAGCCGGC 2760 TCATTTGACA ACAATGGCGC TTCAAACATT TCCATTGCCA GAGGAGGGGC TAAATTTAAA 2820 GATATCAATA ACACCAGTAG CTTAAATATT ACCACCAACT CTGATACCAC TTACCGCACC 2880 ATTATAAAAG GCAATATATC CAACAAATCA GGTGATTTGA ATATTATTGA TAAAAAAAGC 2940 GACGCTGAAA TCCAAATTGG CGGCAATATC TCACAAAAAG AAGGCAATCT CACAATTTCT 3000 TCTGATAAAG TAAATATTAC CAATCAGATA ACAATCAAAG CAGGCGTTGA AGGGGGGCGT 3060 TCTGATTCAA GTGAGGCAGA AAATGCTAAC CTAACTATTC AAACCAAAGA GTTAAAATTG 3120 GCAGGAGACC TAAATATTTC AGGCTTTAAT AAAGCAGAAA TTACAGCTAA AAATGGCAGT 3180 GATTTAACTA TTGGCAATGC TAGCGGTGGT AATGCTGATG CTAAAAAAGT GACTTTTGAC 3240 AAGGTTAAAG ATTCAAAAAT CTCGACTGAC GGTCACAATG TAACACTAAA TAGCGAAGTG 3300 AAAACGTCTA ATGGTAGTAG CAATGCTGGT AATGATAACA GCACCGGTTT AACCATTTCC 3360 GCAAAAGATG TAACGGTAAA CAATAACGTT ACCTCCCACA AGACAATAAA TATCTCTGCC 3420 GCAGCAGGAA ATGTAACAAC CAAAGAAGGC ACAACTATCA ATGCAACCAC AGGCAGCGTG 3480 GAAGTAACTG CTCAAAATGG TACAATTAAA GGCAACATTA CCTCGCAAAA TGTAACAGTG 3540 ACAGCAACAG AAAATCTTGT TACCACAGAG AATGCTGTCA TTAATGCAAC CAGCGGCACA 3600 GTAAACATTA GTACAAAAAC AGGGGATATT AAAGGTGGAA TTGAATCAAC TTCCGGTAAT 3660 GTAAATATTA CAGCGAGCGG CAATACACTT AAGGTAAGTA ATATCACTGG TCAAGATGTA 3720 ACAGTAACAG CGGATGCAGG AGCCTTGACA ACTACAGCAG GCTCAACCAT TAGTGCGACA 3780 ACAGGCAATG CAAATATTAC AACCAAAACA GGTGATATCA ACGGTAAAGT TGAATCCAGC 3840 TCCGGCTCTG TAACACTTGT TGCAACTGGA GCAACTCTTG CTGTAGGTAA TATTTCAGGT 3900 AACACTGTTA CTATTACTGC GGATAGCGGT AAATTAACCT CCACAGTAGG TTCTACAATT 3960 AATGGGACTA ATAGTGTAAC CACCTCAAGC CAATCAGGCG ATATTGAAGG TACAATTTCT 4020 GGTAATACAG TAAATGTTAC AGCAAGCACT GGTGATTTAA CTATTGGAAA TAGTGCAAAA 4080 GTTGAAGCGA AAAATGGAGC TGCAACCTTA ACTGCTGAAT CAGGCAAATT AACCACCCAA 4140 ACAGGCTCTA GCATTACCTC AAGCAATGGT CAGACAACTC TTACAGCCAA GGATAGCAGT 4200 ATCGCAGGAA ACATTAATGC TGCTAATGTG ACGTTAAATA CCACAGGCAC TTTAACTACT 4260 ACAGGGGATT CAAAGATTAA CGCAACCAGT GGTACCTTAA CAATCAATGC AAAAGATGCC 4320 AAATTAGATG GTGCTGCATC AGGTGACCGC ACAGTAGTAA ATGCAACTAA CGCAAGTGGC 4380 TCTGGTAACG TGACTGCGAA AACCTCAAGC AGCGTGAATA TCACCGGGGA TTTAAACACA 4440 ATAAATGGGT TAAATATCAT TTCGGAAAAT GGTAGAAACA CTGTGCGCTT AAGAGGCAAG 4500 GAAATTGATG TGAAATATAT CCAACCAGGT GTAGCAAGCG TAGAAGAGGT AATTGAAGCG 4560 AAACGCGTCC TTGAGAAGGT AAAAGATTTA TCTGATGAAG AAAGAGAAAC ACTAGCCAAA 4620 CTTGGTGTAA GTGCTGTACG TTTCGTTGAG CCAAATAATG CCATTACGGT TAATACACAA 4680 AACGAGTTTA CAACCAAACC ATCAAGTCAA GTGACAATTT CTGAAGGTAA GGCGTGTTTC 4740 TCAAGTGGTA ATGGCGCACG AGTATGTACC AATGTTGCTG ACGATGGACA GCAG 4794 (2) INFORMATION FOR SEQ ID NO:8: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 4803 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8: ATGAACAAGA TATATCGTCT CAAATTCAGC AAACGCCTGA GAATTGACAC GGGGTTGTGA CCATTCCACA GAAAAAGGCA AAAGTACGCC ACTTGGCGTT AAAGCCACTT TCCGCTATAT TCCATTCCGC AATCTGTTTT AGCGAGCGGT TTACAGGGAA GCAACCATGC AAGTAGACGG CAATAAAACC ACTATCCGTA AATTGGAAAC AATTTAACAT TGACCAAAAT GAAATGGTGC AACTCTGCCG TTTTCAACCG TGTTACATCT GACCAAATCT GATTCTAACG GACAAGTCTT TTTAATCAAC CCAAATGGTA ATTATTAACA CTAATGGCTT TACTGCTTCT ACGCTAGACA GCGCGTAATT TCACCCTTGA GCAAACCAAG GATAAAGCAC GGTTTAATTA CCGTTGGTAA AGACGGTAGC GTAAACCTTA GAGGGCGTGA TTAGCGTAAA TGGCGGTAGT ATTTCTTTAC ATCAGCGATA TAATAAATCC AACCATCACT TACAGCATTG ATCAATCTGG GCGATATTTT TGCCAAAGGT GGTAACATTA CGCAATAAAG GTAAACTTTC TGCCGACTCT GTAAGCAAAG CTCTCTGCCA AAGAAGGTGA AGCGGAAATT GGCGGTGTAA GCCAAAGGTG GTAAGTTGAT GATTACAGGT GATAAAGTCA ATCGACCTTT CAGGTAAAGA AGGGGGAGAG ACTTATCTTG GGTAAAAATG GTATTCAATT AGCGAAGAAA ACCTCTTTAG GTATCAGGCA AAGAAAAAGG CGGGCGCGCT ATTGTATGGG GGTAACATTA ATGCTCAAGG TAGCGATATT GCTAAAACTG GGACATGACT TATCCATTGG TGATGATGTG ATTGTTGACG CTAAAGAGTG GTTATTAGAC 1320 CCAGATGATG TGTCCATTGA AACTCTTACA TCTGGACGCA ATAATACCGG CGAAAACCAA 1380 GG ATATACAA CAGGAGATGG GACTAAAGAG TCACCTAAAG GTAATAGTAT TTCTAAACCT 1440 ACATTAACAA ACTCAACTCT TGAGCAAATC CTAAGAAGAG GTTCTTATGT TAATATCACT 1500 GCTAATAATA GAATTTATGT TAATAGCTCC ATCAACTTAT CTAATGGCAG TTTAACACTT 1560 CACACTAAAC GAGATGGAGT TAAAATTAAC GGTGATATTA CCTCAAACGA AAATGGTAAT 1620 TTAACCATTA AAGCAGGCTC TTGGGTTGAT GTTCATAAAA ACATCACGCT TGGTACGGGT 1680 TTTTTGAATA TTGTCGCTGG GGATTCTGTA GCTTTTGAGA GAGAGGGCGA TAAAGCACGT 1740 AACGCAACAG ATGCTCAAAT TACCGCACAA GGGACGATAA CCGTCAATAA AGATGATAAA 1800 CAATTTAGAT TCAATAATGT ATCTATTAAC GGGACGGGCA AGGGTTTAAA GTTTATTGCA 1860 AATCAAAATA ATTTCACTCA TAAATTTGAT GGCGAAATTA ACATATCTGG AATAGTAACA 1920 ATTAACCAAA CCACGAAAAA AGATGTTAAA TACTGGAATG CATCAAAAGA CTCTTACTGG 1980 AATGTTTCTT CTCTTACTTT GAATACGGTG CAAAAATTTA CCTTTATAAA ATTCGTTGAT 2040 AGCGGCTCAA ATTCCCAAGA TTTGAGGTCA TCACGTAGAA GTTTTGCAGG CGTACATTTT 2100 AACGGCATCG GAGGCAAAAC AAACTTCAAC ATCGGAGCTA ACGCAAAAGC CTTATTTAAA 2160 TTAAAACCAA ACGCCGCTAC AGACCCAAAA AAAGAATTAC CTATTACTTT TAACGCCAAC 2220 ATTACAGCTA CCGGTAACAG TGATAGCTCT GTGATGTTTG ACATACACGC CAATCTTACC 2280 TCTAGAGCTG CCGGCATAAA CATGGATTCA ATTAACATTA CCGGCGGGCT TGACTTTTCC 2340 ATAACATCCC ATAATCGCAA TAGTAATGCT TTTGAAATCA AAAAAGACTT AACTATAAAT 2400 GCAACTGGCT CGAATTTTAG TCTTAAGCAA ACGAAAGATT CTTTTTATAA TGAATACAGC 2460 AAACACGCCA TTAACTCAAG TCATAATCTA ACCATTCTTG GCGGCAATGT CACTCTAGGT 2520 GGGGAAAATT CAAGCAGTAG CATTACGGGC AATATCAATA TCACCAATAA AGCAAATGTT 2580 ACATTACAAG CTGACACCAG CAACAGCAAC ACΛGGCTTGA AGAAAAGAAC TCTAACTCTT 2640 GGCAATATAT CTGTTGAGGG GAATTTAAGC CTAACTGGTG CAAATGCAAA CATTGTCGGC 2700 AATCTTTCTA TTGCAGAAGA TTCCACATTT AAAGGAGAAG CCAGTGACAA CCTAAACATC 2760 ACCGGCACCT TTACCAACAA CGGTACCGCC AACATTAATA TAAAACAAGG AGTGGTAAAA 2820 CTCCAAGGCG ATATTATCAA TAAAGGTGGT TTAAATATCA CTACTAACGC CTCAGGCACT 2880 CAAAAAACCA TTATTAACGG AAATATAACT AACGAAAAAG GCGACTTAAA CATCAAGAAT 2940 ATTAAAGCCG ACGCCGAAAT CCAAATTGGC GGCAATATCT CACAAAAAGA AGGCAATCTC 3000 ACAATTTCTT CTGATAAAGT AAATATTACC AATCAGATAA CAATCAAAGC AGGCGTTGAA 3060 GGGGGGCGTT CTGATTCAAG TGAGGCAGAA AATGCTAACC TAACTATTCA AACCAAAGAG 3120 TTAAAATTGG CAGGAGACCT AAATATTTCA GGCTTTAATA AAGCAGAAAT TACAGCTAAA 3180 AATGGCAGTG ATTTAACTAT TGGCAATGCT AGCGGTGGTA ATGCTGATGC TAAAAAAGTG 3240 ACTTTTGACA AGGTTAAAGA TTCAAAAATC TCGACTGACG GTCACAATGT AACACTAAAT 3300 AGCGAAGTGA AAACGTCTAA TGGTAGTAGC AATGCTGGTA ATGATAACAG CACCGGTTTA 3360 ACCATTTCCG CAAAAGATGT AACGGTAAAC AATAACGTTA CCTCCCACAA GACAATAAAT 3420 ATCTCTGCCG CAGCAGGAAA TGTAACAACC AAAGAAGGCA CAACTATCAA TGCAACCACA 3480 GGCAGCGTGG AAGTAACTGC TCAAAATGGT ACAATTAAAG GCAACATTAC CTCGCAAAAT 3540 GTAACAGTGA CAGCAACAGA AAATCTTGTT ACCACAGAGA ATGCTGTCAT TAATGCAACC 3600 AGCGGCACAG TAAACATTAG TACAAAAACA GGGGATATTA AAGGTGGAAT TGAATCAACT 3660 TCCGGTAATG TAAATATTAC AGCGAGCGGC AATACACTTA AGGTAAGTAA TATCACTGGT 3720 CAAGATGTAA CAGTAACAGC GGATGCAGGA GCCTTGACAA CTACAGCAGG CTCAACCATT 3780 AGTGCGACAA CAGGCAATGC AAATATTACA ACCAAAACAG GTGATATCAA CGGTAAAGTT 3840 GAATCCAGCT CCGGCTCTGT AACACTTGTT GCAACTGGAG CAACTCTTGC TGTAGGTAAT 3900 ATTTCAGGTA ACACTGTTAC TATTACTGCG GATAGCGGTA AATTAACCTC CACAGTAGGT 3960 TCTACAATTA ATGGGACTAA TAGTGTAACC ACCTCAAGCC AATCAGGCGA TATTGAAGGT 4020 ACAATTTCTG GTAATACAGT AAATGTTACA GCAAGCACTG GTGATTTAAC TATTGGAAAT 4080 AGTGCAAAAG TTGAAGCGAA AAATGGAGCT GCAACCTTAA CTGCTGAATC AGGCAAATTA 4140 ACCACCCAAA CAGGCTCTAG CATTACCTCA AGCAATGGTC AGACAACTCT TACAGCCAAG 4200 GATAGCAGTA TCGCAGGAAA CATTAATGCT GCTAATGTGA CGTTAAATAC CACAGGCACT 4260 TTAACTACTA CAGGGGATTC AAAGATTAAC GCAACCAGTG GTACCTTAAC AATCAATGCA 4320 AAAGATGCCA AATTAGATGG TGCTGCATCA GGTGACCGCA CAGTAGTAAA TGCAACTAAC 4380 GCAAGTGGCT CTGGTAACGT GACTGCGAAA ACCTCAAGCA GCGTGAATAT CACCGGGGAT 4440 TTAAACACAA TAAATGGGTT AAATATCATT TCGGAAAATG GTAGAAACAC TGTGCGCTTA 4500 AGAGGCAAGG AAATTGATGT GAAATATATC CAACCAGGTG TAGCAAGCGT AGAAGAGGTA 4560 ATTGAAGCGA AACGCGTCCT TGAGAAGGTA AAAGATTTAT CTGATGAAGA AAGAGAAACA 4620 CTAGCCAAAC TTGGTGTAAG TGCTGTACGT TTCGTTGAGC CAAATAATGC CATTACGGTT 4680 AATACACAAA ACGAGTTTAC AACCAAACCA TCAAGTCAAG TGACAATTTC TGAAGGTAAG 4740 GCGTGTTTCT CAAGTGGTAA TGGCGCACGA GTATGTACCA ATGTTGCTGA CGATGGACAG 4800 CAG 4803 (2 ) INFORMATION FOR SEQ ID NO : 9 : (i) SEQUENCE CHARACTERISTICS : (A) LENGTH : 1599 amino acids (B) TYPE : amino acid (C) STRANDEDNESS : single (D) TOPOLOGY : linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9: Met Asn Lys He Tyr Arg Leu Lys Phe Ser Lys Arg Leu Asn Ala Leu 1 5 10 15 Val Ala Val Ser Glu Leu Thr Arg Gly Cys Asp His Ser Thr Glu Lys 20 25 30 Gly Ser Glu Lys Pro Val Arg Thr Lys Val Arg His Leu Ala Leu Lys 35 40 45 Pro Leu Ser Ala He Leu Leu Ser Leu Gly Met Ala Ser He Pro Gin 50 55 60 Ser Val Leu Ala Ser Gly Leu Gin Gly Met Ser Val Val His Gly Thr 65 70 75 80 Ala Thr Met Gin Val Asp Gly Asn Lys Thr Thr He Arg Asn Ser Val 85 90 95 Asn Ala He He Asn Trp Lys Gin Phe Asn He Asp Gin Asn Glu Met 100 105 110 Glu Gin Phe Leu Gin Glu Ser Ser Asn Ser Ala Val Phe Asn Arg Val 115 120 125 Thr Ser Asp Gin He Ser Gin Leu Lys Gly He Leu Asp Ser Asn Gly 130 135 140 Gin Val Phe Leu He Asn Pro Asn Gly He Thr He Gly Lys Asp Ala 145 150 155 160 He He Asn Thr Asn Gly Phe Thr Ala Ser Thr Leu Asp He Ser Asn 165 170 175 Glu Asn He Lys Ala Arg Asn Phe Thr Leu Glu Gin Thr Lys Asp Lys 180 185 190 Ala Leu Ala Glu He Val Asn His Gly Leu He Thr Val Gly Lys Asp 195 200 205 Gly Ser Val Asn Leu He Gly Gly Lys Val Lys Asn Glu Gly Val He 210 215 220 Ser Val Asn Gly Gly Ser He Ser Leu Leu Ala Gly Gin Lys He Thr 225 230 235 240 He Ser Asp He He Asn Pro Thr He Thr Tyr Ser He Ala Ala Pro 245 250 255 Glu Asn Glu Ala He Asn Leu Gly Asp He Phe Ala Lys Gly Gly Asn 260 265 270 He Asn Val Arg Ala Ala Thr He Arg Asn Lys Gly Lys Leu Ser Ala 275 280 285 Asp Ser Val Ser Lys Asp Lys Ser Gly Asn He Val Leu Ser Ala Lys 290 295 300 Glu Gly Glu Ala Glu He Gly Gly Val He Ser Ala Gin Asn Gin Gin 305 310 315 320 Ala Lvs Gly Gly Lys Leu Met He Thr Gly Asp Lys Val Thr Leu Lys 325 330 335 Thr Gly Ala Val He Asp Leu Ser Gly Lys Glu Gly Gly Glu Thr Tyr 340 345 350 Leu Gly Gly Asp Glu Arg Gly Glu Gly Lys Asn Gly He Gin Leu Ala 355 360 365 Lys Lys Thr Thr Leu Glu Lys Gly Ser Thr He Asn Val Ser Gly Lys 370 375 380 Glu Lys Gly Gly Arg Ala He Val Trp Gly Asp He Ala Leu He Asp 385 390 395 400 Gly Asn He Asn Ala Gin Gly Lys Asp He Ala Lys Thr Gly Gly Phe 405 410 415 Val Glu Thr Ser Gly His Tyr Leu Ser He Asp Asp Asn Ala He Val 420 425 430 Lys Thr Lys Glu Trp Leu Leu Asp Pro Glu Asn Val Thr He Glu Ala 435 440 445 Pro Ser Ala Ser Arg Val Glu Leu Gly Ala Asp Arg Asn Ser His Ser 450 455 460 Ala Glu Val He Lys Val Thr Leu Lys Lys Asn Asn Thr Ser Leu Thr 465 470 475 480 Thr Leu Thr Asn Thr Thr He Ser Asn Leu Leu Lys Ser Ala His Val 485 490 495 Val Asn He Thr Ala Arg Arg Lys Leu Thr Val Asn Ser Ser He Ser 500 505 510 He Glu Arg Gly Ser His Leu He Leu His Ser Glu Gly Gin Gly Gly 515 520 525 Gin Gly Val Gin He Asp Lys Asp He Thr Ser Glu Gly Gly Asn Leu 530 535 540 Thr He Tyr Ser Gly Gly Trp Val Asp Val His Lys Asn lie Thr Leu 545 550 555 560 Gly Ser Gly Phe Leu Asn He Thr Thr Lys Glu Gly Asp He Ala Phe 565 570 575 Glu Asp Lys Ser Gly Arg Asn Asn Leu Thr He Thr Ala Gin Gly Thr 580 585 590 He Thr Ser Gly Asn Ser Asn Gly Phe Arg Phe Asn Asn Val Ser Leu 595 600 605 Asn Ser Leu Gly Gly Lys Leu Ser Phe Thr Asp Ser Arg Glu Asp Arg 610 615 620 Gly Arg Arg Thr Lys Gly Asn He Ser Asn Lys Phe Asp Gly Thr Leu 625 630 635 640 Asn He Ser Gly Thr Val Asp He Ser Met Lys Ala Pro Lys Val Ser 645 650 655 Trp Phe Tyr Arg Asp Lys Gly Arg Thr Tyr Trp Asn Val Thr Thr Leu 660 665 670 Asn Val Thr Ser Gly Ser Lys Phe Asn Leu Ser He Asp Ser Thr Gly 675 680 685 Ser Gly Ser Thr Gly Pro Ser He Arg Asn Ala Glu Leu Asn Gly He 690 695 700 Thr Phe Asn Lys Ala Thr Phe Asn He Ala Gin Gly Ser Thr Ala Asn 705 710 715 720 Phe Ser He Lys Ala Ser He Met Pro Phe Lys Ser Asn Ala Asn Tyr 725 730 735 Ala Leu Phe Asn Glu Asp He Ser Val Ser Gly Gly Gly Ser Val Asn 740 745 750 Phe Lys Leu Asn Ala Ser Ser Ser Asn He Gin Thr Pro Gly Val He 755 760 765 He Lys Ser Gin Asn Phe Asn Val Ser Gly Gly Ser Thr Leu Asn Leu 770 775 780 Lys Ala Glu Gly Ser Thr Glu Thr Ala Phe Ser He Glu Asn Asp Leu 785 790 795 800 Asn Leu Asn Ala Thr Gly Gly Asn He Thr He Arg Gin Val Glu Gly 805 810 815 Thr Asp Ser Arg Val Asn Lys Gly Val Ala Ala Lys Lys Asn He Thr 820 825 830 Phe Lys Gly Gly Asn He Thr Phe Gly Ser Gin Lys Ala Thr Thr Glu 835 840 845 He Lys Gly Asn Val Thr He Asn Lys Asn Thr Asn Ala Thr Leu Arg 850 855 860 Gly Ala Asn Phe Ala Glu Asn Lys Ser Pro Leu Asn He Ala Gly Asn 865 870 875 880 Val He Asn Asn Gly Asn Leu Thr Thr Ala Gly Ser He He Asn He 885 890 895 Ala Gly Asn Leu Thr Val Ser Lys Gly Ala Asn Leu Gin Ala He Thr 900 905 910 Asn Tyr Thr Phe Asn Val Ala Gly Ser Phe Asp Asn Asn Gly Ala Ser 915 920 925 Asn He Ser He Ala Arg Gly Gly Ala Lys Phe Lys Asp He Asn Asn 930 935 940 Thr Ser Ser Leu Asn He Thr Thr Asn Ser Asp Thr Thr Tyr Arg Thr 945 950 955 960 He He Lys Gly Asn He Ser Asn Lys Ser Gly Asp Leu Asn He He 965 970 975 Asp Lys Lys Ser Asp Ala Glu He Gin He Gly Gly Asn He Ser Gin 980 985 990 Lys Glu Gly Asn Leu Thr He Ser Ser Asp Lys Val Asn He Thr Asn 995 1000 1005 Gin He Thr He Lys Ala Gly Val Glu Gly Gly Arg Ser Asp Ser Ser 1010 1015 1020 Glu Ala Glu Asn Ala Asn Leu Thr He Gin Thr Lys Glu Leu Lys Leu 1025 1030 1035 1040 Ala Gly Asp Leu Asn He Ser Gly Phe Asn Lys Ala Glu He Thr Ala 1045 1050 1055 Lys Asn Gly Ser Asp Leu Thr He Gly Asn Ala Ser Gly Gly Asn Ala 1060 1065 1070 Asp Ala Lys Lys Val Thr Phe Asp Lys Val Lys Asp Ser Lys He Ser 1075 1080 1085 Thr Asp Gly His Asn Val Thr Leu Asn Ser Glu Val Lys Thr Ser Asn 1090 1095 1100 Gly Ser Ser Asn Ala Gly Asn Asp Asn Ser Thr Gly Leu Thr He Ser 1105 1110 1115 1120 Ala Lys Asp Val Thr Val Asn Asn Asn Val Thr Ser His Lys Thr He 1125 1130 1135 Asn He Ser Ala Ala Ala Gly Asn Val Thr Thr Lys Glu Gly Thr Thr 1140 1145 11S0 He Asn Ala Thr Thr Gly Ser Val Glu Val Thr Ala Gin Asn Gly Thr 1155 1160 1165 He Lys Gly Asn He Thr Ser Gin Asn Val Thr Val Thr Ala Thr Glu 1170 1175 1180 Asn Leu Val Thr Thr Glu Asn Ala Val He Asn Ala Thr Ser Gly Thr 1185 1190 1195 1200 Val Asn He Ser Thr Lys Thr Gly Asp He Lys Gly Gly He Glu Ser 1205 1210 1215 Thr Ser Gly Asn Val Asn He Thr Ala Ser Gly Asn Thr Leu Lys Val 1220 1225 1230 Ser Asn He Thr Gly Gin Asp Val Thr Val Thr Ala Asp Ala Gly Ala 1235 1240 1245 Leu Thr Thr Thr Ala Gly Ser Thr He Ser Ala Thr Thr Gly Asn Ala 1250 1255 1260 Asn He Thr Thr Lys Thr Gly Asp He Asn Gly Lys Val Glu Ser Ser 126S 1270 1275 1280 Ser Gly Ser Val Thr Leu Val Ala Thr Gly Ala Thr Leu Ala Val Gly 1285 1290 1295 Asn He Ser Gly Asn Thr Val Thr He Thr Ala Asp Ser Gly Lys Leu 1300 1305 1310 Thr Ser Thr Val Gly Ser Thr He Asn Gly Thr Asn Ser Val Thr Thr 1315 1320 1325 Ser Ser Gin Ser Gly Asp He Glu Gly Thr He Ser Gly Asn Thr Val 1330 1335 1340 Asn Val Thr Ala Ser Thr Gly Asp Leu Thr He Gly Asn Ser Ala Lys 1345 1350 1355 1360 Val Glu Ala Lys Asn Gly Ala Ala Thr Leu Thr Ala Glu Ser Gly Lys 1365 1370 1375 Leu Thr Thr Gin Thr Gly Ser Ser He Thr Ser Ser Asn Gly Gin Thr 1380 1385 1390 Thr Leu Thr Ala Lys Asp Ser Ser He Ala Gly Asn He Asn Ala Ala 1395 1400 1405 Asn Val Thr Leu Asn Thr Thr Gly Thr Leu Thr Thr Thr Gly Asp Ser 1410 1415 1420 Lys He Asn Ala Thr Ser Gly Thr Leu Thr He Asn Ala Lys Asp Ala 1425 1430 1435 1440 Lys Leu Asp Gly Ala Ala Ser Gly Asp Arg Thr Val Val Asn Ala Thr 1445 1450 1455 Asn Ala Ser Gly Ser Gly Asn Val Thr Ala Lys Thr Ser Ser Ser Val 1460 1465 1470 Asn He Thr Gly Asp Leu Asn Thr He Asn Gly Leu Asn He He Ser 1475 1480 1485 Glu Asn Gly Arg Asn Thr Val Arg Leu Arg Gly Lys Glu He Asp Val 1490 1495 1500 Lys Tyr He Gin Pro Gly Val Ala Ser Val Glu Glu Val He Glu Ala 1505 1510 1515 1520 Lys Arg Val Leu Glu Lys Val Lys Asp Leu Ser Asp Glu Glu Arg Glu 1525 1S30 1535 Thr Leu Ala Lys Leu Gly Val Ser Ala Val Arg Phe Val Glu Pro Asn 1540 1545 1550 Asn Ala He Thr Val Asn Thr Gin Asn Glu Phe Thr Thr Lys Pro Ser 1555 1560 1565 Ser Gin Val Thr He Ser Glu Gly Lys Ala Cys Phe Ser Ser Gly Asn 1570 1575 1580 Gly Ala Arg Val Cys Thr Asn Val Ala Asp Asp Gly Gin Gin Pro 1S85 1590 1595 (2) INFORMATION FOR SEQ ID NO:10: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1600 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10: Met Asn Lys He Tyr Arg Leu Lys Phe Ser Lys Arg Leu Asn Ala Leu 1 5 10 15 Val Ala Val Ser Glu Leu Thr Arg Gly Cys Asp His Ser Thr Glu Lys 20 25 30 Gly Ser Glu Lys Pro Val Arg Thr Lys Val Arg His Leu Ala Leu Lys 35 40 45 Pro Leu Ser Ala He Leu Leu Ser Leu Gly Met Ala Ser He Pro Gin SO 55 60 Ser Val Leu Ala Ser Gly Leu Gin Gly Met Ser Val Val His Gly Thr 65 70 75 80 Ala Thr Met Gin Val Asp Gly Asn Lys Thr Thr He Arg Asn Ser Val 85 90 95 Asn Ala He He Asn Trp Lys Gin Phe Asn He Asp Gin Asn Glu Met 100 105 110 Glu Gin Phe Leu Gin Glu Ser Ser Asn Ser Ala Val Phe Asn Arg Val 115 120 125 Thr Ser Asp Gin He Ser Gin Leu Lys Gly He Leu Asp Ser Asn Gly 130 135 140 Gin Val Phe Leu He Asn Pro Asn Gly He Thr He Gly Lys Asp Ala 145 150 155 160 He He Asn Thr Asn Gly Phe Thr Ala Ser Thr Leu Asp He Ser Asn 165 170 175 Glu Asn He Lys Ala Arg Asn Phe Thr Leu Glu Gin Thr Lys Asp Lys 180 185 190 Ala Leu Ala Glu He Val Asn His Gly Leu He Thr Val Gly Lys Asp 195 200 205 Gly Ser Val Asn Leu He Gly Gly Lys Val Lys Asn Glu Gly Val He 210 215 220 Ser Val Asn Gly Gly Ser He Ser Leu Leu Ala Gly Gin Lys He Thr 225 230 235 240 He Ser Asp He He Asn Pro Thr He Thr Tyr Ser He Ala Ala Pro 245 250 ' 255 Glu Asn Glu Ala He Asn Leu Gly Asp He Phe Ala Lys Gly Gly Asn 260 265 270 He Asn Val Arg Ala Ala Thr He Arg Asn Lys Gly Lys Leu Ser Ala 275 280 285 Asp Ser Val Ser Lys Asp Lys Ser Gly Asn He Val Leu Ser Ala Lys 290 295 300 Glu Gly Glu Ala Glu He Gly Gly Val He Ser Ala Gin Asn Gin Gin 305 310 315 320 Ala Lys Gly Gly Lys Leu Met He Thr Gly Asp Lys Val Thr Leu Lys 325 330 335 Thr Gly Ala Val He Asp Leu Ser Gly Lys Glu Gly Gly Glu Thr Tyr 340 345 350 Leu Gly Gly Asp Glu Arg Gly Glu Gly Lys Asn Gly He Gin Leu Ala 355 360 365 Lys Lys Thr Thr Leu Glu Lys Gly Ser Thr He Asn Val Ser Gly Lys 370 375 380 Glu Lys Gly Gly Arg Ala He Val Trp Gly Asp He Ala Leu He Asp 385 390 395 400 Gly Asn He Asn Ala Gin Gly Ser Asp He Ala Lys Thr Gly Gly Phe 40S 410 415 Val Glu Thr Ser Gly His Asp Leu Ser He Gly Asp Asp Val He Val 420 425 430 Asp Ala Lys Glu Trp Leu Leu Asp Pro Asp Asp Val Ser He Glu Thr 435 440 445 Leu Thr Ser Gly Arg Asn Asn Thr Gly Glu Asn Gin Gly Tyr Thr Thr 4S0 455 460 Gly Asp Gly Thr Lys Glu Ser Pro Lys Gly Asn Ser He Ser Lys Pro 465 470 475 480 Thr Leu Thr Asn Ser Thr Leu Glu Gin He Leu Arg Arg Gly Ser Tyr 485 490 495 Val Asn He Thr Ala Asn Asn Arg He Tyr Val Asn Ser Ser He Asn 500 505 510 Leu Ser Asn Gly Ser Leu Thr Leu His Thr Lys Arg Asp Gly Val Lys 515 520 525 He Asn Gly Asp He Thr Ser Asn Glu Asn Gly Asn Leu Thr He Lys 530 535 540 Ala Gly Ser Trp Val Asp Val His Lys Asn He Thr Leu Gly Thr Gly 545 550 555 560 Phe Leu Asn He Val Ala Gly Asp Ser Val Ala Phe Glu Arg Glu Gly 565 570 575 Asp Lys Ala Arg Asn Ala Thr Asp Ala Gin He Thr Ala Gin Gly Thr 580 585 590 He Thr Val Asn Lys Asp Asp Lys Gin Phe Arg Phe Asn Asn Val Ser 595 600 60S Leu Asn Gly Thr Gly Lys Gly Leu Lys Phe He Ala Asn Gin Asn Asn 610 615 620 Phe Thr His Lys Phe Asp Gly Glu He Asn He Ser Gly He Val Thr 625 630 635 640 He Asn Gin Thr Thr Lys Lys Asp Val Lys Tyr Trp Asn Ala Ser Lys 645 650 655 Asp Ser Tyr Trp Asn Val Ser Ser Leu Thr Leu Asn Thr Val Gin Lys 660 665 670 Phe Thr Phe He Lys Phe Val Asp Ser Gly Ser Asn Gly Gin Asp Leu 675 680 685 Arg Ser Ser Arg Arg Ser Phe Ala Gly Val His Phe Asn Gly He Gly 690 695 700 Gly Lys Thr Asn Phe Asn He Gly Ala Asn Ala Lys Ala Leu Phe Lys 705 710 715 720 Leu Lys Pro Asn Ala Ala Thr Asp Pro Lys Lys Glu Leu Pro He Thr 725 730 735 Phe Asn Ala Asn He Thr Ala Thr Gly Asn Ser Asp Ser Ser Val Met 740 745 750 Phe Asp He His Ala Asn Leu Thr Ser Arg Ala Ala Gly He Asn Met 755 760 765 Asp Ser He Asn He Thr Gly Gly Leu Asp Phe Ser He Thr Ser His 770 775 780 Asn Arg Asn Ser Asn Ala Phe Glu He Lys Lys Asp Leu Thr He Asn 785 790 795 800 Ala Thr Gly Ser Asn Phe Ser Leu Lys Gin Thr Lys Asp Ser Phe Tyr 805 810 815 Asn Glu Tyr Ser Lys His Ala He Asn Ser Ser His Asn Leu Thr He 820 825 830 Leu Gly Gly Asn Val Thr Leu Gly Gly Glu Asn Ser Ser Ser Ser He 835 840 84S Thr Gly Asn He Asn He Thr Asn Lys Ala Asn Val Thr Leu Gin Ala 850 85S 860 Asp Thr Ser Asn Ser Asn Thr Gly Leu Lys Lys Arg Thr Leu Thr Leu 865 870 875 880 Gly Asn He Ser Val Glu Gly Asn Leu Ser Leu Thr Gly Ala Asn Ala 885 890 895 Asn He Val Gly Asn Leu Ser He Ala Glu Asp Ser Thr Phe Lys Gly 900 905 910 Glu Ala Ser Asp Asn Leu Asn He Thr Gly Thr Phe Thr Asn Asn Gly 915 920 925 Thr Ala Asn He Asn He Lys Gly Val Val Lys Leu Gly Asp He Asn 930 935 940 Asn Lys Gly Gly Leu Asn He Thr Thr Asn Ala Ser Gly Thr Gin Lys 945 950 955 960 Thr He He Asn Gly Asn He Thr Asn Glu Lys Gly Asp Leu Asn He 965 970 975 Lys Asn He Lys Ala Asp Ala Glu He Gin He Gly Gly Asn He Ser 980 985 990 Gin Lys Glu Gly Asn Leu Thr He Ser Ser Asp Lys Val Asn He Thr 995 1000 1005 Asn Gin He Thr He Lys Ala Gly Val Glu Gly Gly Arg Ser Asp Ser 1010 1015 1020 Ser Glu Ala Glu Asn Ala Asn Leu Thr He Gin Thr Lys Glu Leu Lys 1025 1030 1035 1040 Leu Ala Gly Asp Leu Asn He Ser Gly Phe Asn Lys Ala Glu He Thr 1045 1050 1055 Ala Lys Asn Gly Ser Asp Leu Thr He Gly Asn Ala Ser Gly Gly Asn 1060 1065 1070 Ala Asp Ala Lys Lys Val Thr Phe Asp Lys Val Lys Asp Ser Lys He 1075 1080 1085 Ser Thr Asp Gly His Asn Val Thr Leu Asn Ser Glu Val Lys Thr Ser 1090 1095 1100 Asn Gly Ser Ser Asn Ala Gly Asn Asp Asn Ser Thr Gly Leu Thr He 1105 1110 1115 1120 Ser Ala Lys Asp Val Thr Val Asn Asn Asn Val Thr Ser His Lys Thr 1125 1130 1135 He Asn He Ser Ala Ala Ala Gly Asn Val Thr Thr Lys Glu Gly Thr 1140 1145 1150 Thr He Asn Ala Thr Thr Gly Ser Val Glu Val Thr Ala Gin Asn Gly 1155 1160 1165 Thr He Lys Gly Asn He Thr Ser Gin Asn Val Thr Val Thr Ala Thr 1170 1175 1180 Glu Asn Leu Val Thr Thr Glu Asn Ala Val He Asn Ala Thr Ser Gly 1185 1190 1195 1200 Thr Val Asn He Ser Thr Lys Thr Gly Asp He Lys Gly Gly He Glu 1205 1210 1215 Ser Thr Ser Gly Asn Val Asn He Thr Ala Ser Gly Asn Thr Leu Lys 1220 1225 1230 Val Ser Asn He Thr Gly Gin Asp Val Thr Val Thr Ala Asp Ala Gly 1235 1240 1245 Ala Leu Thr Thr Thr Ala Gly Ser Thr He Ser Ala Thr Thr Gly Asn 1250 1255 1260 Ala Asn He Thr Thr Lys Thr Gly Asp He Asn Gly Lys Val Glu Ser 1265 1270 1275 1280 Ser Ser Gly Ser Val Thr Leu Val Ala Thr Gly Ala Thr Leu Ala Val 1285 1290 1295 Gly Asn He Ser Gly Asn Thr Val Thr He Thr Ala Asp Ser Gly Lys 1300 1305 1310 Leu Thr Ser Thr Val Gly Ser Thr He Asn Gly Thr Asn Ser Val Thr 1315 1320 1325 Thr Ser Ser Gin Ser Gly Asp He Glu Gly Thr He Ser Gly Asn Thr 1330 1335 1340 Val Asn Val Thr Ala Ser Thr Gly Asp Leu Thr He Gly Asn Ser Ala 1345 1350 1355 1360 Lys Val Glu Ala Lys Asn Gly Ala Ala Thr Leu Thr Ala Glu Ser Gly 1365 1370 1375 Lys Leu Thr Thr Gin Thr Gly Ser Ser He Thr Ser Ser Asn Gly Gin 1380 1385 1390 Thr Thr Leu Thr Ala Lys Asp Ser Ser He Ala Gly Asn He Asn Ala 1395 1400 1405 Ala Asn Val Thr Leu Asn Thr Thr Gly Thr Leu Thr Thr Thr Gly Asp 1410 1415 1420 Ser Lys He Asn Ala Thr Ser Gly Thr Leu Thr He Asn Ala Lys Asp 1425 1430 1435 1440 Ala Lys Leu Asp Gly Ala Ala Ser Gly Asp Arg Thr Val Val Asn Ala 1445 14S0 1455 Thr Asn Ala Ser Gly Ser Gly Asn Val Thr Ala Lys Thr Ser Ser Ser 1460 1465 1470 Val Asn He Thr Gly Asp Leu Asn Thr He Asn Gly Leu Asn He He 1475 1480 148S Ser Glu Asn Gly Arg Asn Thr Val Arg Leu Arg Gly Lys Glu He Asp 1490 1495 1500 Val Lys Tyr He Gin Pro Gly Val Ala Ser Val Glu Glu Val He Glu 1505 1510 1515 1520 Ala Lys Arg Val Leu Glu Lys Val Lys Asp Leu Ser Asp Glu Glu Arg 1525 1530 1535 Glu Thr Leu Ala Lys Leu Gly Val Ser Ala Val Arg Phe Val Glu Pro 1540 1545 1550 Asn Asn Ala He Thr Val Asn Thr Gin Asn Glu Phe Thr Thr Lys Pro 1555 1560 1565 Ser Ser Gin Val Thr He Ser Glu Gly Lys Ala Cys Phe Ser Ser Gly 1570 1575 1580 Asn Gly Ala Arg Val Cys Thr Asn Val Ala Asp Asp Gly Gin Gin Pro 158S 1590 1595 1600 (2) INFORMATION FOR SEQ ID NO:11: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 29 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11: Val Asp Glu Val He Glu Ala Lys Arg He Leu Glu Lys Val Lys Asp 1 5 10 15 Leu Ser Asp Glu Glu Arg Glu Ala Leu Ala Lys Leu Gly 20 25

Claims: /36914 103 CIAIMS What I claim is: 1. An isolated and purified nucleic acid molecule encoding a high molecular weight protein (HMW) HMW3 or HMW4 of a non-typeable Haemophilus .strain or a variant or fragment of said protein retaining the immunological ability to protect against disease caused by a non- typeable Haemophilus strain, having: (a) the DNA sequence shown in Figure 8 (SEQ ID No: 7) and encoding protein HMW3 having the derived amino acid sequence of Figure 10 (SEQ ID No: 9) , or (b) the DNA sequence shown in Figure 9 (SEQ ID No: 8) and encoding protein HMW4 having the derived amino acid sequence of Figure 10 (SEQ ID No: 10) . 2. An isolated and purified nucleic acid molecule encoding a high molecular weight protein (HMW) of a non- typeable Haemophilus strain, which is selected from the group consisting of: (a) a DNA sequence as shown in any one of Figures 8 and 9 (SEQ ID Nos: 7 and 8); (b) a DNA sequence encoding an amino acid sequence as shown in Figure 10 (SEQ ID Nos: 9 and 10) ; or (σ) a DNA sequence encoding a high molecular weight protein of a non-typeable Haemophilus strain which hybridizes under stringent conditions to any one of the DNA sequences of (a) and (b) . 3. The nucleic acid molecule of claim 2 wherein the DNA sequence (c) have at least about a 90% identity of sequence to the DNA sequences (a) or (b) . 4. A vector for transformation of a host comprising the nucleic acid molecule of claim 2. 5. An isolated and purified high molecular weight (HMW) protein of non-typeable Haemophilus or any variant or fragment thereof retaining the immunological ability to protect against disease caused by a non-typeable Haemophilus strain, which is characterized by at least one surface-exposed B-cell epitope which is recognized by monoclonal antibody AD6. 6. The protein of claim 5 which is HMWl encoded by the DNA sequence shown in Figure l (SEQ ID No: l) , having the derived amino acid sequence of Figure 2 (SEQ ID No : 2) and having an apparent molecular weight of 125 kDa. 7. The protein claim 5 which iε HMW2 encoded by the DNA sequence shown in Figure 3 (SEQ ID No: 3) and having the derived amino acid sequence of Figure 4 (SEQ ID No: 4) and having an apparent molecular weight of 120 kDa. 8. The protein claimed in claim 5 which is HMW3 encoded by the DNA sequence shown in Figure 8 (SEQ ID No: 7) and having the derived amino acid sequence of Figure 10 (SEQ ID No: 9) and having an apparent molecular weight of 125 kDa. 9. The protein claimed in claim 5 which is HMW4 encoded by the DNA sequence shown in Figure 9 (SEQ ID No: 8) and having the derived amino acid sequence shown in Figure 10 (SEQ ID No: 10) and having an apparent molecular weight of 123 kDa. 10. A conjugate comprising a protein aε claimed in claim 5 linked to an antigen, hapten or polysaccharide for eliciting an immune response to said antigen, hapten or polysaccharide. 11. The conjugate as claimed in claim 10 wherein said polysaccharide is a protective polysaccharide against Haemophilus influenzae type b. 12. A synthetic peptide having an amino acid sequence containing at least six amino acids and no more than 150 amino acids and corresponding to at least one protective epitope of a high molecular weight protein HMWl, HMW2, HMW3 or HMW4 of non-typeable Haemophilus influenzae, wherein the epitope is recognized by at least one of monoclonal antibodies AD6 and 10C5. 13. he peptide as claimed in claim 12 wherein the epitope is located within 75 amino acids of the carboxy terminus of the HMWl or HMW2 protein.

Inventors: BARENKAMP STEPHEN J, BARENKAMP, STEPHEN, J.
Applicants: BARENKAMP STEPHEN J, BARENKAMP, STEPHEN, J.
Application year: 1997
Main classification: C07H21
IPC codes: A61K38, A61K39, A61P37, C07K14, C12N15